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ABSTRACT 
Tuberculosis remains the world’s deadliest communicable bacterial disease with an 
unacceptably high death rate. In 2013 an estimated 1.5 million people died as a direct 
result of TB, and nine million new cases were reported.1 Multi-drug resistant (MDR) and 
extensively drug-resistant (XDR) tuberculosis cases are on the rise and without novel 
approaches to combat their spread, tuberculosis will continue to claim the lives of 
millions worldwide. One such novel approach is to rejuvenate the use of the second-line 
antibiotic ethionamide. 
Ethionamide is a structural analogue of the first-line pro-drug isoniazid, which is 
used widely and to which there is growing resistance. Ethionamide was introduced in 
the 1960s and primarily used in cases of drug-resistant TB due to its severe adverse 
effects. This makes ethionamide an exploitable target for small-molecule booster drugs. 
Expression of the enzyme responsible for ethionamide activation, EthA, is 
regulated by a transcriptional repressor EthR which can be inhibited to improve 
ethionamide activation and so reduce ethionamide treatment doses and bring an old 
drug new life in the clinic. EthR inhibitors are currently in development; here, 
chemoinformatic pipelining and virtual screening in GOLD were used to identify hits 
with novel scaffolds for hit-to-lead efforts from an initial library of over six million drug-
like molecules.  
Thermal shift assays were used to identify EthR-binding molecules and SPR was 
utilised to confirm and potentially quantify binding affinities. Herein are reported the co-
crystal structures of several hit molecules, used to confirm and characterise the EthR-
ligand complexes. 
Through the application of computational, biophysical and crystallographic 
methods, this thesis presents several novel scaffolds for development against EthR. 
These novel hits will be developed to expand our arsenal against the growing, global 
problem of drug-resistant TB. 
 
 
 
  
                                                             
1 World Health Organisation, Global Tuberculosis Report 2014. 
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INTRODUCTION 
The overriding aim of the work presented here was to use computational methods to 
identify small molecules with novel scaffolds capable of binding EthR, with a view to 
developing those hits into new inhibitor series. 
 Chapters one and two of this thesis serve as reviews, split between the 
computational aspects (chapter one) and the main biological focus (chapter two) which 
are entwined throughout this thesis. Chapter one charts the rise and implementation of 
computer software for the design, development and screening of drug molecules in silico. 
This includes a detailed look at the software package used for virtual screening against 
EthR, GOLD. Conversely, chapter two describes the previous development of EthR 
inhibitors, culminating in the current lead compound from a 1,2,4-oxadiazole series and 
several avenues of fragment-based drug discovery research. 
 Chapter three describes the computational methods applied in the design and 
implementation of a virtual screening protocol. Beginning with an initial library of over 
six million compounds, detailed knowledge of the protein was used to filter down to a 
cohort of 1.3 million candidates which were clustered and sampled in order to screen a 
rich and diverse set of chemical compounds against EthR. In chapter four, post-screening 
work yielded a set of non-stringent filters based on score, physiochemical properties and 
protein-ligand interaction analysis; these filters reduced the potential screening set 
exponentially to a small cohort of only 85 compounds for testing against the protein. 
 Biophysical testing in the form of thermal shift assays (chapter five), surface 
plasmon resonance (chapter six) were used to identify and characterise the binding of 
hit molecules to EthR. Finally, co-crystallisation studies detailed in chapter seven 
demonstrate hit molecules bound to EthR.  
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CHAPTER I: 
STRUCTURE-BASED DRUG DISCOVERY 
This first chapter summarises the history and state of drug discovery and design, firmly 
placing the following work in the realm of pre-clinical research, followed by a detailed 
discussion of key computational tools and techniques employed later in this thesis for 
structure-based drug discovery. Finally this chapter will cover key successes of 
structure-based drug design targeting a variety of human diseases. 
 
1.1 Drug Discovery and Development 
The successes and failures of the pharmaceutical industry are often and understandably 
high-profile. Business run on improving human health is a business one naturally wishes 
to see succeed, but what form that success takes depends on if it is measured in human 
health improvements, or profits; the pharmaceutical industry has to balance both. In the 
recent past, discoveries and developments have come thick and fast; as we turned the 
corner into the new millennium, the state of the pharmaceutical industry was vastly 
different from its post-WWII high and it has become necessary to change the way drug 
design and development are approached. This section gives a short history of the 
evolution of the pharmaceutical industry, and demonstrates the current pipeline for drug 
development and discovery. 
 
1.1.1 The 20th Century Rollercoaster 
Modern drug treatment, which can be accurately called chemotherapy, began in the early 
years of the 1900s but was revolutionised during the Second World War with the 
discovery and application of antibiotics. Up to the 1960s the pharmaceutical industry 
boomed with drugs to fight infectious bacterial diseases, becoming what is typically 
referred to as “Big Pharma” – large, transnational corporations which were the 
cornerstone of post-war economies. However, from the 1970s onward, a “low-hanging 
fruit”1 effect became apparent, where it seemed the easy targets of discovery on the 
metaphorical drug tree had been found and only the harder-to-reach “high fruit” 
remained. With these easy wins gone priorities for drug companies changed as 
developing new antibiotics became a challenge with high financial risk. With a culture of 
complacency and a need to maintain high profits, in a world where vaccinations were 
close to eradicating infectious diseases, and where chronic and age-related diseases 
were on the rise thanks to an increased life expectancy in industrial nations, attention 
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turned from antibiotics to chemotherapy for more chronic illnesses such as cancer, 
diabetes and cardiovascular disease. Since the 1980s antibacterial drug approvals have 
dropped – to only two in the period 2008-20102 – despite numerous infectious diseases 
developing antibiotic resistance.  
 The recent Ebola virus outbreak from West Africa in 20143 has highlighted the 
risks and ease of disease spread in a globalised world, even with a virus which is, relative 
to the likes of influenza, difficult to contract. Moreover, intercontinental migration, 
tourism, and population displacement not only increase disease spread but in so doing 
can increase the spread of antibiotic-resistant disease. In a 2014 review of antibacterial 
development,2 Stewart T. Cole reports that in Europe, the ECDC (European Centre for 
Disease Control) estimated multi-drug resistant bacterial infections such as tuberculosis 
were responsible for 25,000 deaths annually, costing the EU in excess of €1.5 billion. Cole 
goes on to report that studies in the USA indicated that MRSA (methicillin-resistant 
Staphylococcus aureus) claimed more lives annually than emphysema, HIV/AIDS, 
Parkinson’s disease and homicide combined.  With such a global antibiotic crisis there 
are questions as to why new anti-infective research is so stagnant and unyielding of new 
chemical entities. The problem is, unsurprising, complex, and many reasons and 
solutions have been suggested. 
 In the specific case of antibiotics (particularly broad-spectrum drugs of which 
only two4 have been approved in the last 40 years), the work became cost ineffective 
compared to more lucrative areas and a gradual shift towards these chronic, non-
communicable diseases resulted in a lack of expertise in the antibiotic area. However, 
this did not provide long-term security for BigPharma5 – the costs of drug development 
soared towards the end of the twentieth century, until in 2010 the cost of developing a 
new chemical entity reached an reported estimate of $2bn.1 Of course the cost of making 
a drug is a highly disputed figure, with most estimates professed by drug companies such 
as Eli Lilly being in the billion dollar range. A simple study by Forbes utilised a rough 
yardstick of R&D investment of several major drug companies, divided by the number of 
drugs successfully brought to market in a given period; this placed costs between $4bn 
and $11bn.6 Alternatively, a study by Light and Warburton7 suggested that reported 
“costs” are perhaps “padded” with legal and non-research expenditures (such as 
marketing and insurance), and their study places a more modest median figure of $43.4 
million on development. One interesting point made by Light and Warburton is that such 
high cost estimates in the billion dollar range may be self-fulfilling prophecies. 
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Whatever the real cost figure, there is strong investment in drug discovery and 
development and yet attrition (failure) rates for small molecules stand at 93% (for drugs 
entering clinical trials but not, ultimately, reaching the market). In the light of such 
difficulties, many recent reviews1,2,5,8–13 have covered the scientific and financial 
challenges faced in the industry and how advances could be made to mitigate these costly 
losses, including shifts in scientific approach and partnerships between academia and 
industry. However, one clear overriding conclusion can be drawn: more time, care and a 
better distribution of efforts must be made on the pre-clinical development phase, where 
currently only a third of financial investment and time is spent.  
  
1.1.2 Contemporary Practice 
A typical drug development pipeline, from target discovery to approved drug on the 
market, has two main phases: pre-clinical, which covers everything at the molecular level 
before human clinical trials; and clinical, which involves proof-of-concept, efficacy and 
safety trials in patients (figure 1.1). The whole drug discovery and development process 
takes, on average, ten to fifteen years. 
Figure 1.1: Schematic representation of the typical drug discovery and development pipeline. The pre-
clinical (purple), clinical (green) and approval (blue) stages are colour-coded for clarity. 
 
The pre-clinical phase is the last step before an application is made for clinical trials, in 
the form of an Investigational New Drug Application (in the US, with the FDA) or a 
Clinical Trial Application (in Europe with the EMA).6 The pre-clinical stage is therefore 
the last opportunity to gather data for (or against) investing in clinical trials, involving 
extensive in vivo testing on animal models. Pharmacokinetic and pharmacodynamic 
(PK/PD) data9 is acquired from non-human subjects at this point, typically elucidating 
Target 
Discovery
Target 
Validation
Hit 
Discovery
Hit 
Screening
Hit-to-Lead
Lead 
Optimisation
Pre-Clinical
Phase 0 Phase 1
Phase 2
Phase 3
Approval 
Stage
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what actions the body takes on the drug (PK) and what effect the drug has on the body 
(PD). It is often beneficial for multiple candidates to undergo pre-clinical PK/PD tests. 
As this phase is the last laboratory-based (as opposed to clinic-based) step in the 
development pipeline, the pre-clinical step has been cited as the point at which most 
improvement can be made to reduce attrition rates in the clinic; this includes not only 
improving the data collection,8 but also the methods. Effective in vivo models are 
essential to qualify both the target and the candidate molecule, determine therapeutic 
doses and justify entry into clinical trials.1 
 Before drug approval there are four phases to a typical clinical trial: phases 0 to 
3. The PK/PD studies in non-human models are repeated on a small number of patients 
(typically less than ten) in sub-optimal doses; this is the first test on patients with the 
disease to be treated, and determines bioavailability and half-life of the drug in humans. 
Phase I involves a larger (~100) cohort of patients who are subjected to a range of doses 
– still typically sub-therapeutic - to check efficacy and determine the therapeutic dose to 
be used in phase II. For this very reason most drugs (barring rare extreme reactions)14 
progress through to phase II, which is the point at which a true proof-of-concept test 
occurs. Phase II involves a few hundred patients, dosed at the now-determined 
therapeutic level. The efficacy and safety of the drug is put to the test, and it is at this 
point at which large numbers of drugs fail. An in-house study at Pfizer in 20129 analysed 
44 programs which reached phase II trials in the period 2005-2009 in order to determine 
what lessons could be learned. The study itself was revealing; of the 44 case studies, only 
a third were deemed to have achieved “proof-of-concept” with the target modulated by 
the administered drug. A smaller number of the case studies (25%) were able to 
modulate the target but were deemed unsafe, and a disturbingly larger percentage – 43% 
- did not “adequately demonstrate” the mechanism and so failed proof-of-concept.9 
  At phase III the drug in trial is now proven to have an effect (if indeed, it has 
passed through to phase III), and trials are conducted on thousands of patients. It is clear 
that phase II is the key hurdle and that, for all the care in design and optimisation in pre-
clinical drug discovery, it is rare to develop a drug which succeeds in safely treating 
patients. Yet for the 93% of drugs entering clinical trials which fail there are still 7% of 
small molecule drugs which are successful and subsequently approved.1  
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1.2 Computational Tools and Methods 
The drug discovery work presented in the following chapters involves a variety of 
computational and biophysical techniques; the latter will be explained in context in their 
relevant chapters, however for the sake of brevity when explaining the protocols 
implemented and choices made, the computational tools and methods will be discussed 
in detail here. This primarily focuses on the development of docking algorithms, and the 
software GOLD which was used for this purpose. 
 
1.2.1 Chemoinformatics and Chemical Space 
To return to the discussion of attrition rates in clinical trials, much discussion has been 
made about the medicinal chemistry approaches13 which dictate hit-to-lead 
programmes, and how this may influence success or failure. A trend has been identified 
by which hit molecules are “inflated” through the optimisation process in both molecular 
weight and lipophilicity in order to increase potency and cell permeability; this is 
typically to their detriment, reflected by attrition rates, and termed ‘molecular obesity’. 
A review by Haan15 coined the phrase in 2011 and demonstrated that, for molecules 
which pass their proof-of-concept test and yet are still pulled from clinical trials, reason 
for failure typically lies with toxicological issues; that is, the drugs in question work on 
their target, but fail their patient. Haan points to molecular obesity as a potential cause, 
simply adding mass rather than reappraising the entire compound. 
 Multiple chemoinformatic metrics and rules-of-thumb for quantifying a drug’s 
chemical properties have grown around trying to guide drug design. With reference to 
key indicators, those metrics discussed in detail will be lipophilicity, measured by logP, 
Lipinski’s ‘rules’ which are a guideline for oral bioavailability, and Veber’s augments to 
Lipinski’s ‘rules,’ which added considerations of polar surface area and the number of 
rotatable bonds in a molecule. 
 
1.2.1.1 Metrics of Lipophilicity 
Lipophilicity is tied to the ability of a drug molecule to pass through the cell membrane, 
which is comprised of lipids. One particular method of describing the lipophilicity of a 
molecule is the partition co-efficient P, which is the ratio of concentrations of the 
compound to be found in a two-compartment, closed system at equilibrium, comprised 
of octanol (organic) and water (aqueous). It is more typically used in the logarithmic 
form logP.  
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Acquisition of experimental logP data is rare, as for a database of compounds it would be 
understandably time-consuming. Therefore, in the 1970s a general method of calculating 
logP values was introduced and has been subsequently developed into a plethora of 
methods for logP calculation, with structure-based methods being the fastest and easiest 
to calculate for large databases of compounds. Structure-based (2D) methods for logP 
calculation fall into two subcategories: fragmental methods (such as CLogP), and atom-
based methods (such as AlogP and XlogP); these named examples will be described in 
more detail. 
Fragmental methods reduce a molecule to fragments with correction factors, a 
typical drawback being that some fragments which are poorly (or not at all) defined 
prevent a calculation; or that there are arbitrary fragments which may not represent the 
fragment as a whole. 
CLogP utilises an equation common to all fragmental methods (equation 1.1), and 
derives terms from data on simple molecules; it is the most widely used calculation. 
log 𝑃 =  ∑ 𝑎𝑖𝑓𝑖
𝑛
𝑖=1
+  ∑ 𝑏𝑗𝐹𝑗
𝑚
𝑗=1
 
Equation 1.1: Fragment-based methods for logP calculation utilise fragmental constants (f) for a fragment, 
and the incidence (a) of that fragment in the query molecule. The second term utilises a correction factor F, 
and its frequency (b). 
 
Utilising the 2D molecular structure of a molecule, CLogP defines a fragment as an atom 
or group of atoms bounded by “isolating carbons”, which are bound to heteroatoms by 
only single or aromatic bonds; it will be defined as a polar fragment if the isolating carbon 
is bound to anything other than hydrogen. Tables of fragmental constants for CLogP were 
derived using experimental logP values on known structures,16 and consequent 
regression analysis on constituent functional groups. Constants for carbon and hydrogen 
were derived from small alkanes and, for more complex fragments, correction factors 
are used. Additionally, interaction factors account for electronic effects through bonds, 
making correct atom and bond assignment of the input structure essential. 
Atom-based methods use single atoms rather than fragments and sum the 
contributions of different types of atoms. Ambiguity is avoided as a large number of atom 
environments are classified, but atom-based models do not account for long-range 
interactions.  
ALogP is based on the Ghose-Crippen approach which operates without a 
correction factor, according to equation 1.2. In this approach there are 120 atom types 
classified, derived from a training set of nearly 900 structures; for example carbons are 
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classified by hybridisation state and depending upon the nature of their neighbour.  
ALogP is also known as ALogP98, and is a refined version of the Ghose-Crippen Approach 
utilising an additional 68 atomic definitions from a training set of 9000 structures. 
 
log 𝑃 =  ∑ 𝑎𝑘𝑁𝑘 
 
Equation 1.2: ALogP sums the products of atom (a) type (k) by the number of times (N) the type (k) 
appears in the query molecule. 
 
Contrastingly, XLogP includes a correction factor. A total of 90 atom types (compared to 
a larger 186 atom types for ALogP) and 10 correction factors are used, the latter of which 
compensate for some intramolecular interactions such as internal hydrogen bonds. The 
calculation for XLogP is given below as equation 1.3. 
 
log 𝑃 =  ∑ 𝑎𝑖𝐴𝑖
𝑀
𝑖=1
+ ∑ 𝑐𝑗𝐶𝑗
𝑁
𝑗=1
 
 
Equation 1.3: XLogP contains two terms. The first summation is the contribution (a) and occurrence (A) of 
the atom (i). The second summation are contributions (c) and occurrence (C) of the necessary correction 
factor. 
 
A study by Mannhold et al.16 in 2008 compared up to 30 different logP calculation 
methods on a more than 96,000 compounds (266 public, 882 from Nycomed and over 
95,000 from Pfizer). They reported only seven methods which produced reasonable 
accuracy for the larger datasets, and of those they cited ALogP and XLogP as among the 
most consistent. 
 
1.2.1.2 Lipinski and Veber: Oral Bioavailability Trends 
GlaxoSmithKline and Pfizer have developed internal rules to control molecular obesity 
and problem compounds. As molecular weight and logP are convoluted in the theory of 
molecular obesity, the GSK 4/400 rule arose from a study of 30,000 compounds which  
showed those having a CLogP < 4 and a molecular weight < 400 displayed a more 
favourable ADMET (absorption, delivery, metabolism, excretion and toxicity) profile. 
This is similar to the Pfizer 3/75 rule, which utilises a CLogP < 3 and a total polar surface 
area of greater than 75 Å3; compounds fitting this profile showed a reduced in vivo 
toxicity profile compared to those of the inverse properties. 
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However by far the most famous of the ‘drug-like’ metrics is Lipinski’s “Rule of 5” (RO5). 
In 1997 Lipinksi et al. studied a subset of 2254 compounds which had entered phase II 
trials and therefore had good physiochemical properties. The aim of the study was to 
identify properties correlated with oral bioavailability, and the results showed most 
were small and somewhat lipophilic. Therefore, Lipinksi et al. proposed that generally 
an orally active drug molecule would conform to at least three of the following four 
criteria, firstly, a CLogP < 5; secondly, the drug would have a molecular weight lower 
than 500 g mol-1; thirdly, the molecule would contain no more than 10 hydrogen bond 
acceptors; and finally, the molecule would contain no more than 5 hydrogen bond 
donors. Lipinski intended the RO5 to be a conservative indicator, in that they described 
90% of the drugs which achieved phase II clinical trials. 
 In 2004 Lipinski responded to what he called the “rule-of-five revolution” with a 
short perspective, which addressed misinterpretations of the original 1997 paper as well 
as offering tool-like (ie. probe) and lead-like (ie. fragment) property guidelines. Lipinksi 
reiterated that “passing the RO5 is no guarantee that a compound is drug-like,” as his 
RO5 had been applied as such by many. He acknowledged Veber et al.’s observation that 
compounds with greater than 10 rotatable bonds correlated to lower oral bioavailability 
in rats, adding that for in vitro screening ligand affinity “on average decreases 0.5 kcal 
for each two rotatable bonds.” Veber et al. also indicate a polar surface area of equal or 
less than 140 Å2 associated with good oral bioavailability. These metrics, derived from a 
study of compounds with good ADMET profiles, yielded powerful tools for drug 
development. 
 
1.2.1.3 Guidelines vs. Rules 
It seems obvious to say, but there is no clear rule-of-thumb or definitive metric which 
can be used to define what makes a good drug - or even a drug likely to succeed. Lipinski 
et al.’s approach, followed by Veber et al.’s are correlations of success and 
physiochemical property, but outliers will always exist. For hit identification screening, 
it is better to sample a wide range of chemical space in order to identify novel 
chemotypes, however databases of commercially available structures such as ZINC 
contain 35 million compounds, a practically untestable number.  
Therefore in terms of hit identification by screening it is best to use such metrics 
described here to guide a search towards a starting point with beneficial properties, and 
trust that potent compounds will be identified if the protocols have been implemented 
correctly. For medicinal chemists the challenge is then to optimise the structure with the 
dangers of ‘molecular obesity’ in mind. 
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1.2.2 Docking and Virtual Screening 
The advent of protein crystallography, with the solution and publication of the structures 
of myoglobin17 and haemoglobin,18 opened the doors to a new realm of rational, 
structure-based drug design. Even before sufficiently sophisticated molecular graphics, 
pioneering work used scale models of haemoglobin and prior knowledge of ligands to 
develop novel compounds effecting oxygen liberation.19,20 As computer processing 
power began to increase it became possible to solve the more complex problems with 
algorithms, first for representing molecular shape and surface,21,22 and on, to calculating 
protein-ligand interactions,23 grid-based search methods, and shape complementarity,24 
until finally the first automated molecular docking program from the Kuntz group was 
released in 1989.25 This section will describe evolution of docking from the development 
of the initial algorithms for automated rigid docking in the 1980s, through the 
development of flexible docking in the 1990s, and into the 2000s and the post-millennial 
work to improve the accuracy of scoring functions, and to more accurately represent the 
biophysical realities in what is a very derivative, isolated method of binding simulation. 
 
1.2.2.1 From Molecular Graphics to DOCK (1978-1989) 
Docking as a method of discovering and designing a drug molecule which interacts with 
its protein target in three dimensions relies upon three core aspects: firstly, accurately 
positioning a ligand in its binding conformation with the receptor; secondly, in scoring 
or assigning the energy of such binding; and thirdly, representing this on screen. In 1978 
Greer and Bush21 described a method for calculating the molecular surface to be 
represented as a contour map, based on the proposition by Richards26 the year before, 
utilising water position and implied van der Waals interactions where water is excluded 
in the structure. In the following five years molecular graphics were developed27–29 
capable of displaying the structures and surfaces on a workstation screen with real-time 
manipulation, and so with representations came the ability to conduct manual docking 
without a scale model taking up a bench.  
The first automated docking program, DOCK,25,30 traces its roots back to the 
development of molecular graphics more literally than most; it was within the Kuntz 
group at UCSF, where these graphics were developed, that the first algorithm for 
calculation of protein-ligand interactions was written and published in 1982. A version 
of molecular docking had occurred before, for example with Levinthal et al.19 and the 
design of novel ligands for haemoglobin; however, the new geometric approach from 
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Kuntz et al.23 was the first step towards automation of the docking process, and making 
library screening feasible even later down the line. 
 Earliest versions of DOCK utilised a geometric approach. DOCK described the 
protein binding surface using spheres,25 which were derived from tangents from one 
solvent-accessible surface22 point meeting another; a resulting sphere has its centre at 
the meeting point and a radius to the surface. Various factors prune the number of 
spheres, such as only the smallest possible sphere generated being kept, and only one 
sphere per receptor atom. Spheres are grouped where they overlap and so the largest 
cluster of spheres should correspond to the binding site (spheres of radius greater than 
5 Å are discarded as being likely to project into solvent). Ligand spheres are created by 
inverting the tangent, projecting into the ligand structure rather than out as in the 
receptor. Spheres are paired, by matching centre-to-centre distances within a distance 
threshold, and a minimum of four such matches are required to yield a ligand orientation. 
The algorithm repeats to find multiple potential orientations. Scoring was done simply 
by determining to what extent the ligand atoms violated the lower bounds of the van der 
Waals radii of the atoms, summed over all ligand and receptor atoms. When compared 
to modern scoring functions (such as those described in section 1.3.1.2 for GOLD), this is 
highly simplistic but the best compromise considering the limited computing power at 
the time. 
From this point onward progress was swift. DOCKER,31 a program from Blundell 
group, is a manual polypeptide-protein docking program which, though manual, allows 
for two molecules up to 400 atoms in size, one of which can be flexible, with real-time 
movement. The algorithm calculates van der Waals and accessible surface areas, with an 
interaction calculation and energy minimisation to a local minimum within the 
calculated energy. Though not widely applied, it does represent the first program of note 
for such a purpose. 
 In 1983 Connolly22 published a method of calculating the solvent accessible 
surface of a macromolecule. The Connolly method uses a probe sphere which represents 
a solvent molecule, and the algorithm positions this “solvent molecule” tangentially to all 
protein atoms at thousands of positions; each “solvent molecule” which does not overlap 
van der Waals radii with a protein atom identifies a point on a solvent-accessible grid-
point map of the surface. The area and co-ordinates of the resulting points are calculated 
to give a continuous surface which can be displayed in the molecular viewer in three-
dimensions in real-time. It allowed areas and volumes to be calculated and, as it did not 
rely on atomistic wire-mesh or space-fill models, it was faster and showed only those 
surfaces of relevance for docking. 
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Work by DesJarlais et al.32 in 1986 built on early versions of DOCK by introducing some 
limited flexibility of substrate. By splitting the ligand into smaller, rigid fragments to be 
docked separately and rejoining the fragments later in the docking process for energy 
minimisation, geometries which “may not have been found” by manual docking were 
found, and were close to the original test-case X-ray crystal structures used. Crucially, 
the matching of ligand to receptor site was by shape complementarity, a method 
DesJarlais et al. expanded upon in a later paper.24 
 Shape complementarity was an extension of the sphere-based geometric 
mapping described above, by which the spheres are used to generate a surface which 
describes the ligand shape and the receptor shape, and these are matched. For rigid 
molecules, this allowed much faster computation, and DOCK introduced a new scoring 
function to reward good contacts (ideal van der Waals distances) and penalise poor 
contacts (violating van der Waals distances).24 Eventually, this expanded to include non-
bonded terms from an AMBER force field33 to simulate electrostatic as well as shape 
complementarity; this would provide a more robust scoring function which could be 
used to select molecules from a database for testing.25 
Finally, the first version of DOCK was made publically available in 1989, although 
the paper was not published until three years later to coincide with the improved 2.0 
release.25 This program was the first of its kind and was the culmination of almost a 
decade of development. 
 
1.2.2.2 The 1990s: Honing Docking Algorithms 
Moore’s Law derives from an observation made by Gordon E. Moore,34 head of the Intel 
Corporation, in 1965; he noted that the number of transistors on a dense integrated 
circuit (such as those found in computer hardware) double every two years. This has 
since been a self-fulfilling prophecy, as it is both true and used as a design guideline in 
industry. In a simpler form, it means that computer processing power doubles every two 
years, and this also holds true. In 1989, the Intel 489 processor had 1.2 million 
transistors and a speed of 25 MHz; by 1999, the Intel Pentium III processor used 28 
million transistors and had a speed of 733 MHz. This exponential increase in computing 
power through the 1990s allowed great strides forward in docking algorithms, and the 
main question to be answered was how to treat a ligand as flexible and retain tractable 
speeds for screening large databases.  Multiple methods grew from the DOCK 
implementation, and some key developments in ligand flexibility and novel docking 
algorithm approaches will be discussed here. 
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The previous work by DesJarlais et al.32 on fragmental approaches to ligand flexibility 
(detailed above) was a starting point for incremental methods, published by Leach and 
Kuntz in 1992.35 Their method, dubbed “Directed DOCK” utilises an anchor fragment – a 
portion of the molecule which has the least conformational flexibility – and the 
assumption is made that ligands will preferentially adopt low energy conformations. 
Multiple orientations are generated for the anchor through a conformational search, the 
results of which are pruned and clustered, and then representatives from each cluster 
form the centre-point of the systematic conformational exploration of the rest of the 
molecule. This method was later implemented in FlexX.36 
 The Directed DOCK method still considered the protein to be completely rigid, 
however Leach went on to describe a method of introducing some flexibility to the 
receptor in 1994,37 by which the protein backbone remains rigid but side chains can 
adopt positions from library of conformers derived from observed orientations in 
protein crystal structures.  
 Two key programs were made available in the 1990s, which are widely used two 
decades later: these are GOLD and FlexX, and they utilise different approaches to the 
docking problem. FlexX implements an incremental approach, based on the work by 
Leach and Kuntz described above. 
 GOLD utilises a genetic algorithm,38,39 which is a non-deterministic approach to 
docking. This means that despite identical starting points and as the conformations go 
through a combinatorial optimisation, the docking process is random and the results will 
never by definition be identical. This is achieved by encoding rotatable bond torsion 
angles in 8 byte strings, and concatenation of these strings correspond to a conformation 
of the molecule. A randomly generated initial population of these strings (ie. 
conformations) undergo various types of alteration – by swapping substrings 
(crossover) or switching bit values to their opposite number (mutation) – and are 
scored.40 This is discussed in greater detail in section 1.3.1 with relevance to the GOLD 
implementation.  
 In contrast to GOLD, FlexX36,41 is based on the Directed DOCK35 approach with a 
scoring function derived from a de novo design software, LUDI.42 LUDI addressed the 
conformational flexibility problems of the 1980s development by using a library of 
fragments, placed and scored in an active site, which was mapped for interactions using 
non-bonding contact information from the Cambridge Structural Database (CSD).43 By 
this method, LUDI would generate completely novel compounds from its fragment and 
bridging molecule library. FlexX36 combined the incremental methods35 with the scoring 
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from LUDI42 and added conformational searching with torsional preferences determined 
by observations from the CSD. 
By the mid-1990s, flexible ligand docking was feasible, and could be achieved by 
multiple methods across a range of programs. It was now possible to screen libraries of 
compounds (and given the growing computer processing power, without 
supercomputer access) and some limited protein flexibility was possible. To bridge the 
gap between flexible side-chains with a rigid backbone, and with full molecular dynamics 
simulations, Knegtel et al.44 introduced ensemble docking in 1997 as a method of 
representing dynamic protein movement and conferring a kind of receptor flexibility.  
 Knegtel et al. noted that, with multiple co-crystal structures of different ligands 
with the same receptor, there could be sometimes seen “modest but significant” changes 
in conformation; and, though a limited number of models could not represent the full 
range of conformational space available to a protein in solution, could provide a better 
model for ligand discovery.44 
Two methods of utilising protein ensembles were suggested for use in DOCK 3.5: 
an “energy-weighted” method, and a “geometry-weighted” method.44 The “energy-
weighted” method of ensemble docking calculates the interaction energies for every 
atom of each protein structure, and a weighted potential is calculated from this to 
average over all macromolecule structures. Attractive potentials are given priority over 
repulsive potentials, unless the repulsive potential is present in all structures; this 
method allows for small local variations. Contrastingly, the “geometry-weighted” 
method calculates the mean position and a variance for every atom over all structures, 
allowing greater flexibility and allowing ligands to take advantage of greater site 
plasticity, but this method gives higher ambiguity in the effects of binding on the protein 
structure. 
 The ensemble docking method gave the option in docking to avoid the 
“computationally demanding” task of free energy calculations on fully flexible protein-
ligand complexes with explicit solvent (ie. molecular dynamics) and instead take 
advantage of multiple experimental crystal structures of receptor structures.  
 
1.2.2.3 Post Millennium: Towards A Realistic Model 
Prior to 2000, docking strategies typically consisted of a flexible ligand and a largely rigid 
protein, perhaps with a co-factor which was considered part of the protein model, but 
little else. Ensemble docking44–46 had been introduced but was as yet undeveloped as a 
method of representing protein dynamics, and factors such as water and covalent adduct 
formation were not common-place implementations. As computational power continued 
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its upward trajectory, attention shifted from pose generation algorithms (which were 
fairly well-honed thanks to the 1990s) and onto the task of more accurately simulating 
the protein environment. 
Over ten years since the first docking program DOCK was released, DOCK 4.030 
implemented flexible docking by incremental methods (like FlexX) and random search  
approaches. Alternatively, another program DARWIN47 utilised CHARMM48 force fields 
as a scoring function along with a genetic algorithm for conformational optimisation (see 
section 1.3.1.3 for discussion of scoring functions). With desktop units housing 
increasing computational processing power, a variety of programs and methods were 
being developed and implemented all over the scientific community. In 2004, another 
widely used program Glide49 was developed which uses an initial approximation of the 
binding orientation to narrow down docking candidates; this is followed by a refinement 
using random sampling.  
Water molecules can play significant and essential roles in binding. To utilise 
water molecules in molecular docking, a variety of methods have been implemented. For 
example, FlexX36 determines favourable potential water positions in the binding site 
during a pre-processing phase of the docking experiment;50 then, during the incremental 
docking, water molecules in these putative positions are evaluated for the ability to form 
hydrogen bonds with the ligand. Any inclusion of water is used to further optimise the 
ligand position.  
Alternatively, GOLD51 implemented water models which (contrary to FlexX) are 
fully rotatable, can be bound or displaced, and if displaced then confer a reward in the 
scoring function (equation 1.4.)52 The original fitness (σo, discussed in section 1.3.1.3) is 
altered by a summation over all atoms (ligand, protein and other waters) which interact 
with each specific water molecule in binding. The summation term utilises the occupancy 
of the water (o(w) is either 1, and on, or 0, and off) the intrinsic binding affinity of water, 
σi(w); and an energy penalty, as movement of water incurs a loss of entropy as a rigid-
body (σp). 
 
Fitness =  𝜎𝑜 + ∑ 𝑜(𝑤)(𝜎𝑝 +  𝜎𝑖(𝑤))
𝑤
 
Equation 1.4: The original fitness function (σo) is altered by the summation over all ligand, protein 
and other waters the water molecule interacts with. GOLD’s fitness functions are discussed in 
section 1.3.1.3.52 
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The authors conclude in their validation of GOLD’s water implementation that including 
water molecules where relevant could improve docking score correlations with 
experimental affinities.52 
 Two highly comprehensive reviews in 200553,54 demonstrated that with the 
plethora of docking programs available, it had become difficult, though necessary, to 
compare methodologies and performance. Mohan et al.54 stress the importance of 
understanding the strengths, approximations and limitations of docking software. The 
need for standardised test data was highlighted, as well by Cole et al.,53 and this need was 
later addressed by the CCDC/Astex set55 and the DUD set (directory of useful decoys). 
Decoys will be discussed in more detail in chapter four.56  
 As a final point in the cherry-picking of post-millennial developments in docking, 
Durrant and McCammon57 described in 2011 the growing role of molecular dynamics in 
drug discovery. Though not yet feasible for database virtual screening, molecular 
dynamics are now a powerful technique for identifying allosteric binding sites and 
enhancing docking methodologies (for example for simulating hits from initial virtual 
screens) with atomistic models including explicit solvent. However, even simulations of 
100 ns take weeks on a multi-processor machine; powerful as molecular dynamics 
simulations are, they are far from a reasonable solution as yet. 
Despite over three decades of development, at the end of the 2000s the “docking 
problem” remains; our ability to predict binding modes of molecules hinges not on our 
computational power, but on our fundamental knowledge of how proteins and ligands 
interact. We have ensemble docking and some modelling of flexible loop movements to 
bridge the gap between a rigid or semi-rigid protein model and full molecular dynamics 
simulations, and under replicative test conditions, the most popular docking programs 
(FlexX,36 Glide, and GOLD51) are able to replicate binding modes and have been utilised 
in the identification of various small molecule inhibitors.58–67 The problem resoundingly 
lies with the ability of these programs to predict the energy of binding; though in silico 
screening is (in terms of the scientific method) experimental, the results are only a model 
of the system and therefore must be tested in vitro using biophysical methods. 
 
1.3 Docking and Chemoinformatic Software in SBDD 
Many computational packages and strategies have been given as examples in the 
previous section. Here, software used in the course of the work presented in this thesis 
will be discussed in detail. 
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1.3.1 Docking and Virtual Screening: GOLD 
1.3.1.1 The Genetic Algorithm 
The problem of sampling the astronomical search spaces in docking have been touched 
upon, as well as strategies for finding global minima. Genetic algorithms (GAs) have 
already been mentioned in this chapter as one such strategy, explained as using 
concatenated 8-byte strings representing torsions of rotatable bonds, which undergo 
certain alterations to increase diversity and avoid local minima. Here, the GOLD 
implementation is described in greater detail.38–40,68 
To begin, each conformation of the ligand (each concatenated 8-byte string) is 
designated a chromosome, and is therefore also a docking pose. This pose is not only the 
conformation but the position (x, y, z) of the molecule. An initial population of 
chromosomes (collection of concatenated strings) is created at random, and these are 
scored and ranked according to the chosen fitness function parameters.38  
 Populations in GOLD are arranged on “islands”; the default settings distribute 
populations of 100 chromosomes on each of the five islands. Therefore, GOLD creates an 
initial cohort of 500 ligand conformations in strings. The use of islands prevents 
conversion on any one conformation too early, as one of the possible genetic operators 
is migration of chromosomes between islands; strings can be transferred wholly from 
one cohort to another. 
As in nature, selection pressures favour the fitter members of the population, 
which is maintained at 500 conformations. The selection pressure parameter in GOLD is 
the ratio of the likelihood of a fit chromosome to be chosen over an average chromosome, 
to become a parent chromosome.68 As a default, this is set to 1.1, therefore the better 
scoring child pose is more likely to replace an average one in the parent population. 
Niches describe the similarity between chromosomes; two individual 
chromosomes share a niche if their donor and acceptor atom co-ordinates are within a 
root mean square deviation (RMSD) of 1.0 Å. GOLD controls niche sizes to prevent 
convergence and increase diversity within the population. Therefore, if the number of 
individuals in a niche exceeds the parameter ‘nichesize’, a suitably higher scoring child 
chromosome will replace the least fit chromosome in that over-filled niche, rather than 
the least fit chromosome in the entire population. The default value of nichesize in GOLD 
is set at 2. Overall, this means the initial population is of 500 individuals in populations 
of 100 to each of the five islands, and largest niche contains two chromosomes within 1.0 
Å similarity. 
The GOLD genetic algorithm contains three specific operators (figure 1.2) which 
dictate the change in the chromosome drawn from the population: mutation, crossover, 
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and migration. Which operator is used and how frequently depends on the weights 
assigned to them, determining which is selected as though on a ‘roulette wheel’. In GOLD, 
mutation and crossover have weights of 95 and migration has a weight of 15 as 
determined from the development of the algorithm; this means mutation and crossover 
are equally likely to be picked as the operator, but both are vastly more likely than 
migration. 
 
Figure 1.2: Examples of the three genetic operations, migration (movement between islands), crossover 
(swapping parts of strings encoding poses), and mutation (direct change of string). 
 
Migration has already been explained as the movement of chromosomes between 
islands; if this scores higher than a chromosome in the population of the new island, it 
replaces the least fit. If the migrated chromosome is not fitter than any in the new island, 
it is discarded. Migration converges different populations on higher scoring poses. 
 Crossover works much as the natural counterpart. As the poses are encoded in 
strings, the crossover operator exchanges substrings to create a new child chromosome. 
Similarly, mutation introduces random changes to the parent chromosome by swapping 
the bit values for their opposite number (0 to 1 and 1 to 0). Both crossover and mutation 
increase diversity in the population as they will essentially swap or change randomly the 
conformation of a pose, allowing the rapid generation and scoring of a vast number of 
potential ligand conformations. These conformations eventually converge in a run to 
give just one result. 
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1.3.1.2 Anatomy of a GOLD Run 
The number of GA operations is distinct to the number of GA runs: for example 100,000 
operations such as migration or mutation will be conducted in one run, giving one pose. 
A docking experiment could conduct 10 GA runs, giving 10 poses. Schematic figure 1.3 
demonstrates the typical process. 
Each run consists of a number of operations, and GOLD will use information such 
as the number of rotatable bonds and the ligand flexibility to determine how many GA 
operations are required for optimal search and speed. Then, if search efficiency is 
selected to be 100%, GOLD will set up the optimal number of operations. In GOLD’s 
virtual screening settings, this is reduced to 30%, which improves speed in an attempt 
to get a good answer, while compromising slightly on exhaustive accuracy.  
 The user is required to specify termination conditions when running a docking, 
and whichever is satisfied first will end the runs; these are early termination and diverse 
solutions. Early termination will stop the runs when a user-defined number of solutions 
have been found within a user-defined RMSD; for example 5 solutions within 1.5 Å of 
each other. Even if ten runs have been instructed, if five solutions are found, the docking 
will end. However, early termination can be misleading, as the poses may not represent 
the true global minimum. In virtual screening it is better to acquire an understanding of 
the range of possible binding poses of the ligand to the binding site, making early 
termination unfavourable. 
The diverse solutions option, in contrast, will end the docking when a user-
defined number of solutions within a cluster have been found, and this cluster will have 
an internal RMSD consensus; for example, 3 solutions to a cluster where all solutions are 
within 1.5 Å. The diverse solutions setting allows for a wider range of potential poses, but 
will take longer in run-time. 
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Figure 1.3: Schematic flowchart of the GOLD genetic algorithm. 
 
  1.3.1.3 Scoring: GOLD Fitness Functions 
GOLD offers four fitness functions for the user to choose from when docking; a force-field 
function (GoldScore), one is knowledge-based (ASP), and two are empirical scoring 
functions (Chemscore and CHEMPLP).  
Force-field functions assume binding is due to a sum of individual parameter 
scores and these parameters are themselves individual subsystems; for example, the 
internal torsional energy term would have no effect on the internal Van Der Waals (VdW) 
term, despite the torsion of the ligand influencing internal attractions and repulsions.68  
Knowledge-based fitness functions use databases of known protein-ligand 
complexes, using the frequency of observations of an interaction to score the posed 
ligand interactions in context. Contrastingly, empirical functions use protein-ligand 
structures with corresponding binding affinity data create a scale factor, which is then 
used on the estimated total free energy. These functions are typically trained by 
regression to correlate scoring value with binding affinity, making them a prime choice 
for virtual screening. 
Though each fitness function has a particular strength, it is the empirical function 
CHEMPLP which has been the default function in GOLD for versions 5.0 and later.  Here, 
each of the four functions will be briefly described, with detail for CHEMPLP to highlight 
why it is the favoured fitness function for virtual screening and lead optimisation on 
EthR.  
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GoldScore 
GoldScore is, as previously stated, a force-field fitness function. The GoldScore function 
has been optimised for ligand binding position, rather than for ligand binding affinity, 
making GoldScore inappropriate for predicting strongly binding ligands or binding 
constants (unpublished results, CCDC). GoldScore was not used as a scoring function in 
this work, and so will be only briefly summarised. At its simplest, GoldScore sums four 
component energy terms: external VdW energy, internal VdW energy, intermolecular 
hydrogen bond energy and internal torsional energy. Additional components from 
constrained values can be used, eg. for hydrogen bond contacts. For values such as 
hydrogen bond energies and atomic radii, empirically derived values are used which are 
standard to all GOLD fitness functions. The fitness score given for the pose is a negative 
sum of the component energy terms, with the external VdW term multiplied by 1.375 to 
encourage hydrophobic contacts between the ligand and the protein. 
 
ASP: Astex Statistical Potential 
As a knowledge-based fitness function, ASP uses a database of known complexes to 
derive atom-atom potentials. Interactions between specific ligand and protein atoms are 
scored based upon the frequency of their observation in the database set, a set which is 
typically derived from the PDB. The key advantage of ASP is that it can be targeted to 
certain protein classes, such as kinases, by changing the database from which the 
potentials are derived. In this situation, ligands which bind the receptor and make 
contacts seen in other kinases would score highly, making ASP customisable. However, 
when not tailored, the ASP effectively takes potentials from a set representative of the 
entire PDB, and in that case has accuracy comparable to GoldScore and ChemScore. 
 
ChemScore 
ChemScore is an empirical function derived from 82 protein-ligand complexes for which 
binding affinity data is available.68,69 This particular function estimates the total free 
energy change based on physical contributions from hydrogen bonding, metal binding, 
lipophilic interactions and rotational energy, each with a scale factor derived from linear 
regression of the empirical data. The final ChemScore term includes clash and torsional 
penalties to discourage close contacts and strain in the ligand conformations. The 
ChemScore scoring function is therefore scaled by linear regression against known 
binding affinities to give a correlation between molecular recognition, high scores and 
predicted high binding affinity. The following breakdown of the ChemScore function is 
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taken from two papers by Eldridge et al.70 and Baxter et al.,69 as well as the GOLD 5.2 user 
guide.68  
 ChemScore estimates the change in total free energy according to equation 1.5, 
where each term is a product of a physical contribution to binding multiplied by the 
regression co-efficient (equation 1.6). To achieve the final ChemScore value, clash 
penalty and internal torsion terms are included to penalise close contacts and poor 
ligand conformations (equation 1.7). 
 
∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =  ∆𝐺0 + ∆𝐺ℎ𝑏𝑜𝑛𝑑 +  ∆𝐺𝑚𝑒𝑡𝑎𝑙 +  ∆𝐺𝑙𝑖𝑝𝑜 + ∆𝐺𝑟𝑜𝑡 
 
Equation 1.5: The estimation of free energy change upon binding, where each term is a product defined by 
equation 1.6. 
 
 
 
 
∆𝐺0 =  𝑣0 
∆𝐺ℎ𝑏𝑜𝑛𝑑 =  𝑣1𝑃ℎ𝑏𝑜𝑛𝑑 
∆𝐺𝑚𝑒𝑡𝑎𝑙 =  𝑣2𝑃𝑚𝑒𝑡𝑎𝑙 
∆𝐺𝑙𝑖𝑝𝑜 =  𝑣3𝑃𝑙𝑖𝑝𝑜 
∆𝐺𝑟𝑜𝑡 =  𝑣2𝑃𝑟𝑜𝑡 
 
Equation 1.6: The breakdown in terms of equation 1.4, where each energy contribution is a physical term 
(P, discussed in detail below) scaled by a factor determined by regression on protein-ligand structures (v). 
 
𝐶ℎ𝑒𝑚𝑆𝑐𝑜𝑟𝑒 =  ∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔 + 𝑃𝑐𝑙𝑎𝑠ℎ +  𝑐𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑃𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙
+ (𝑐𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡𝑃𝑐𝑜𝑣𝑎𝑙𝑒𝑛𝑡 +  𝑃𝑐𝑜𝑛𝑠𝑡𝑟𝑎𝑖𝑛𝑡) 
 
Equation 1.7: The ChemScore value is a combination of equation 1.4, plus clash and internal torsion terms. 
If covalent docking and/or docking constraints are used, additional terms in brackets are utilised. 
 
To aid in scoring contacts, ChemScore uses block functions, which utilise an ideal and a 
maximum allowed value for a contact (such as a hydrogen bond, metal bond, or lipophilic 
interaction) and reduces the score contribution for deviations from the ideal (scoring 
1.0) to the maximum (scoring 0.0). The block function (B) takes the form shown in 
equation 1.8, which is shown graphically in figure 1.4. This function is sometimes 
smoothed using a Gaussian function to give the graphical form shown in figure 1.4 
(equation not shown). 
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𝐵 (𝑥, 𝑥𝑖𝑑𝑒𝑎𝑙 , 𝑥𝑚𝑎𝑥) =  {
1 if 𝑥 ≤  𝑥𝑖𝑑𝑒𝑎𝑙
1.0 −  
𝑥 −  𝑥𝑖𝑑𝑒𝑎𝑙
𝑥𝑚𝑎𝑥 − 𝑥𝑖𝑑𝑒𝑎𝑙
 if 𝑥𝑖𝑑𝑒𝑎𝑙 ≤ 𝑥 ≤ 𝑥𝑚𝑎𝑥
0 if 𝑥 >  𝑥𝑚𝑎𝑥
} 
 
Equation 1.8: The block function allows ChemScore to scale contacts which are not ideal. The function B is 
applied to the P terms in the fitness function (equation 1.9). 
 
Figure 1.4: Graphical representation of the block function shown in equation 1.8 (left) and after Gaussian 
smoothing (right).37,38 
  
Some of the individual terms will now be discussed, including the metal binding terms, 
clash and torsion terms, and lipophilic contact terms. Firstly, the hydrogen bond terms 
are computed over all potential donor-acceptor pairs and each term in summation – 
distance, angle and directionality – utilises the smoothed block functions above; this 
reduces the hydrogen bond contribution depending on deviation from the ideal values. 
This means a hydrogen bond of ideal geometry - with ideal hydrogen-acceptor distance, 
ideal D-H···A angle, and ideal directionality - would have a value of 1.0. There is no 
distinction between ionic and non-ionic hydrogen bonds, and water molecules are treat 
as part of the receptor. 
 The ChemScore parameters have various default figures for these ideal values. 
For distance, for example, the ideal distance between the donor hydrogen atom and the 
acceptor atom is 1.85 Å, with a tolerance for remaining ideal of 0.25 Å; therefore a 
hydrogen bond of ideal distance is 1.6 – 2.1 Å. However, the maximum deviation is 
0.65_Å, and so a hydrogen bond will score 0.0 at 2.5 Å and beyond. 
 Similarly, for the hydrogen bond angle of D-H···A, the ideal angle is 180°, with a 
tolerance of 30°, and as such the ideal range begins at 150°. Hydrogen bonds with heavy 
atoms (D-H···A-X) have a larger tolerance of 70°. The maximum deviation is 100° and so 
an interaction of hydrogen with an acceptor with an angle smaller than 100° is not, 
strictly speaking, regarded as a hydrogen bond. This large tolerance will be discussed 
again in chapter five, as it becomes relevant to filtering on protein-ligand hydrogen 
bonds after virtual screening. The hydrogen bond co-efficient (v1, in equation 1.6) is set 
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to -3.34 as default, determined from Eldridge et al.’s development using the 82 complex 
training set for ChemScore.70 
 Metal binding terms are treat similarly to hydrogen bonds, in that they are 
calculated over all possible pairs, and the acceptor is a ligand ion capable of metal 
binding. Equation 1.9 shows the summation, in which all terms are subject to the 
Gaussian-smoothed block function (B) described previously with a Gaussian smearing 
sigma value (σ). The ideal distance is 2.6 Å, with 3.0 Å as the allowed maximum binding 
interaction. The associated regression-determined co-efficient, to bring the calculated 
values in line with the observed values from the training set, is set as -6.03 as determined 
by Eldridge et al..70  
 
𝑃𝑚𝑒𝑡𝑎𝑙 =  ∑ ∑ 𝐵(𝑟𝑎𝑀 , 𝑅𝑖𝑑𝑒𝑎𝑙 , 𝑅𝑚𝑎𝑥, 𝜎𝑚𝑒𝑡𝑎𝑙)
𝐴𝑙𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑚𝑒𝑡𝑎𝑙𝑠
𝐴𝑙𝑙 𝑙𝑖𝑔𝑎𝑛𝑑
𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟𝑠
 
∆𝐺𝑚𝑒𝑡𝑎𝑙 =  𝑣2 𝑃𝑚𝑒𝑡𝑎𝑙 
 
Equation 1.9: The metal-binding term ΔGmetal utilises the regression co-efficient v2, and the physical 
contribution P, which sums over all ligand and metal ions with a Gaussian smoothed block function, B. 
Term raM represents the actual distance, with the ideal and maximum R distances given. 
 
The lipophilic interaction takes a similar form, though the actual distance of lipophilic 
interactions is calculated per atom pair and given as rll. The ideal atom-atom distance is 
4.1 Å by default, with a maximum separation of 7.1 Å. The coefficient v3 is -0.117 as 
default.70 The rotatable bond, clash penalty and torsion terms take different forms to 
define their physical (P) contribution to binding.  
 The rotatable bond term is used to approximate the loss in entropy which would 
be incurred by a single, acyclic bond becoming non-rotatable upon binding. This was 
implemented as Eldridge et al. found that a simple count of those rotatable bonds which 
became frozen was unreliable for estimating the contribution of flexibility, and changes 
in the composition of the training set would cause wide variations in the coefficients 
required. Their solution was a more complex term (equation 1.10) but a more stable one 
across the data; Eldridge et al. do concede, however, that the term is not “particularly 
satisfactory” in estimating the actual entropic penalty due to the approximations 
involved and restricting the definition to effects on rotatable bonds and flexibility 
without consideration of solvation effects or lipophilic interactions.70 
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𝑃𝑟𝑜𝑡 = 1 + (1 − 
1
𝑁𝑟𝑜𝑡
) ∑
(𝑃𝑛𝑙(𝑟) +  𝑃
′
𝑛𝑙(𝑟))
2
𝑟
 
Equation 1.10: The rotatable-bond freezing term of ChemScore utilises the number of rotatable bonds 
(Nrot) in the ligand and the percentages of non-hydrogen atoms on either side of the rotatable bond that are 
not lipophilic. 
 
The regression coefficent associated with the rotatable bond term has the default value 
in the ChemScore parameter file of 2.56. 
There are three clash terms for different, previously described, interactions: one for 
hydrogen bonds, one for metal interactions, and a third for all other ligand protein 
interactions.69 The purpose of the clash terms, in conjunction with the internal torsion 
term, is to prevent poor geometries in docking. Above, distances for interactions were 
given as ideal and maxima; the clash terms come into play when distances are shorter 
than the ideal. There are two values of rclash: for contacts to protein sulphur atoms, the 
ideal distance is 3.35 Å, for all other contacts the ideal is 3.10 Å;69 the ideal values for 
metal and hydrogen bond interaction distances have already been given. The three 
equations for hydrogen bond, metal interaction and ‘other’ clash terms are given below 
as equations 1.11, 1.12 and 1.13 respectively. 
 
𝑃𝑐𝑙𝑎𝑠ℎ−ℎ𝑏𝑜𝑛𝑑 =  
20.0 × (𝑟ℎ𝑏𝑜𝑛𝑑 − 𝑟)
∆𝐺ℎ𝑏𝑜𝑛𝑑  × 𝑟ℎ𝑏𝑜𝑛𝑑
 
 
Equation 1.11: The hydrogen bond clash term for the interactions with a distance shorter than rhbond. The 
value of 20.0 is an empirically-derived weighting term to notably penalise the overall score value. Without 
the weighting term, values of Pclash would be too small to impact the fitness in a discriminatory way. 
 
𝑃𝑐𝑙𝑎𝑠ℎ−𝑚𝑒𝑡𝑎𝑙 =  
20.0 × (𝑟𝑚𝑒𝑡𝑎𝑙 − 𝑟)
∆𝐺𝑚𝑒𝑡𝑎𝑙  × 𝑟𝑚𝑒𝑡𝑎𝑙
 
 
Equation 1.12: The metal interaction clash term for the interactions with a distance shorter than the ideal. 
 
𝑃𝑐𝑙𝑎𝑠ℎ−𝑜𝑡ℎ𝑒𝑟 = 1.0 +  
4.0 × (𝑟𝑐𝑙𝑎𝑠ℎ − 𝑟)
𝑟𝑐𝑙𝑎𝑠ℎ
 
 
Equation 1.13: The other clash term, for which the ideal distance varies depending on the contact type. 
The weighting term here is smaller to allow for some close non-polar contacts but performs the same role 
as in the other clash terms. 
 
The internal ligand torsion term uses pairs of atoms in rotatable bonds and their 
hybridisation states, along with clash terms to approximate ligand energy. The torsion 
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term is given as equation 1.14 below, where A, n and Φ vary for sp3-sp3, sp3-sp2 and sp2-
sp2 bonds.69 
𝑃𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 =  ∑ 𝐴𝑖
𝐴𝑙𝑙 𝑟𝑜𝑡𝑎𝑡𝑎𝑏𝑙𝑒
𝑏𝑜𝑛𝑑𝑠
(1 − cos (𝑛Φ − Φ0) 
 
Equation 1.14: The internal ligand torsion term depends upon the bond type for values of A, n and Phi. 
 
Finally, terms for covalent bonding adapt the already described terms by (a) reducing 
the clash term, (b) adding torsion terms for the rotatable part of the protein-ligand 
covalent bond, and (c) adding a valence-angle bending term to penalise poor covalent 
linkage geometries.  
All values discussed here are part of the ChemScore parameters file, which can be 
customised by editing the text file and instructing GOLD to use the altered version. 
However, all default terms were derived from extensive parameterisation by the 
program developers and as such rarely require changes; in the course of this work, no 
changes were made to these defaults. 
 
CHEMPLP 
CHEMPLP, derived from the piecewise linear potential (PLP) and select bonding terms 
from ChemScore, is the default scoring function in GOLD.68,71 Like ChemScore, CHEMPLP 
is an empirical function (equation 1.15).  
 
𝑓𝑖𝑡𝑛𝑒𝑠𝑠𝑃𝐿𝑃 =  −(𝑤𝑃𝐿𝑃 ∙ 𝑓𝑃𝐿𝑃 +  𝑤𝑙𝑖𝑔−𝑐𝑙𝑎𝑠ℎ ∙ 𝑓𝑙𝑖𝑔−𝑐𝑙𝑎𝑠ℎ +  𝑤𝑙𝑖𝑔−𝑡𝑜𝑟𝑠 ∙ 𝑓𝑙𝑖𝑔−𝑡𝑜𝑟𝑠 +  𝑓𝑐ℎ𝑒𝑚−𝑐𝑜𝑣
+  𝑤𝑝𝑟𝑜𝑡 ∙ 𝑓𝑐ℎ𝑒𝑚−𝑝𝑟𝑜𝑡 + 𝑤𝑐𝑜𝑛𝑠 ∙ 𝑓𝑐𝑜𝑛𝑠)  
𝑓𝑖𝑡𝑛𝑒𝑠𝑠𝐶𝐻𝐸𝑀𝑃𝐿𝑃 = 𝑓𝑖𝑡𝑛𝑒𝑠𝑠𝑃𝐿𝑃 − (𝑓𝑐ℎ𝑒𝑚−ℎ𝑏 +  𝑓𝑐ℎ𝑒𝑚−𝑐ℎ𝑜 +  𝑓𝑐ℎ𝑒𝑚−𝑚𝑒𝑡) 
 
Equation 1.15: GOLD’s CHEMPLP scoring function utilises the PLP fitness, adjusted with ChemScore 
terms. PLP is used to model steric complementarity between the protein and the ligand; lig-clash is a 
heavy-atom clash penalty; lig-tors is a ligand torsion potential; cons handles constant contributions. Other 
terms (chem-cov for covalent docking and chem-prot for flexible side chains and waters) are included as 
necessary. Terms from ChemScore (hydrogen bonding, CHO intereactions and metal bonding) add 
additional scoring terms. 
 
The PLP terms determine the steric complementarity between the ligand and the 
protein, using simple atom type designations: donor, acceptor, donor/acceptor, nonpolar, 
and metal. The interactions between protein and ligand atom types are then 
characterised according to table 1.1. 
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Table 1.1: PLP interaction types in the CHEMPLP scoring function. 
 protein atom type 
ligand atom type donor acceptor don./acc. nonpolar metal 
donor repulsive hydrogen 
bond 
hydrogen 
bond 
buried repulsive 
acceptor hydrogen 
bond 
repulsive hydrogen 
bond 
buried metal 
donor/acceptor hydrogen 
bond 
hydrogen 
bond 
hydrogen 
bond 
buried metal 
nonpolar buried buried buried nonpolar buried 
 
Interactions between protein and ligand, as defined in table 1.1, depend on the type of 
atom. Metal atoms chelate only acceptors and atoms capable of acting as acceptors (or 
donors, ie. don./acc), and hydrophobic interactions can occur between two nonpolar 
atoms; however, polar atoms are typically buried by nonpolar atoms. Hydrogen bonds 
occur between two oppositely polar atoms, otherwise repulsion occurs. 
 CHEMPLP utilises ChemScore terms for hydrogen and metal bonds, and 
additionally terms for internal clash and torsional potentials, all described previously. A 
term is added in the presence of C-H donors, which can interact with oxygen acceptor 
atoms – this is the CHO potential. Terms can be added to CHEMPLP for covalent docking, 
flexible side chains and water molecules in addition to restraints (such as on hydrogen 
bond formations), making CHEMPLP highly customisable. 
 CHEMPLP was evaluated against the other fitness functions in GOLD and shown 
to be fastest - slightly faster than ChemScore on average docking times - and more 
successful in reproducing known binding conformations in a 298-complex test set within 
2 Å: ChemScore up to 67%, GOLDScore up to 79% and CHEMPLP to 87%.68,71 Overall, and 
across various speed and accuracy scenarios, CHEMPLP outperformed ChemScore and 
GOLDScore with notably higher success rates at lower average search times, and so was 
implemented as GOLD’s default function.51 
 
1.3.1.4 GOLD Optional Docking Constraints 
GOLD is able to constrain various features, including distances, hydrophobic regions, and 
hydrogen bond constraints, depending upon the docking required  
There are two kinds of hydrogen bond constraints, one which specifies both 
ligand and protein atoms, and one that specifies only a protein donor atom. The former 
‘Protein HBond’ setting is not suitable for virtual screening, but the latter ‘Hydrogen 
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Bond Constraint’ allows ligands which make a favourable interaction to score more 
highly. The constraint itself is incorporated into the fitness function, with a user-defined 
minimum geometry weight score, which determines how good the interaction has to be 
to be considered a hydrogen bond between 0 and 1. This is defaulted at 0.005, meaning 
even weak hydrogen bonds are considered. A constraint weight is also used to penalise 
poses which do not form the hydrogen bond; this is deducted from the fitness score. 
 
1.3.1.5 Protein and Ligand Flexibility in GOLD 
Even at a basic level, GOLD does not treat the protein as completely rigid; this is a 
distinction from other software for docking such as Autodock Vina72 and FlexX.36 Though 
GOLD offers the possibility to enable flexible side chains, dock into multiple crystal 
structures (ensemble docking), or use soft potentials to compute flexible loops, when 
these functions are not in use, some flexibility is applied to the binding pocket regardless. 
Hydroxyl groups on serine, threonine and tyrosine are rotated during docking and 
optimised, maximising hydrogen bonding potential; NH3⁺ groups on lysine residues 
undergo the same treatment.  
 Flexible residues are allowed to undergo torsional rotations, which are distinct 
from the simple hydrogen donor optimisation which happens for Ser, Thr, Tyr and Lys 
residues. Side chains only move around acyclic bonds, and the specific rotamers must be 
defined. Rotamers can be defined by a library of crystallographically observed examples, 
or by defining specific ranges of torsional angle values. A maximum of ten flexible 
residues can be allowed in GOLD, as they increase the search space and computational 
strain. They can increase the number of false-positive results, therefore flexible residues 
should be used sparingly and only with absolute confidence. 
 Two specialised settings allow for more detailed consideration of protein 
flexibility: using soft potentials, and using ensemble docking. The former uses altered 
Van der Waals contributions to account for loop movements; ‘ensemble docking’ docks 
ligands to multiple protein models, which can take into account backbone movements. 
 GOLD does not alter ligand bond lengths or valence angles; this necessitates an 
optimal input model. Similarly, stereochemistry is not altered and therefore all 
stereoisomers should be generated and docked individually. Ideally small-molecule 
crystal structures would be used, however this is not always possible (and for libraries 
not including the CSD, likely impossible). In the course of the docking, the ligand 
conformation is changed to find the steric fit between that and the protein binding 
pocket. GOLD offers various options to fix or rotate certain parts of a molecule, including: 
detecting internal hydrogen bonds (both in the protein and the ligand); matching ring 
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conformations to templates from the CSD for accurate ligand geometries; rotating 
protonated carboxylic acids for donor and acceptor function; flipping cis-trans amide 
bonds and planar nitrogens; and fixing all, terminal, or specific rotatable bonds. This 
gives GOLD a full range of ligand flexibility options for docking. 
 
1.3.2 Chemoinformatics: KNIME 
The size and complexity of available small-molecule databases - such as ZINC which 
contains over 35 million compounds,73 and the CSD43 which contains over 700,000 
crystal structures – would make virtual screening a monumental task of time and 
resources if not for our ability to apply our knowledge of what features constitute a good 
lead, fragment or drug in pre-processing filters. To aid in this, pipelining and data mining 
software has become invaluable.  
KNIME is an open-source data mining and pipelining software.74 In KNIME, nodes 
representing Java scripts are assembled in a user-friendly graphical user interface (GUI), 
into a workflow pipeline which parses data in tables.   
For chemoinformatics, KNIME is especially powerful. Community contributions 
include a plethora of packaged chemistry nodes including CDK,75 RDKit, nodes for the R 
statistical package, and nodes for adding user scripts in MATLAB and Python, among 
others.  
 For enacting on chemical structures 1D, 2D and 3D structures can be read-in to 
KNIME; for 3D structures the most common formats used are SDF or SYBYL MOL2 and, 
when written out from KNIME, additional data can be included in tags within SDF files. 
As the SDF format was used extensively, an annotated example can be found in Appendix 
A, the product of the example pipeline in figure 1.3.  
An example of a KNIME pipeline is show as figure 1.5, in which the structure of 
testosterone is imported in the MOL2 format (previously retrieved by name and 
exported using Avogadro) and metrics for Lipinski Rule-of-Five compliance, XlogP and a 
number of other metrics (under the Molecular Properties node) are calculated. 
Testosterone is then exported in MOL2 format (identical to input) and SDF format, which 
retains calculated properties as additional tags in the file. Not shown are nodes which 
can filter columns and rows, nodes which concatenate tables, and nodes capable of 
complex clustering functions. Where relevant, these will be discussed in detail in context. 
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Figure 1.5: Example KNIME pipeline for chemoinfomatic data calculation. The input MOL2 file is converted 
first to SDF format, then to a proprietary CDK format75 for the calculation of Lipinksi RO5 compliance and 
XLogP in standalone nodes, and a list of different properties in the Molecular Properties node (including 
volume, polar surface area, ALogP, and others). Finally, the table is converted into MOL2 format (which 
does not keep the properties in appended tags) and SDF format (which does). 
 
1.3.3 Chemical Space: Mogul and the CSD 
 The Cambridge Structural Database43,76 is the primary repository for small molecule 
crystal structures (and associated data). Currently containing over 700,000 small 
molecule crystal structures, with nearly 40,000 added annually, the CSD is a peerless 
archive of structural data. This wealth of information can be accessed, mined and applied 
using the CSD’s associated software package; of particular relevance here is the 
knowledge-based library Mogul, which uses the structural data in the CSD to generate 
distributions of preferred molecular geometries. 
 Mogul has many applications, from generating restraint libraries for refining 
crystal structures, to validate conformations of deposited co-crystal ligand structures,77 
and for the design of new leads in drug development programmes. In the course of 
computational protein-ligand modelling Mogul, as a quantitative and rapid method of 
pose-evaluation, can be especially powerful for the assessment of docked ligand 
conformations. 
 
1.4 Implementation of SBDD Techniques 
Virtual screening and docking trace their roots to the early eighties49 and, given how long 
drug discovery and development can take, we are only beginning to see the fruits of those 
labours exiting the clinic.78 Over the last few decades papers and citations of virtual 
screening work has increased exponentially (figure 1.6), showing a field which is still 
refining its approach but beginning to yield some positive results.  
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Figure 1.6: Data compiled from ISI Web of Knowledge. Graph left shows articles published using the term 
“virtual screening” to end of 2014 and graph right shows citations to June 2015 of those articles using the 
same term. Both show a dramatic increase since 1995. 
 
There were some early successes, particularly in the antiviral field, however the drug 
widely accepted to be the first to be derived from structure-based drug design methods 
is the anti-glaucoma drug dorzolamide.79 
Dorzolamide is an inhibitor of carbonic anhydrase, an enzyme discovered in 
1932. In the mid-1980s Merck developed a topically-active carbonic anhydrase inhibitor 
with sub-nanomolar activity, able to reduce fluid secretion in the eye.80 Utilising 
molecular modelling and X-ray crystallography structures, they added lipophilic 
substituents which were able to control steric and energetic problems, resulting in 
dorzolamide (Ki = 0.37 nM). The structure of dorzolamide is given as figure 1.7, and in its 
first year on the market, 1996, it was the most widely prescribed anti-glaucoma product 
in the US. 
 
Figure 1.7: Chemical structure of dorzolamide, an inhibitor of carbonic anhydrase for glaucoma.81 
 
As a topical medicine (utilised in eye-drops),81 and one developed before Lipinski et al.’s 
paper on oral bioavailability rules, it does not conform to the “rule of five”. However, 
what is particularly interesting about dorzolamide is the sulphoxide oxygens form a 
hydrogen bond to a glutamine residue (Gln92) in the binding site (figure 1.8).  
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Figure 1.8: Dorzolamide bound to carbonic anhydrase II (inset), hydrogen bonding with glutamine residue 
and a water molecule, as well as co-ordinating with bound zinc.82 It occupies the same position and is 
oriented similarly to its progenitor compound derived from docking studies.80 
A molecule with this particular feature would, potentially, not be found or developed by 
design in current thinking,13,83 as sulphoxides are poor hydrogen bond acceptors and can 
be metabolically problematic. That stated, dorzolamide was derived from previously-
known and potent inhibitors, and is a topical rather than oral treatment, reducing the 
impact on the liver and so metabolic activity. This perhaps highlights the restrictive 
conventions which have developed over the years in drug development, and which may 
contribute to the overall dissatisfaction with drug development success. 
 Another widely known example is the development of neuraminidase inhibitors 
for the treatment of influenza. The first neuraminidase structure was solved to 2.9 Å in 
1983 by Graeme Laver and colleagues.84 Zanamivir85,86 was extensively prescribed 
during the 2009 H5N1 ‘swine flu’ outbreak as Relenza. Zanamivir mimics a transition 
state of the neuraminidase substrate N-acetylneuraminic acid and was identified using 
GRID, which scores the energy between a functional group probe and a protein, which is 
mapped onto a three-dimensional grid of a particular mesh size (1.0 Å in this case). This 
determined an amino group beneath an aspartate residue (Asp151) to be a key hotspot, 
and a transition state mimic was designed to occupy that site and form a hydrogen bond 
with the amino group.86,87 Co-crystal structures of zanamivir have been published for 
influenza A subtypes N1,88 N2,89 N3,90 N987,91 and influenza B.92 Zanamivir bound to 
neuraminidase subtype 1 from the 2009 H1N1 is shown as figure 1.9.89 
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Figure 1.9: Zanamivir (green) bound to N1 from 2009 H1N189 alongside the original docking poses of  
a, 4-amino-Neu5Ac2en, and b, 4-guanidino-Neu5Ac2en, the derivatives of N-acetylneuraminic acid. 
Docking poses are reproduced from figure 1 of von Itzstein et al.86 
 
Presented here are just two examples where early implementation of structure-based 
drug design yielded drugs for clinical use, without touching upon the plethora of HIV 
successes. To conclude, structure-based drug design by computer-aided methods have 
shown increasing viability, versatility and clinical success. 
 
1.5 Conclusion 
In comparing and contrasting various approaches to docking small molecules to 
proteins, it is clear these techniques can be useful tools for drug discovery. Docking 
studies now utilise algorithms capable of considering ligand flexibility as standard, 
protein flexibility to varying degrees, and essential co-factors and water molecules in the 
search for good scoring poses.  
The techniques and approaches described in this chapter have been 
implemented in a drug discovery project for a qualified protein target EthR from 
Mycobacterium tuberculosis, one of the causative agents of TB. Unlike development of a 
new antibiotic, this project takes advantage of an antibiotic already present on the 
market, and is intended to act as a co-drug with the aforementioned antibiotic to improve 
its efficacy. This work is presented, culminating in multiple hits for optimisation. 
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CHAPTER II: 
ETHR: A VIRTUAL SCREENING TARGET FOR 
TB CO-DRUGS 
Tuberculosis, commonly referred to as TB, is a global health problem which claimed the 
lives of an estimated 1.5 million individuals in 201393 and, though often thought to be a 
relic of the pre-WWII world, it in fact remains second only to HIV as the leading cause of 
death by an infectious disease. TB also presents a growing drug-resistance problem 
worldwide, with 3.5% of the 9 million newly reported cases of TB in 2013 being classified 
as multi-drug resistant.93  
 The DOTS (directly-observed treatment short course) was introduced and 
refined through the 1990s to manage TB treatment, with an emphasis on commitment 
of governments, non-governmental organisations and care providers at all levels to 
deliver a regular drug supply, administration of which was directly observed by a health 
worker.94 DOTS also included a standard daily antibiotic regimen of, for drug susceptible 
TB, four drugs taken over six to eight months: isoniazid, rifampicin, pyrazinamide and 
ethambutol.95 The first-line drugs were all developed and put into use in the 1950s and 
1960s, since which time no significant antitubercular drug has been found in 
replacement, however there are second-line recourses when the primary treatment fails. 
 Multi-drug resistant tuberculosis (MDR-TB)96 is classified as a resistance of 
Mycobacterium tuberculosis, the causative bacterium, to isoniazid and rifampicin. 
According to the World Health Organisation’s latest annual global report on TB, MDR-TB 
has highest prevalence in Eastern Europe and central Africa (figure 2.1), and the 24-
month second-line treatment was implemented in 82% of those cases eligible in 2012.  
Unfortunately, success rates of the second-line treatment were only 48% in 2012 
(of those MDR cases detected in 2010), owing to problems of access, patient compliance, 
and follow-up by health services. These factors have led to the recent emergence of 
extensively drug resistant TB (XDR-TB).97 XDR-TB was detected in 92 countries in 2012, 
with the highest incidence in Eastern Europe (figure 2.1). It is estimated that 9.6% of 
MDR-TB cases in 2012 are in fact XDR-TB, with 32% of MDR cases being resistant to 
either a fluoroquinolone, or a second-line injectable antibiotic (such as kanamycin) or 
both; if an MDR-TB case is resistant both second-line alternatives such as these, it 
qualifies as an XDR case. 
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Figure 2.1: Top, percentage of TB cases which became multi-drug resistant and thus notified as MDR-TB. 
Data shown is for the most recent year for which data was available, which varies among countries. 
Bottom, countries which reported at least one case of XDR-TB in 2012 according to WHO.98 
The role and classification of second-line antibiotics is two-fold. Firstly, they are held in 
reserve to prolong their efficacy, being applied only when the cheaper and more widely 
used antibiotics fail thus allowing our arsenal of drugs to remain useful for as long as 
possible.99 Secondly, these second-line antibiotics often have poorer patient tolerance 
than those in the first line, and so administration is undertaken only if absolutely 
necessary.100,101 As MDR-TB and XDR-TB rise, more patients will  necessarily have to turn 
to these for treatment taking from 12 to over 24 months.102 One such poorly tolerated 
second-line drug is ethionamide,103 a structural analogue of the front-line isoniazid 
(figure 2.2).104  
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Figure 2.2: Chemical structures of isoniazid and analogue ethionamide.104,105  
 
Both are type I pro-drugs and they share a common target: when activated within the 
mycobacterium isoniazid and ethionamide each form an inhibitory adduct with NAD 
against InhA,106 a carrier protein which is part of the fatty acid elongation system (FAS-
II) which produces mycolic acids for the M. tuberculosis cell wall.107 Both isoniazid and 
ethionamide therefore disrupt cell wall formation, but they have separate and distinct 
activation mechanisms.108 The bioactivation of isoniazid by the protein KatG109 is 
efficient such that low therapeutic doses are sufficient in treatment; the same cannot be 
said of ethionamide and its activator. Ethionamide is required in very high doses 
(typically 10-20mg/kg daily, compared to isoniazid dose of 5mg/kg during active 
infection) and as such, results in a variety of negative side effects including (but not 
limited to) hepatotoxicity and mental disturbances.105,110 
 
2.1 Target Discovery 
 
Figure 2.3: A summary of the mechanism by which ethionamide acts in M. tuberculosis – ethionamide is 
activated by EthA (expression of which is controlled by EthR) and forms an adduct inhibitor of InhA, 
preventing fatty acid synthesis. 106,107,111,112 
 
In 2000, Baulard et al.108 published their discovery of the ethionamide activator protein 
which they called EthA (figure 2.3), and also noted the presence of a neighbouring open 
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reading frame which was homologous to known members of the TetR family of 
transcriptional repressors. In their paper Baulard et al. demonstrated that over-
expression of ethA caused hypersensitivity of M. tuberculosis, M. bovis BCG and M. 
smegmatis to ethionamide, while over-expression of the neighbouring putative 
transcriptional repressor conferred resistance. Thus they proposed EthA to be the 
activator of ethionamide, and the neighbouring transcriptional repressor to control ethA 
expression; they named this TetR-like transcriptional repressor EthR, and made the first 
suggestion that EthR could be a viable target for co-operative treatment with 
ethionamide (ETH).108 The first crystal structures of EthR were published in 2004, 
determined by two distinct research groups.111,113 Figure 2.4 shows the repressor in its 
homodimeric form, and the monomer from the two independently determined crystal 
structures..111,113  
 
 
Figure 2.4: Crystal structures of EthR. Left, the homodimer (PDB: 1U9O).111 Right, overlay of the 
monomeric EthR (PDB: 1U9N in grey, PDB: 1T56113 in green.) Ligands hexadecyl octanoate (grey) and 
dioxane (green) are shown in b for comparison. 
 
As expected, EthR showed the same canonical fold as other TetR-like repressors and high 
similarity within the N-terminal DNA binding region (a helix-turn-helix motif)114 but 
little among C-terminal ligand-binding domain.115  In the case of EthR, this ligand-binding 
domain is formed by five helices which together make a long, linear channel in the 
domain. In the crystal structures published by both research groups this channel was 
occupied. Dover et al.113 determined two six-membered rings (dioxane, components of 
their crystallisation buffer, shown in figure 2.4) within the channel of their structure; 
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however, Frénois et al.111 fortuitously co-crystallised hexadecyl octanoate, a long 
hydrophobic ester, within the ligand-binding channel. 
 As the structure was determined from crystals of recombinant EthR produced in 
Escherichia coli, the ligand is not a natural one (though it may resemble in some fashion 
the natural ligand, as EthA catalyses the conversion of ketones to their esters; the natural 
ligand is currently unknown).116  This demonstrated the ability of EthR to bind a 
lipophilic molecule. Interestingly, EthR has to-date only been crystallised in forms which 
are inactive, geometrically incompatible with DNA-binding. The major grooves of B-DNA 
are spaced at intervals of 34 Å,117 yet in the case of EthR the HTH motifs are situated 18 
Å too far apart to contact these grooves correctly for function.118 It has been proposed by 
Frénois et al.111 that this is exemplary of a natural inhibitory mechanism of EthR, by 
which ligand binding induces a conformational change in the protein rendering EthR 
unable to bind DNA; this is further supported if the ligand is an ester produced by EthA, 
constituting a method of feedback to EthA’s transcriptional regulator. This putative 
mechanism together with a ligand-bound crystal structure paved the way for validation 
of EthR’s potential as a drug target for co-operative ethionamide treatment. 
 
2.2 Target Validation & Screening 
Between 2004 and 2009 work was undertaken to find a line of drug-like ethionamide 
boosters which culminated in the Willand et al. paper in Nature Medicine.119 It was noted 
that the ligand-binding cavity occupied by hexadecyl octanoate has a largely symmetrical 
profile, with hydrophobic and aromatic residues lining the upper and lower regions with 
a polar “patch” in between. In the Frénois et al structure of EthR,111 a water molecule 
forms a hydrogen bond with the nitrile of an asparagine residue; in the Dover et al. 
structure, the hydrophobic regions are populated by six-membered rings.113 Therefore, 
this suggested the observed inactive conformation of EthR could be induced by small 
lipophilic molecules which could equally exploit the hydrophobic and polar regions of 
the binding channel. 
Willand et al. developed a simple, <500 Da pharmacophore model of two 
hydrophobic ends connected by a hydrogen bond-capable linker of 4-6 Å. A series of 131 
compounds were synthesised based on sampling the diversity of the hydrophobic ends 
and the nature and length of the spacer. Various chemoinformatic properties were 
calculated for these 131 compounds (cLogP, polar surface area, number of hydrogen 
bond donor/acceptors) and the best compromises according to Lipinski’s rule of five 
were retained.120 
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An SPR (surface plasmon resonance) assay was used to determine if, and quantify how 
well, the compounds inhibited the ability of EthR to bind DNA.118,121 Willand et al. found 
this screen highlighted a series able to reduce the EthR-DNA interaction by more than 
50%; this was exemplified by the compound BDM14500 (IC50 of 38 µM), which was 
subsequently co-crystallised with EthR (figure 2.5).119  
As anticipated, the EthR-BDM14500 co-crystal structure was in a conformation 
incompatible with DNA-binding (HTH distance 50.3 Å). BDM14500 was shown to have 
no bacteriotoxic effect alone, but was able to inhibit M. tuberculosis H37Rv growth on 
solid agar plates at a quantity of 20 nmol BDM14500 with 2 µg ethionamide, where 
double that dose of ethionamide alone was unable to do so; this demonstrated the 
synergistic, co-drug effect and provided a demonstrable EthR inhibitor hit for 
optimisation.119 
 
2.3 Lead Optimisation of EthR Inhibitors 
Analogues of BDM14500 were prepared by Willand et al.119 and evaluated using the 
previously used SPR assay. Two of these, BDM31343122,123 and BDM31381, were found 
to have IC50s of 3.3 µM and 522 nM respectively.  
 
 
Figure 2.5: Ligands BDM14500 (a),119 BDM31343 (b)123 and BDM31381 (c)119 bound to EthR. Panel d 
shows the location of the G106W mutant which induces an inhibitory conformation.123  
 
Both inhibitors were able to boost ethionamide efficiency, BDM31343 by a factor of 10 
and BDM31381 by a factor of 20. BDM31343 had the best pharmacokinetic profile and 
boosting activity in vivo, allowing a three-fold decrease in ethionamide dosage. Willand 
et al. noted that although this is already a substantial decrease which would assist in 
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reducing ethionamide’s negative side effects, they anticipated they would be able to 
improve on their design. 
 The crystal structure of EthR bound by BDM31381 and a later structure of EthR 
with BDM31343 both demonstrated the previously observed DNA-binding 
incompatibility, and by binding in the same region of the cavity (not shown) the allosteric 
control theory gained more corroborating evidence. In 2011, Carette et al. were able to 
induce this inhibited conformation by mutating a single residue (G106W) in the ligand-
binding channel (figure 2.5).123 
 Notably, Willand et al.119 observed that in contrast to BDM14500, BDM31343123 
and BDM31381 oriented in the binding channel such that it was their carbonyl oxygen 
rather than the oxadiazole which formed the hydrogen bond with Asn179. This would 
come to be frequently observed, and further docking studies using BDM31343 and two 
other analogues predicted the ability of EthR to support two binding modes within the 
linear ligand-binding channel, centred around this important, hydrogen-bonding Asn179 
residue.122 
 
Figure 2.6: Left, chemical and co-crystal structures of the original EthR inhibitor hit BDM14500 (right, 
orange), and the analogue for target-guided synthesis BDM14801 (right, olive).119,124  
 
In order to probe the plasticity of the ligand-binding channel, and determine if new 
protein conformations could be exploited in ligand design, a technique called kinetic 
target-guided synthesis was used.124,125 In target-guided synthesis, protein is incubated 
with an inhibitory compound and reactive fragments to irreversibly form new products 
in situ. An analogue of BDM14500 named BDM14801 was used for the in situ reaction 
(figure 2.6) to encourage elongation of the ligand at the carbonyl tail region. The protein 
was incubated in six aliquots with clusters of ten aromatic and aliphatic alkynes each 
such that condensation reactions between substrates would yield products of notably 
different molecular weights. The small alkynes were selected primarily for their 
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potential ability to interact with the hydrophobic regions of the EthR ligand-binding 
channel, specifically Phe114, Phe184 and Trp138 at the top of the channel. The major 
kinetic product was identified and classified BDM14950 (figure 2.7) and determined by 
SPR to have an IC50 of 580 nM. 
 
Figure 2.7: Chemical structure of the target-guided synthesis product BDM14950, and as bound in the co-
crystal structure PDB:3O8H.124  
 
The crystal structure of BDM14950 bound to EthR showed Phe184 and Phe114 had 
undergone re-arrangement (compared to previous structures with shorter ligands) to 
accomodate the longer BDM14950; this is despite phenylalanine being one of the amino 
acids with the lowest propensity towards flexibility within protein structures.126 Willand 
et al.124 note in their presentation of BDM14950 that due to the rearrangement of 
residues required to accommodate the longer ligand, traditional docking and virtual 
screening methods may only have been able to probe the lower region of the ligand 
binding channel. This will be discussed further in the next chapter. 
 Subsequently, structure-activity relationships were established by Flipo et 
al.,127,128 which varied the carbonyl tail or oxadiazole head regions of this series further. 
Variations in the tail region showing the best improvement of potency without 
compromising solubility came from aliphatic chains, with emphasis on the introduction 
of fluorinated alkyl groups; Flipo et al. also investigated replacing the piperidine six-
membered ring for five-membered pyrrolidines.127 The second study from Flipo et al.128 
varied head groups instead and yielded the current lead compound in this series. 
BDM41906, which has an IC50 of 400 nM and occupies the lower region of the EthR 
ligand-binding channel, incorporates a fluorinated alkyl chain tail and a thiazolyl head 
ring (figure 2.8). Presently, this compound is undergoing further tests in mouse models. 
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Figure 2.8: The chemical structure of BDM41906, and as bound to EthR. 
 
2.4 Further Drug Development on EthR Inhibitors 
Until 2012, published development of EthR inhibitors was limited to one series and one 
research group. However in 2012, Flipo et al.129 presented a new line of inhibitors which 
were identified from a whole-cell phenotypic assay of over 14600 compounds; a 960-
compound library was synthesised to optimise the hit and these were tested by a thermal 
shift assay. The thermal shift assay was used in the course of the research detailed in this 
thesis and will be discussed in chapter five.  
 
Figure 2.9: An N-phenylphenoxyacetamide class EthR inhibitor presented by Flipo et al.129 
 
The new series (figure 2.9) exploits the Asn179 residue in the centre of the channel for 
hydrogen bonding while maintaining hydrophobic contacts at the top and bottom of the 
channel. Work is ongoing with this new family of EthR inhibitors. 
43 
 
In 2013 a different group with a different approach tackled EthR; fragment-based 
screening by Surade et al.130 identified a ligand with micromolar binding affinity and a 
novel chemotype. A thermal shift assay similar to that used by Flipo et al.129 was used to 
screen a fragment library of 1250 molecules, and hits were confirmed by an SPR assay 
based on that used by Engohang-Ndong et al.121 Four of the best performing fragments 
(figure 2.10) were soaked into EthR crystals and resulting crystal structures 
(unpublished) reportedly showed clear hydrogen bonding interactions with Asn179, and 
favourable hydrophobic interactions. Analogous compounds were made via fragment 
linking; these designed molecules were docked into the fragment hit crystal structure of 
EthR using GOLD39,51 and, when found to have suitable binding poses, they were tested 
using the SPR functional assay. This yielded a compound with a low micromolar binding 
affinity (figure 2.10).   
 
Figure 2.10: Hit fragments and the resulting micromolar inhibitor from Surade et al.130 
 
This approach yielded a new series of EthR inhibitor leads, and Surade et al.130 emphasise 
and credit the use of fragment-based approaches for identifying binders with low 
micromolar affinities which could lead to more selective lead compounds. 
In 2014 Villemagne et al. published a study in which the fragment-based 
approaches of growing, linking and merging were utilised (along with crystallography 
and in silico docking) to identify a novel chemotype for EthR inhibition.131 Application of 
fragment-based approaches are clearly robust for this protein and such on-going, high-
impact research shows EthR to be a credible target with strong potential for real-world 
applications. 
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2.5 Conclusion 
EthR is a mycobacterial transcriptional repressor which has undergone nearly a decade 
of target validation and inhibitor screening using ligand-based and fragment-based 
methods. To date, there are three distinct leads which were all derived from medium-to-
high throughput biological methods. 
 As none of these EthR inhibitors has yet entered clinical phase trials, it is 
important that as many avenues of discovery are explored as possible due to the 
unfortunate success rates of drugs entering the process. A recent study132 which looked 
at clinical phase progression, from Phase I through to FDA approval in the US (Food and 
Drugs Administration) between 2004 and 2010, found that only 7% of small molecule 
chemical drugs which entered Phase I trials were ultimately approved for the market. 
This compares to a 15% success rate for biologics – natural products and their 
derivations. These EthR inhibitors would fall into the former category rather than the 
latter, and therefore it is logical to cultivate multiple options in order to increase the 
possibility of success and eventual implementation in a TB drug cocktail for treatment. 
 In contrast to the previous work on EthR just described, this thesis details an in 
silico screening approach using a starter database of 6.1 million compounds to identify 
hits with novel scaffolds for hit optimisation.  
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CHAPTER III: 
VIRTUAL SCREENING PROTOCOL 
DEVELOPMENT 
In silico screening has several advantages over high-throughput laboratory screening 
methods, including the ability to develop a selective ‘assay’ to identify likely binders with 
speed and efficiency. With an unusually rich amount of data on the EthR target, namely 
multiple crystal structures and established biological validation protocols, an informed 
protocol can be derived and honed from observations of the binding site and known 
protein-ligand interactions. 
 
3.1 Protein Characterisation 
Any docking or virtual screening protocol requires two components: a protein structure 
and a ligand structure. As multiple crystal structures of EthR have been published in the 
course of target discovery and validation and are available for use, two options are 
available: use all in an ensemble approach, or determine which would be best suited to 
the purpose at hand and use only one structure; the latter is preferable, as to use multiple 
protein structures with potentially hundreds of thousands of ligands would be extremely 
computationally expensive. Additionally, as these multiple structures are structurally 
(and statistically, RMSD across backbone and side-chains) very similar, such a large scale 
ensemble docking would be redundant. 
 Therefore multiple techniques were employed to make the most informed choice 
of protein model, including ensemble docking and cavity comparisons by Relibase+.133 
For the purposes of explanation and contrast of different crystal structures of the same 
EthR protein construct it is necessary to refer to structures individually. For clarity 
structures will be referred to by their four-character alphanumerical PDB code. 
 
3.1.1 Crystal Structures of EthR 
EthR, as described previously, is a bacterial DNA-binding protein of the TetR 
superfamily115,121,134  which forms a dimer possessing a pair of helix-turn-helix motifs 
which bind DNA, and a pair of ligand-binding regions. It has been demonstrated that 
small molecules able to occupy these ligand-binding regions can cause a structural 
perturbation of the DNA-binding ‘heads’ thus preventing DNA-binding.111,119,121  
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 Of the twelve EthR structures listed in table 3.1, all but 3Q0V were crystallised as 
monomers in the asymmetric unit with the space group P41212; 3Q0V has the lower 
symmetry space group P41 to accommodate the dimer in the asymmetric unit.  
 
Table 3.1: List of EthR structures in the PDB circa summer 2012 when work was undertaken. a denotes 
structures available in Relibase+ 3.1 at that time. 
PDB Code Resolution / Å Space Group Ligand IC50 / nM 
1U9N 111,a 2.30 P41212 hexadecyl octanoate -- 
1T56 113,a 1.70 P41212 diethylene dioxide -- 
3G1L 119,a 1.70 P41212 BDM14744 Unknown 
3G1M 119,a 1.70 P41212 BDM31381 522 
3G1O 119,a 1.85 P41212 BDM14500 38000 
3O8G 124,a 1.90 P41212 BDM14801 7400 
3O8H 124,a 1.90 P41212 BDM14950 580 
3SDG 128 1.87 P41212 BDM41425 2800 
3SFI 128 2.31 P41212 BDM41906 400 
3TP0 123 1.90 P41212 BDM31343 3300 
3Q0U 135 1.70 P41212 BDM31379 5600 
3Q0V 136 1.95 P41 BDM31369 900 
 
Chapter two described EthR in the context of a druggable target and detailed the 
allosteric inhibitors developed. For developing the virtual screening (VS) protocol EthR 
was considered structurally. The first step was to compare the available crystal 
structures of EthR and catalogue their differences to determine which would be best 
suited as the protein model for screening.  
. To achieve this objective comparison, Relibase+ was used with the first 
published EthR structure, 1U9N as the search model. This would compare the protein 
structures to 1U9N, independent of ligand-binding metrics such as KD or IC50 which 
depend on the ligand subject. 
 
3.1.2 Relibase+ and CavBase 
Relibase+ is PDB-derived database which extends entries with cavity, secondary 
structure, ligand, and water characterisation.133,137 The CavBase138 feature in particular 
can be used to characterise and compare ligand binding cavities across the PDB. Notably, 
only protein-ligand structures are curated and there is an understandable delay between 
deposition in the PDB and addition to the Relibase+ release, hence why several 
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structures in table 3.1 were present in the PDB at the time of the work, but were not in 
the version of Relibase+ which was most current. 
 CavBase comparison searches are independent of sequence, instead matching 3D 
property descriptors generated using a dummy atom, which represents an area of the 
binding site – each of these defines a shape and chemical characteristic and is called a 
pseudocentre. The properties currently codified in CavBase are: donor, acceptor, 
donor/acceptor, aromatic, aliphatic, pi, and metal. Cavities are detected using a version 
of LIGSITE139 and then least-squares fitting is utilised to superimpose similar binding site 
areas, matching properties over short pair-wise distances of less than 1 Å. A similarity 
score is given as a ‘raw score’ in the results of the CavBase search which represents the 
overlap of the respective surface patches – in fact the overlap of the dummy-atom 
pseudocentres (table 3.2). 
 By using CavBase on EthR, it was possible to characterise the binding sites of 
Relibase+-deposited structures by volume and pseudocentre, to highlight and contrast 
the differences. For EthR, a comparison search was performed against a total of 60,528 
proteins. This set only includes EthR protein structures 3O8H, 3O8G, 3G1M, 3G1L, 3G1O 
and 1T56, due to the curated nature of Relibase+ (table 3.1). This does exclude five 
structures which are not present in Relibase+, however these were used in subsequent 
ensemble docking performance experiments (setion 3.1.3). 
 A resolution limit of 2.9 Å was set on the database search to ensure confident 
matches to structures of a similar or higher resolution than 1U9N, which has a resolution 
of 2.3 Å. The default scoring function was used but no limits were put on the minimum 
score to save or minimum size of permitted ligand; instead the top 100 matches were 
saved.  
 As expected, the top six results from the CavBase search were the other available 
EthR structures named above.  Results from CavBase are tabulated with the volume of 
each cavity (table 3.2). A total of 97 pseudocentres within the 1U9N binding channel 
were identified and utilised. The ‘raw score’ is expressed as a percentage in the 
‘normalised’ score, but the number of psuedocentres matched is also given, with the root 
mean square deviation of those pseudocentres superimposed (RMS in table 3.2). 
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Table 3.2: The top seven results of the CavBase comparison of the 1U9N binding channel cavity with 60,528 
proteins in the Relibase+ database. A total of 97 pseudocentres were identified in the 1179 Å3 cavity.  
Cavity Raw 
Score 
Normalised 
Score 
# Matched 
Centres 
RMS Cavity Volume / Å3 
1U9N.1 - - 97 - 1179.38 
3O8H.1 59.7 68.6 63 0.300 1018.90 
3G1L.1 41.7 47.9 43 0.261 742.50 
1T56.1 39.0 44.8 41 0.322 806.10 
3O8G.1 34.2 39.3 37 0.485 817.60 
3G1M.1 33.9 38.9 36 0.433 778.90 
3G1O.1 33.8 38.9 37 0.503 872.60 
 
The highest EthR result, 3O8H, only matched 63 pseudocentres despite the cavity 
similarity measured with an RMS of 0.300 Å. Several reasons for this can be suggested, 
such as that the Asn179 residue (an acceptor in 1U9N) is in the donor position in 3O8H 
and all other published EthR structures (including those not represented in the 
Relibase+ 3.1 release but present in the PDB) and so that region of the cavity will be, in 
terms of this pseudocentre mapping, very different. Also the volume of the cavity, as 
measured by the solvent-accessible area, is smaller within 3O8H by 160 Å3 due to subtle 
side-chain positional changes (figure 3.1). 
 
Figure 3.1: Differences in side chain positions at the top of the ligand binding channel cause differences in 
channel volume. Panel a compares the two largest cavities, 1U9N (grey) and 3O8H (cyan) which differ by 
160 Å3. Panel b compares 1U9N with 3G1O (pink), which differ by over 300 Å3. 
 
The cavity volume difference between 1U9N and 3O8H is driven by the positions of 
Arg128 and Gln125, which differ greatly between the two structures (figure 3.1). The 
difference in cavity volume between 1U9N and 3G1O exceeds 300 Å3 and this is due to 
the movement of Phe184, which can be seen on the right of panel b in figure 3.1, above. 
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In 3G1O, with this phenylalanine residue down, this upper part of the binding channel is 
inaccessible to any ligand. 
 Ultimately, the Relibase+ analysis demonstrates that despite close similarity 
between structures by RMSD, the rearrangement of side-chains in the presence of longer 
ligands results in cavities differing in volume by up to 300 Å3. For virtual screening 
purposes it was decided one representative EthR structure should be used to reduce the 
computational burden and avoid redundancy as much as feasibly possible. With notable 
differences in volume, ensemble docking was used to determine what effect this had on 
ligands binding EthR in silico. 
 
3.1.3 Ensemble Docking with EthR Structures 
Ensemble docking is a method by which ligands are docked into multiple protein models 
to account for protein flexibility in the backbone and structural variation lost in typical 
crystal structures.45,46 Each ligand is docked into all presented protein structures, with 
the resulting poses being scored and saved depending on the user-defined termination 
parameters. This method has successfully been used for hit discovery with homology 
models,140 molecular dynamics simulations,66 and even NMR structures65 in addition to 
crystal structures59 within the last decade.  
With multiple ligand-bound crystal structures of EthR available, a cross-docking 
experiment was devised to determine which of the protein structures was the most 
“receptive”. Cross-docking is a form of ensemble docking by which the ligands of a set of 
ligand-bound crystal structures are extracted and then docked back into the ensemble. 
Therefore the most receptive structure would accept the most ligands, with a good 
differentiation of scores, and so be the preferred screening model. 
For ensemble docking, all protein structures must be aligned so they can share 
the same search space; GOLD is able to perform a simple transformation to overlay the 
eleven EthR structures, in this case with reference to 3TP0. Figure 3.2 shows the 
alignment of these eleven structures in PyMol to an average RMSD of 0.56 Å over all Cα 
atoms. A protocol was adapted from previous work with small molecule crystal 
structures for the ensemble docking.122 Therefore, all structures were aligned to the co-
ordinates of the EthR structure 3TP0. 
 Eleven of the twelve structures listed in table 3.2 were utilised for cross-docking 
to establish which protein structure would perform best under virtual screening 
conditions. The structure 1T56 from the Dover group was omitted to form a cohort of 
structures from one research group, ensuring consistency among the crystal structure 
determination methods. In preparation for docking, all water molecules were removed 
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from each structure and, as GOLD uses an all-atom model, hydrogen atoms added to 
satisfy unfilled valences. For each of the eleven protein structures, the ligands were 
removed and saved as separate structure files. Ten of the extracted ligands were docked; 
hexadecyl octanoate, the ester ligand of 1U9N, was omitted as it was not a drug-like 
molecule.  
 
Figure 3.2: Left, alignment in PyMol of the eleven EthR crystal structures to be used for ensemble docking. 
Right, structure 3TP0 with red ball denoting centre of search space, with residues in grey included in 10Å 
radius; purple residues not included in solvent accessible binding site (made in Hermes). 
 
The search space was defined as a 10 Å radius around a central point in the binding site, 
spanning from the upper residues Phe184 and Trp138, to the lower part of the channel 
including Trp103 and Trp207 (figure 3.2).122 GOLD’s default settings for ensemble 
docking were used with a user-defined goal of 25 GA runs per ligand and the default 
scoring function (CHEMPLP). Maximum ligand flexibility settings were used. All 25 
resulting poses were saved, with termination specified when the diverse solutions 
criteria (cluster size of 2 with an RMSD of 1 Å) were satisfied.  
It has been previously noted that the residue Asn179 differs in structure 1U9N 
to the rest of the EthR structures in that the carbonyl of this residue is presented to the 
binding channel surface rather than the nitrile. Close inspection of the 1U9N structure 
showed that if the residue were to be flipped in keeping with the other structures, a 
supporting hydrogen bond network is formed (figure 3.3). It was supposed that in the 
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1U9N structure, being of a lower resolution than the others, the Asn179 residue built 
into the electron density in an incorrect orientation.  
 
Figure 3.3: Left, the orientation of N179 in the original PDB 1U9N (which lacks hydrogen atoms). Right, 
the flipped orientation and resulting hydrogen bond formed with W207 upon setup for docking.  
 
Therefore, the decision was taken to run the ensemble cross-docking twice: once with 
the Asn179 residue of 1U9N in place as published, and again with the residue flipped 
180° in GOLD to present the nitrile in accordance with the other structures. The 
histogram of results for the original and flipped 1U9N are shown in figure 3.4. 
 
Figure 3.4: Histograms showing the number of ligand poses docked for each structure. Small variations 
are to be expected due to the stochastic nature of docking in GOLD.  
 
Comparison between the original and flipped cross-docking experiments shows a similar 
pattern in the quantity and distribution of the docking results, with the notable exception 
of the edited 1U9N. Small variations are to be expected – solutions for 3TP0 and 3SFI 
vary by 20 poses – however 1U9N changes by 108 solutions, preferentially binding more 
ligands than all other structures when Asn179 is able to act as a hydrogen bond donor. 
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This is likely due to a bias toward hydrogen bond acceptors in the ligand structures, and 
the large volume of the 1U9N binding channel compared to other structures. 
 The promiscuity of both 3G1M and 1U9N makes each a strong choice as the 
potential binding protein structure for virtual screening, and indeed if they were 
considerably different both could be utilised and the ensemble docking adapted for a 
virtual screening protocol. However, given the strong structural similarity between the 
two (with an RMSD over all non-hydrogen atoms of 0.27 Å), it would be an unnecessary 
addition to an already computationally straining process.  
 Therefore it was decided to use the 1U9N structure of EthR for virtual screening 
- and in so doing maximising the area for potential ligand binding - and use the properties 
of known actives with the published co-crystal structures as guides when filtering the 
ligand structures before the screening itself.  
 
3.2 Acquisition, Filtering and Clustering of a Ligand Database 
3.2.1  The ZINC Database “DrugsNow” Set 
Compound structures for virtual screening were sourced from ZINC, a free online 
database (zinc.docking.org).141 The ZINC database contains over 35 million 
commercially-available compounds which can be downloaded in various 3D formats, 
ready to be used in docking. The database is organised into “ready-to-download” subsets 
filtered by physical properties and availability. The Drugs Now subset was downloaded 
to be used for virtual screening due to the pre-application of Lipinski’s Rules and the 
apparent availability of the compounds therein. When downloaded, the Drugs Now 
subset consisted of approximately 6.06 million compounds. 
 
3.2.2 Filtering in KNIME 
Pipeline software KNIME (discussed in chapter one) was used to apply additional filters 
to the Drugs Now subset downloaded from the ZINC database, and to calculate some 
simple chemical property descriptors. Figure 3.5 shows the filtering pipeline which 
reduced the subset to 1.3 million compounds. Twenty descriptors were calculated, listed 
in table 3.3, chosen to describe the physiochemical properties of each compound in 
simple terms with integer values. Filters were applied in stages in order to reduce the 
heavy computational burden of calculating all twenty descriptors on all 6.06 million 
compounds. All twenty descriptors were also calculated for the ten known active EthR-
binding ligands described previously. 
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Figure 3.5: KNIME workflow for the calculation of descriptors and filtering of the Drugs Now subset. The 
orange SDF Reader node brings the input from the ZINC database; green nodes are calculators from the 
KNIME Chemistry Nodes package and the yellow filter nodes are part of KNIME’s core node set. 
 
Firstly, a filter was applied to exclude any molecule without a volume between 200 Å3 
and 700 Å3 (the first yellow box in figure 3.5). The value of 700 Å3 was chosen to include 
molecules which could occupy the main cavity of EthR (table 3.2, ranging from ~740-840 
Å3). Though the cavity of 1U9N is ~1100 Å3, the decision was taken to exclude long, large 
molecules which would occupy the whole volume in order to identify small, varied 
scaffolds which can be further modified in downstream medicinal chemistry efforts to 
exploit the additional volume. This volume filter is the most stringent, reducing the 
cohort by 50%. 
 
Table 3.3: Descriptors calculated in KNIME using the workflow in figure 3.4. Not all properties were used 
for pre- or post-screening filtering. 
molecular weight volume # hydrogen bond 
donors 
# hydrogen bond 
acceptors 
# heteroatoms # rings (any type) # rotatable bonds # halide atoms 
# f atoms # ester groups # hydroxyl groups # keto groups 
# methyl groups # sulphide groups # sulphonyl groups # thiol groups 
# thioester groups # Lipinski violations TPSA AlogP 
 
The polar region of the pocket includes the residues Asn179 and Asn176, which in the 
crystal structures of EthR have been shown to act as hydrogen bond donors through their 
NH2 side-chain group. A filter was imposed to include only those molecules with at least 
one hydrogen bond acceptor in order to encourage intermolecular interactions between 
the ligand and the protein. 
 The upper limit for rotatable bonds was set at six or fewer, to disfavour widely 
flexible molecules,142  and a filter was imposed to ensure all molecules had at least one 
ring system of any kind. Together with the volume filter, the decreased flexibility and the 
inclusion of ring systems will exclude undesirable long, flexible molecules and retain 
shorter, wider, drug-like compounds. The penultimate filter excludes any molecule with 
an AlogP above 3, as any molecule with a value above the imposed threshold here would 
be extremely hydrophobic. 
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The final filter simply restricts the molecular weight of the included compounds to a 
range of 190 to 400. While molecular weight and molecular volume are correlated, this 
filter was chosen to exclude any large compounds which had managed to escape 
previous filters, and was based on the molecular weights of known actives. 
 The workflow used was the result of over a month of extensive literature study 
and parameterisation to obtain reasonable, effective filters. Due to the computational 
load of calculating and filtering on properties for over six million compounds, slices of 
approximately 131,000 compounds were introduced to the workflow separately. This 
resulted in 46 sets of ~131,000, each requiring an hour of clock-time to complete the 
workflow to give ~28,000 compounds per slice, or approximately 1.3 million compounds 
total. 
 
3.2.3 Clustering the Filtered Ligand Set 
While feasible to screen all 1.3 million compounds against EthR, it was not desirable; 
analogues and highly similar structures would populate the filtered set and so it would 
be more efficient to take a representative proportion to screen. A clustering pipeline was 
developed to group molecules by different ring chemistries (figure 3.6).  
 
Figure 3.6:  Overview of the clustering pipeline for the 1.3 million compounds filtered from the ZINC 
database Drugs Now subset. Marvin Sketch was used for defining ring structures.  
 
All molecules were handled in SDF format at either end, which kept all information from 
previous KNIME functions as appended tags, and multiple structures were kept in single 
text files. The first decision made was to remove any molecules which the RDKit rejected 
Sketch 
Substructure
Substructure 
Filter
No Match
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for structural anomalies (a total of 7 from 1.3 million) and a total of 5,265 rhodanines, a 
member of a class of molecules known as pan-assay interference compounds (PAINs) 
which provide false positives in a variety of biophysical assays to little known biological 
effect.143 
 The ring definitions were ordered with some respect to frequency in drug 
molecules. Where some rings had multiple possible arrangements (ie. oxadiazoles 1,2,4 
or 1,3,4; and triazoles 1,2,3 and 1,2,4) the filtered results were concatenated into one 
output. Some sulphonyls caused confusion to the cluster filter on heterocycles as the pre-
filtering did not distinguish between in-chain sulphonyls and sulphonyl-like 
arrangements in rings. Therefore, a sulphonyl filter was imposed before the final three 
clusters were formed. The last clusters are ‘other heterocycles’ either of five or six 
membered rings which had not been previously identified (6,091); any kind of seven-
membered cycle, as defined by Murcko Scaffold144 (10,768); and the last cluster was 
named ‘other’, to encompass structures with prolyl or eight-membered rings, and 
structures with only adamantanes or other similar cage groups (52,297). Table 3.4 
shows the full list of clusters with their populations. 
With the 1.3 million pre-filtered set clustered, subsets had to be taken from each 
for docking. Different sampling percentages were explored for creating the final docking 
set, with a target of approximately 500,000 compounds for screening. The decision was 
taken to make the groups as even as possible, taking different proportions from each. For 
small clusters of fewer than 10,000 compounds, such as thiadiazoles (8805), the cluster 
was taken in its entirety. For large clusters of greater than 100,000 compounds, fractions 
were taken so no single cluster was populated greater than 50,000 compounds (or ~10% 
of the final docking set of ~500,000). This results in a rather uneven sampling, with 
clusters of 40,000 down to clusters of only 6000 compounds, however this is more even 
than the initial screening, and as docking of each compound is independent, the 
composition of the screening set would not bias the screening itself in any way, unless 
the protein interactions favoured a particular chemistry (which would be an interesting 
result in and of itself). 
Ultimately, the docking set consisted of 409,201 compounds (table 3.4), with the 
largest cluster, that of pyrazoles, containing 40,035 compounds (9.8% of the cohort) and 
the smallest, that of 6-membered ring triazoles, containing 4,150 compounds (1.0% of 
the cohort). 
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Table 3.4: Proportioning the clusters for docking, in order to take roughly a third of the filtered set in total, 
as equally represented as possible. The ‘5’, ‘6’ and ‘7’ prefixes refers to the ring size. 
Cluster Name Cluster Size Screening 
Cluster Size 
Cluster Name Cluster Size Screening 
Cluster Size 
5imidaz 121369 36411 6tria 4150 4150 
5pyraz 133450 40035 5thiaz 36150 10845 
5pyrrol 240174 24017 5tetraz 9372 9372 
5triaz 49055 14717 6pip 182898 18290 
5oxaz 39025 11708 6oxane 29035 14518 
5oxadiaz 11439 11439 6diox 11814 11814 
5thidiaz 8805 8805 6morph 38142 11443 
6pyrim 107658 32297 5thio 22934 11467 
6pyraz 91590 27477 5oxodiox 28635 28635 
6pyrida 16227 16227 Sulphonyls 32986 32986 
Hetother 6091 6091 Other 52297 15689 
7cycle 10768 10768 Total 1284064 409201 
 
3.3  Preliminary Docking Tests: Training Sets and Parameter Optimisation 
3.3.1 “Decoy” Set for Probing GOLD Parameters 
Small training sets seeded with compounds known to be active inhibitors of EthR served 
two key purposes; firstly, a decoy set was formed by which to test the developed docking 
protocol for the ability to prioritise active compounds; and secondly, the set gave a 
dataset of manageable size for fast docking in order to probe the functions and 
limitations of GOLD in the protocol development process. 
For decoy sets, it would be ideal to use known inactives to form a set seeded with 
known actives, to test a protocol for its ability to prioritise those with biological activity. 
Without such information available for EthR, a set was derived from a similarity search. 
Using the lead compound from the work published by Flipo et al. in 2012,128 the structure 
of BDM41906 was used to design a query of the ZINC database based on simple 
physiochemical properties, chosen to be similar to the actives to avoid artificial 
enrichment and to provide a challenge to the docking protocol. Molecules were selected 
from the ZINC database at random given a set of physiochemical properties as filters. The 
properties in question were based on guidance from Lipinski’s rules,120 with seven or 
fewer rotatable bonds; five or fewer hydrogen bond donors; up to ten hydrogen bond 
acceptors; a molecular weight between 300-500 g mol-1; and an xlogP lower than 3. A 
total of 350 of these were chosen to satisfy a recommended 36:1 ratio of unknowns to 
actives (of which there were nine used), as suggested by Wallach et al. in 2011.145  
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Given the virtual screening set was derived from the same source with similar filters 
imposed through KNIME, cross-over was to be expected (though, of the decoy set of 350 
compounds, only 4 are present in the virtual screening set and none in the biophysical 
set for screening); however the key aim of the decoy set would be fulfilled if the leads 
were prioritised in the top 10% of the results. The docking protocol described below was 
evolved from the ensemble docking described previously. 
 
3.3.2 Optimising GOLD Parameters for EthR 
There were five key protocols tested and carefully analysed for active enrichment with 
the decoy set, focussing on both 1U9N (which has a more extended binding site owing to 
the Phe184 twisting up to expose the auxiliary pocket) and 3G1M (which performed well 
in the ensemble docking but has a binding site of smaller volume). In each case, the 350 
molecule decoy set of compounds were used in addition to nine active EthR inhibitors 
from the published crystal structures (BDM14500,119 BDM14801,124 BDM14950,124 
BDM31343,123 BDM31369 from 3Q0U, BDM31379 from 3Q0V, BDM31381,119 
BDM41425128 and BDM41906128). Similarly, a search space radius of 10 Å about a central 
point in the binding site was defined, the co-ordinates for which differ based on the slight 
structural variation between proteins used, though an effort was made to make this 
centre positioned in the same structural environment to that used for the ensemble 
docking described previously. For 1U9N, the centre point was defined as [x = 32.5127, y 
= 73.6746, z = 11.1142]; for 3G1M, the centre point was defined as [x = 31.987, y = 
74.0719, z = 10.2291]. Autoscale of 100% (1.0) was employed, with automatic genetic 
algorithm settings utilised for 10 GA runs per ligand, of which the best five were kept. 
Finally, CHEMPLP was used as the scoring function, and the Diverse Solutions definition 
for end-point were defined as clusters of two molecules at least 0.5 Å in difference by 
RMSD.  
 Two of the five decoy docking protocol experiments were with 1U9N and 3G1M 
respectively, unedited (but for the Asn179 residue of the former) and no additional 
protein flexibility. The third changed the parameters for 3G1M to include five library-
defined rotamers of the phenylalanine residue F184 to ascertain if opening up the option 
of the longer binding site would affect enrichment. The fourth and fifth experiments were 
cross-docking ensemble experiments combining 3G1M and 1U9N (aligned to the latter) 
under non-flexible (four) and flexible (five) phenylalanine conditions. 
 For each docking experiment, all proved able to prioritise actives in the top 10% 
of results by fitness score, and therefore early enrichment was not helpful in 
differentiating protocols. Inclusion of the flexible phenylalanine F184 in 3G1M gave no 
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noticeable advantage to using that protein structure over 1U9N, and the ensemble 
results again showed 1U9N able to dock more ligands (data not shown); therefore, 1U9N 
was retained as the protein model for virtual screening. Focus instead shifted to 
prioritising a protocol which was fast, would potentially be feasible to run on a desktop 
PC with a limited core capacity, and would still be able to prioritise active ligands. 
 To increase the speed of the docking, autoscale search efficiency was dropped to 
the GOLD default for virtual screening of 30% and then to 20%, and the 1U9N solo 
protocol was rerun to give good early enrichment from training to test set in each case. 
The diverse solutions setting was altered to define cluster sizes of one pose only with a 
1 Å RMSD, to increase the sample of conformational flexibility in the results; this proved 
successful. Various search space radii were tested but smaller radii did not best utilise 
multiple residues lower in the pocket. Similarly a radius of 12 Å was able to include the 
upper auxiliary pocket but the Asn179 interaction was deemed most important, and as 
GOLD is known to artificially enrich hydrophobic ligands due to the scoring function (see 
chapter 1), the decision was taken not to encourage the hydrophobicity to the potential 
detriment of crucial hydrogen bonding lower in the channel. Finally, to determine the 
disk space and real-time running time on the desktop PC being used, ten thousand of the 
intended virtual screening ligands were run using this protocol to extrapolate to an 
estimate for the virtual screening output.  
 The final protocol can be found as the CONF file used in the appendix. To 
summarise, a 20% autoscale was used, with a search radius of 10 Å. GOLD’s automatic 
function was used for the genetic algorithm, with five GA runs conducted per ligand and 
all poses saved. Diverse clusters of one pose per cluster with an RMSD of 1 Å between 
clusters were defined. 
 
3.3.3 Running the Virtual Screening Protocol 
Using previous runs and the 10,000 ligand test run, it was possible to estimate how long 
the protocol would take to complete on a PC, and how much file-space for output would 
be required. Though file-space using the SDF output format was not a problem given the 
option of external hard-disk drives, it became clear the running time would be 
problematic; unfortunately, for the protocol and the 409,201 ligands, it was determined 
a run-time run of over 52 days would be likely on the desktop PC running the Ubuntu 
12.04 LTS (64-bit) operating system, using four Intel® Xeon® CPU W3530 processors at 
2.80 GHz and 12.5 GB memory. It was undesirable to reduce the number of ligands for 
screening any further, and so the decision was taken to turn to a supercomputer. 
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As such, the CONF file, edited protein structure (1U9N with hydrogens, no water 
molecules or ligands, and a flipped Asn179 residue in SYBYL MOL2 format) and ligands 
for docking (409,201 in 23 SDF files) were sent via FTP to the CCDC server. The virtual 
screening protocol was set up there on my behalf and run (taking approximately 3-4 
hours), utilising the University of Cambridge High Performance Computing facilities, 
specifically the Darwin Supercomputer.  
 With five poses for each of the 409,201 ligands screened, over two million poses 
resulted. 
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CHAPTER IV: 
POST-SCREENING FILTERING PROTOCOL 
 
The virtual screening consisted of five poses for each of the 409,201 ligands screened. A 
total of over 2 million ligand poses had therefore been generated and required analysis 
and filtering to derive a cohort of compounds suitable for experimental testing against 
EthR. To achieve this the GoldMine software tool, as part of the GOLD Suite (CCDC) which 
had been used for screening, was utilised for the post-screening data processing. 
 GoldMine allows for analysis of docking results with a variety of customisable 
descriptors to characterise binding interactions. This can include simple physical 
descriptors (such as molecular weight and the number of rotatable bonds) but extends 
to characterising the protein-ligand interactions of docking poses, such as hydrogen 
bonds or whether particular regions are occupied by a ligand. Via descriptors it is also 
possible in GoldMine to characterise unexploited interaction potential in occluded polar 
and hydrogen bond-capable atoms. 
 This chapter details the rational process by which unfavourable ligands were 
excluded from the pool of potential binders in order to derive a small set of promising 
compounds for biophysical evaluation. 
 
4.1 Retrieval of Data 
In preparing for the virtual screening, various test sets were used to optimise and fine-
tune protocols; one such set used was a 10,000 molecule set referred to as ‘minidock’ 
(see chapter three) which was subject to the full virtual screening protocol. This set was 
used in the familiarisation with the GoldMine interface. This initial work was undertaken 
in the CCDC. 
The virtual screening output consisted of five sets of co-ordinates (poses) for 
each of the ligands. Docking failed to identify poses for six compounds from the 409,201 
screened resulting in 409,195 successfully docked ligands.  
  
4.2 Filtering 
As five poses were generated for each ligand, a total of 2,045,975 poses resulted. To 
create a GoldMine database of all poses would be an exceptional computational burden 
– to put this in context, it took the best part of eight hours (wall-clock time) to set up the 
GoldMine for ~40,000 compounds so it would have taken around 16 days to set up over 
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2.05 million, assuming the software would even allow it and remain usable and 
functional. Therefore the decision was taken to take only the top-scoring pose of each 
ligand -making the assumption that the best scoring pose of that ligand would make the 
best interactions and have the best conformation - giving the highest scoring 10% of 
ligands, a total of 40,919. 
 
4.2.1 Filter by Fitness 
To filter by fitness and retrieve the top 10% of top-scoring poses, a Python script was 
used. This script, which accessed each directory sequentially, read the associated text file 
which lists the poses in order of rank; if the highest scoring pose listed there scored 
higher than any in the current buffered list of top 40,919 ligands, it replaced the lowest 
scoring pose, otherwise the script moved to the next ligand directory of poses. This 
Python script can be seen in appendix A.  
To determine the proportions of each cluster retained in these results, the top 
ten percent were re-clustered through the pipeline detailed in section 3.2.3 and shown 
in appendix A; these data are shown as a graph in figure 4.1.  
 
Figure 4.1: Graph of re-clustered virtual screening output, according to KNIME pipeline in section 3.2.3. 
Blue bars shows the distribution in the virtual screening input set of 409,200 compounds; orange bars 
show the number of molecules from those clusters present in the top 10% of virtual screening output. 
Cluster names given on the y-axis refer to the ring chemistry used, detailed in chapter three. 
 
The re-clustering shows that the virtual screening output contains a range of chemical 
diversity and the output is roughly proportional to the distribution of input structures. 
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Therefore the virtual screen is not biased toward a certain type of chemistry. This is 
particularly encouraging as the docking process is stochastic and so each ligand and pose 
is unique and unbiased. As this virtual screening approach was taken to identify novel 
scaffolds for EthR inhibitors, the top ten percent of the output is clearly very diverse. 
 
4.2.2 Hydrogen Bond Geometry Filter 
All descriptors calculated in KNIME for the filtering of the ZINC database subset were 
carried forward through screening and into the GoldMine, allowing filters to be used 
beyond simply the fitness score and its components. GoldMine and Hermes also have 
functionality to calculate novel descriptors based on docking poses. 
 With this in mind, the first descriptor calculated within GoldMine was used to 
define a minimum hydrogen bond contact angle. The hydrogen bond tolerance in GOLD, 
as previously discussed in section 1.3.1.3, has a minimum angle of 100 degrees. The 
descriptor was intended to filter out ligands which do not form hydrogen bonds to the 
protein, and ligands which do not form hydrogen bonds at optimal geometries; this was 
implemented first as it was clear from previously developed inhibitors for EthR that 
hydrogen bonding in the polar region of the EthR ligand binding site is especially 
important. 
The definition of a hydrogen bond can be edited with respect to actual distance 
or Van der Waals distance, and the required hydrogen bond angle can also be user-
defined. To understand the effect of these descriptors on the filtering of molecules prior 
to their application to the virtual screening results, the minidock set was again used. An 
initial filter on the fitness, retaining the top 10% of the scoring ligands, resulted in 1846 
poses for 907 ligands. Initially, the default hydrogen bond definition parameters were 
used, with a minimum angle of 90° and a maximum distance being the sum of the Van 
der Waals radii of the donor and acceptor (which was kept constant). This default-
parameters descriptor reduced the set to 1182 poses for 693 ligands, a reduction which 
demonstrates 24% of the ligands were not forming a registerable hydrogen bond to the 
protein.  
By increasing the minimum angle through 100°, 110° and 120°, the number of 
ligands was reduced incrementally to 669, 653 and 629 ligands respectively. The final 
parameter, with a minimum angle of 120° and a maximum distance being the sum of the 
Van der Waals radii, retained 69% of the ligand population. Whether this parameter 
would be used as a final filter was not decided, however it could be considered an 
additional property for consideration. 
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4.2.3 Calculation of Additional Descriptors 
To prioritise likely binders, filters upon different characteristics were added or edited in 
an additional, rational process until a set of non-stringent but decisive filters were 
combined. Ideally, it was hoped these filters would exclude those ligands which were less 
likely to bind EthR or were unfavourable due to physiochemical characteristics, and 
prioritise those which were more promising. To cultivate multiple options for filter 
parameters, GoldMine’s descriptor calculators were used. 
Additional descriptors can be calculated on ligands in GoldMine, including the 
number of buried donatable hydrogens, buried acceptors, and buried polar atoms, as 
well as the number of ligand atoms forming hydrogen bonds and the number of atoms 
causing protein-ligand clashes. All of these descriptors were calculated for the full set of 
40,919 ligands in order to maximise the amount of information available on the docked 
structures.   
 
 
 
Figure 4.2: Left, heatplot output from GoldMine showing frequency of the occluded ligand donor and 
acceptor atom counts, with colour-scale shown on right of red denoting denser populated bins. Right, 
Histogram showing distribution of calculated ligand clash counts, distinct from the score contribution 
shown in figure 4.4. 
 
Of the 40,919 ligands, 23,261 possess at least one occluded (obstructed or unfulfilled) 
polar atom; 25,164 possess at least one occluded donatable hydrogen and 39,850 ligands 
have at least one occluded hydrogen bond acceptor atom (figure 4.2, left); and distinct to 
the previous angle-dependent hydrogen bond filter, a total of 25,941 make at least one 
hydrogen bond (as defined at 90°). Finally, a ligand clash count was calculated, which 
ranged from zero to 32 (figure 4.2, right). 
In addition to calculated descriptors, both those carried from the pre-screening 
pipeline and those defined and calculated via GoldMine, components of the scoring 
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function were looked at as useful indicators of favourable in silico binders. Though 
components of the scoring fitness function contribute to an overall discernment of 
predicted binders, some terms (such as for CH---O interactions) when taken in isolation 
did not help in identifying likely poor binders for exclusion. However, three terms from 
the CHEMPLP fitness function were found to be of particular relevance for assisting in 
the exclusion of unfavourable poses: the ligand torsion term, the ligand clash term – 
distinct from the clash count calculated - (figure 4.3), and the internal correction term 
(figure 4.4).  
 
 
Figure 4.3: Histograms of scoring fitness contributions for the ligand torsion (left), and ligand clashes 
(right) Equations for these terms can be found in chapter one. 
 
 
Figure 4.4: Histogram of the PLP ligand correction term from the CHEMPLP scoring function. Equation for 
this term can be found in chapter one. 
 
4.2.4 Iterative Filter Design 
Firstly, the hydrogen bond contact descriptor was applied (detailed above), compounded 
with a filter on the hydrogen bonding scoring term from Chemscore with a minimum 
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value of 0.1. In principle this would reduce the screening result set to only those which 
formed a ‘good’ hydrogen bond; this filter returned a total of 17,249 ligands (42.15%).  
 In chapter one, physiochemical rules-of-thumb for drug molecules were 
discussed, including a maximum polar surface area of 120 Å3 as suggested by Veber.142 
This was not implemented in the pre-screening pipeline, and so was added here. Figure 
4.6 shows the distribution of the total polar surface area (TPSA) of molecules in the 
screening output set.  
From figure 4.5 (overleaf, left), it is apparent that the majority of molecules fall 
below the 120 Å3 threshold, and indeed implementation of this parameter shows a total 
of 39,704 ligands remain. When added to the hydrogen bond parameters (with a score 
increased to 0.5), the overall set is reduced to 13,786 ligands (33.6%). This filter iteration 
was considered to be filter1. 
 
 
Figure 4.5: Left, histogram output from GoldMine, showing the distribution of the total polar surface area 
of molecules within the screening output. A minority of molecules possess extremes of this property. Right, 
the distribution of calculated AlogP of molecules within the output. In pre-processing, a filter restricted the 
set to AlogP ≤ 3. 
 
A parameter which had been utilised in the pre-screening process was AlogP, and values 
calculated for the more potent active compounds using the same node gave a range from 
-3 to +1.  Figure 4.6 shows a histogram for this property in the screening set. With the 
active-derived range of -3 to +1 implemented, a total of only 5,453 ligands remain – 13% 
of the screening output. When implemented alongside the other parameters, the initial 
set of 40,919 is reduced to only 2,363 ligands (5.77%). 
Although quite stringent, this filter is based on the properties of ligands known 
to bind EthR, and allows for compounds that must be quite lipophilic to interact with the 
binding site as well as pass through the mycobacterial cell membrane. The combination 
of filter1 with the addition of the AlogP filter was named filter2.  
66 
 
Several parameters were considered as additions to filter2, specifically from the 
atom descriptors calculated in GoldMine (figure 4.2). These were implemented in filter3: 
the extremes of occluded ligand donor and acceptor atoms were excluded with a filter of 
0-2 atoms (39,772 ligands) and 0-4 atoms (38,266 ligands) respectively. On figure 4.2, 
this excludes the low-populated blue areas on the heat plot. The occluded polar atom 
count was similarly restricted to 0-2 atoms, including 39,466 ligands, and the ligand 
clash count was restricted to a maximum of 16 (figure 4.3, right). Filter3 reduced, 
through small exclusions, the screening output from 40,919 ligands to 1,761 (4.30%). 
 There were three iterations of filter4, all of which only slightly altered already-
implemented parameters in the filter. This included putting a lower-band limit on TPSA 
of first 70Å3 (filter4), then revised to 75Å3 (filter 4a) to coincide with Veber’s 
recommendations. The ligand clash count was reduced by one point to 15 (filter4), and 
for filter4b, the number of occluded ligand acceptor atoms was reduced to a range of 0-
3. Initially filter4 included 1,303 ligands, but small changes through filter4a (1,097) and 
filter4b reduced this to only 889 ligands (2.17%). Though a small percentage of the total 
virtual screening output, this remained too high a collection of ligands for comfortable, 
valuable visual inspection, and filter4c reduced the clash count further to 14, and the 
TPSA range to 75-115Å3, reducing the set only to 777 ligands. 
 Filters 5 and 6 introduced components of the scoring function as parameters to 
the filter, namely the PLP ligand torsion term, the PLP ligand clash term, and the 
Chemscore internal correction term (these are discussed fully in section 1.3.1.3, 
histograms as figure 4.4).  Specifically, filter5 set upper-bound limits of 4 and 2 
respectively for the ligand torsion (including 32,844 ligands) and ligand clash (31,950 
ligands) terms. Overall, this gave a set of 506 ligands. The addition of an upper-bound 
limit of 4 for the internal correction term (24,776 ligands) in filter6 reduced this further 
to 447 ligands.  
 These filters in combination were sufficient to exclude extreme examples of any 
one descriptor, but in combination provided a small set for visual examination and final 
selection for laboratory testing. Therefore, filter7 was a careful change to the ranges 
acceptable in ligand selection, to provide non-stringent over-biasing descriptor filters 
and a small ligand cohort. Table 4.1 summarises filter7. 
It was possible to remove the filter on occluded acceptor atoms and, with small 
changes to the number of occluded polar and donor atom filters as well as the scoring 
function terms used, bring the total number of ligands included after filtering to only 284 
(0.69%). As can be seen in table 4.1, only the TPSA and AlogP filters exclude more than 
half the ligands, and they were decisive in returning a set of manageable size for visual 
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inspection. Also included in table 4.1 is the overall CHEMPLP fitness, though the selection 
of the top 10% of ligands occurred during file retrieval not in GoldMine; nevertheless, it 
is a filter upon which ligands were selected and it must be considered as such explicitly. 
Figure 4.6 shows the result of the filtering process on the number of ligands included for 
consideration, which follows an exponential decline through each iteration.  
 
 
Table 4.1: Parameters of final filter, filter7. 
Parameter Range Ligands Included 
CHEMPLP Fitness Top 10% 40919 
Hydrogen Bond Angle ≥ 120° 1 : 6 21949 
TPSA 75 : 110 15033 
AlogP -3 : +1 5390 
Ligand Hydrogen Bond Count 1 : 7 25941 
Occluded Donor Atoms 0 : 1 33603 
Occluded Polar Atoms 0 : 1 33231 
Ligand Clash Count 0 – 14 32399 
PLP Ligand Torsion 0.027 : 3.000 28248 
PLP Ligand Clash 0 : 2.000 31950 
Chemscore Internal Correction 0 : 3.000 20529 
 
 
Figure 4.6: Bar chart displaying the effect of each iterative filter on the overall set. In this case “total set” is 
the 40919 ligands derived by retrieving the top 10% of ligands by fitness score. The trend-line in green 
indicates the exponential decrease through each iteration of filter, with the R-squared given as 0.77. 
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Through GoldMine, the virtual screening output of over 400,000 compounds had been 
reduced to a small set of potential binders which possess the ideal physiochemical 
properties and interaction characteristics with the protein. The filters implemented have 
resulted in exponential reduction to a small set of less than 300 ligands for manual 
inspection and selection. 
 
4.2.5 Visual Inspection Aided by Mogul 
Mogul utilises structural data in the CSD (currently containing over 700,000 small 
molecule crystal structures), to evaluate the poses of the selected ligands in conjunction 
with a general visual inspection to make an informed decision on the quality of the 
docking result. By comparing the torsions and ring structures of the ligand docking into 
EthR during virtual screening to the Cambridge Structural Database, those with unusual 
torsion angles could be evaluated for taking forward. 
 Similarly, general chemical knowledge and medicinal chemistry understanding 
was used in the evaluation of likely good hit candidates. For example, thiols are known 
typically for their use in chelating metals, known to cause adverse reactions and are 
generally highly reactive. For such compounds these potential disadvantages were 
considered against any favourable protein-ligand interactions, as troublesome chemical 
groups could be replaced by bioisosteres in lead optimisation stages if active against 
EthR; additionally, they were not excluded prior to screening for similar reasons.  
Through this process of manual inspection and evaluation, the 284 ligands were 
reduced to 133 ligands, largely due to poor geometries in ligand orientation, as identified 
via Mogul. 
 The next step was to remove any duplicate scaffolds, in order for the cohort of 
compounds for biophysical screening to avoid treading the same ground; after all, for 
any active compounds identified, output at any stage of this screening pipeline would be 
probed for similar compounds for testing, and the duplicates which made it through to 
this part of the filtering would be the first choice for further investigation.  
The 133 ligands were imported into KNIME74 and the RDKit nodes used to 
calculate the Murcko scaffold144 of each structure, which was subsequently converted 
into a SMILES string. By counting the number of unique SMILES strings duplicates could 
be quickly identified. For 124 ligands the scaffold occurred only once, which is ideal for 
the diversity of testing set desired. However, three scaffolds occurred twice each, and a 
fourth scaffold was present for three ligands.  
 For the ligands ZINC08980600, ZINC15789306 and ZINC06952722, the 
structures differ by the nature of their terminal group: a t-Butyl ester group, a dimethyl 
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group, or an ethyl ester respectively (figure 4.7). The scores were also similarly clustered 
between 86.55 and 84.94.  
 
Figure 4.7: Ligands ZINC06952722, ZINC15789306 and ZINC08980600 which share a Murcko scaffold. All 
three form hydrogen bonds to Asn179 and Asn176, and pi-stack against Phe110. 
 
The docking poses for each were examined and the differences were minimal; however, 
ZINC08980600 made better hydrophobic contacts, and the geometry of the hydrogen 
bonds formed was improved over the two scaffold duplicates, and so ZINC089080600 
was taken forward while ZINC15789306 and ZINC06952722 were excluded. 
 
 
Figure 4.8: ZINC01226689 differed from ZINC00889208 in that the latter molecule possessed a nitro 
group in the meta group as opposed to the para position. 
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The decision between ZINC01226689 and ZINC00889208 was more straightforward, as 
they differed only in the position of the nitro group on the terminal phenyl ring (figure 
4.8); the former made better hydrogen bond contacts and as such, scored far higher and 
so ZINC01226689 was included for biophysical assay against EthR. 
 Similarly, the ligands ZINC00073180 and ZINC00072059 (figure 4.9) differ in 
score by only four points and in structure by only a methyl group. While the score was 
higher for the methylated form, this group made no observable important contacts and 
so this small increase in score could be an artefact of an increased hydrophobic 
interaction surface. Moreover, the torsion of the amide function within the methylated 
form was shown to be more unusual via Mogul, and so it was decided to take the 
unmethylated form ZINC00072059.  
 
Figure 4.9: ZINC0072059 was included but ZINC0073180 was not, due to the former possessing more 
acceptable torsion around the amide function. 
 
Finally, based upon the favourable contacts made between the far-higher scoring 
ZINC10777920 with Asn179 and Tyr148 in the protein, this compound was chosen over 
closely-related ZINC15754437. 
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Figure 4.10: The protein-ligand contacts made by ZINC1077920 were far more favourable than the closely 
related structure ZINC15754437, as methyl sulphone groups are typically poor hydrogen bond acceptors. 
 
A final total of 128 ligands were selected, however many compounds were no longer 
commercially available and therefore the final cohort of molecules for biophysical testing 
against EthR, as listed in appendix B, consists of 85 compounds.  
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CHAPTER V: 
THERMAL SHIFT ASSAYS ON POTENTIAL 
ETHR INHIBITORS 
Extrinsic fluorescent dyes, which rely on covalent or non-covalent probes rather than 
the inherent protein fluorescence from residues such as tryptophan or tyrosine, can be 
used for a variety of purposes in measuring the protein solution state. Covalent probes 
are typically used for measurements such as FRET, whereas non-covalent probes are 
utilised for a variety of other purposes: for example, non-covalent fluorescence probes 
have been used to monitor surface hydrophobicity;146 as active site probes;147 to monitor 
chemical degradation;148 to characterise protein aggregation and fibrillation 
events;149,150 to characterise proteins and differentiate between closely-related protein 
family members;151 and to monitor folding and unfolding processes.152 Dyes typically 
work by charge transfer from an electron donating group to a cyclic system153,154 when 
the dye moves from a polar (ie. aqueous) environment to a more hydrophobic, apolar 
environment (ie. when hydrophobic protein core residues are exposed during unfolding 
or conformational change).  
This chapter details the use of such non-covalent fluorescent molecular probes 
in identifying compounds which bind a target protein. This is possible using a thermal 
shift assay (TSA), also known as Differential Scanning Fluorimetry (DSF)151 or 
Thermofluor.155 Figure 5.1 shows a typical protein melting curve, represented by heating 
EthR in the presence of fluorescent probe SYPRO Orange (Invitrogen). 
 
 
Figure 5.1: Protein melting curve (native EthR). The protein remains folded and the probe largely 
quenched until the Tm of the protein is reached and hydrophobic core residues are exposed. 
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The protein melting curve is a standard denaturation curve, monitored by the 
fluorescent probe. Theoretically, as the temperature increases, the protein gains more 
kinetic energy but does not unfold. When the melting temperature (Tm) of the protein is 
approached, the protein begins to unfold and denature, exposing the usually-buried 
hydrophobic residues of the protein core to the aqueous environment. This causes the 
probe to be unquenched and an increase in fluorescence is directly proportional to the 
unfolding of the protein, reaching a maximum when all the protein is unfolded. A 
decrease in fluorescence is then observed at high temperatures due to aggregation of the 
degraded protein products which serves to once again sequester hydrophobic residues 
and quench the probe in solution. 
 This method has been used in the past to determine optimum stabilising 
solutions for crystallisation,156,157 evidenced as a positive shift in the curve and resulting 
Tm. In recent years, this has been adapted for high-throughput screening of potential 
binding compounds in drug discovery programs, due to its scalability, simplicity of 
execution, and low protein and compound consumption.157 Rather than, in crystallisation 
screening Thermofluor assays, changing the buffer and metal conditions, a ligand 
screening assay keeps the buffer conditions constant and varies only the compound to 
be screened. 
  
5.1 Thermal Shift Assays on EthR 
The first use of a thermal shift assay with EthR was reported in 2011,123 to compare the 
wild-type functional protein with a site mutant G106W which was unable to bind DNA, 
and each with ligands BDM31343, BDM31381 and BDM14801 to demonstrate their 
effectiveness in binding the wild-type but not the G106W mutant (figure 5.2).  
 
Figure 5.2: Ligands BDM31343,123 BDM31381119 and BDM14801124 bound to EthR. The G106W mutant 
precludes ligand binding by blocking the binding site, and induces the inhibitory conformation of EthR.123 
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Carette et al.123 utilised proprietary dye SYPRO Orange (Invitrogen) to monitor the 
protein unfolding and a Lightcycler 480 (Roche), a real-time PCR apparatus for 
microtitre plates. Samples were heated from 37 to 85°C, at a rate of 0.04°C/s. 
Fluorescence was measured at excitation/emission wavelengths of 465/510 nm. The 
protein and buffer conditions are detailed below in section 5.3. In this case, the thermal 
shift assay was used for corroborating the biophysical behaviour of a mutant EthR; in 
2012 and 2014 the assay was adapted for the discovery of inhibitors with novel scaffolds, 
and fragment inhibitors respectively. 
 For the identification of novel N-phenylphenoxyacetamide derivative 
inhibitors129 the authors used a thermal shift assay to screen 22 compounds, identified 
through phenotypic screening, against a reporter-modified strain of Mycobacterium 
smegmatis. All of these compounds demonstrated, in dose-response experiments, IC50 
values below 10 µM. Six compounds, of the 22 screened by thermal shift, showed a 
significant change of greater than 4°C in the melting temperature. Among these, three 
were members of this novel N-phenylphenoxyacetamide family, with the best activity 
being an IC50 of 2.9 µM and ΔTm of 6.4°C.129 
 In the development of fragment-derived inhibitors for EthR, Villemagne et al.131 
identified a small fragment used in previous click-chemistry approaches124 as having a 
weak binding affinity for EthR. This fragment showed a very small shift of 0.1°C to the 
Tm, a weak but notable difference given the sensitivity and accuracy afforded due to a 
0.04°C/s temperature change rate. Orthogonal testing with SPR determined the 
fragment in question to have a 160 µM IC50 for the inhibition of DNA binding by EthR. 
Subsequent fragment growing and linking approaches yielded eleven small compounds 
with a range of ΔTm from 0.56 to 6.1°C, however only three of the initial eleven 
demonstrated an ability to boost ethionamide activity in M. tuberculosis-infected 
macrophages at an EC50 below 10 µM. Subsequently one of these compounds was taken 
forward for development and of the five resulting compounds which demonstrated the 
ability to shift the Tm by 2.3 to 11.2°C, only three were able to effectively boost 
ethionamide.131  
 This aptly demonstrates the supposed propensity of thermal shift assays toward 
false-positive inhibitor identifications.158 Thermal shift assays are often misunderstood 
as a method of inhibitor identification but this is not the case: thermal shift assays 
identify molecules which alter the melting temperature of the target protein. Ideally, 
molecules which do this are those which bind the protein and would have an inhibitory 
effect; however, it is also possible that these molecules form transient interactions or 
otherwise alter the aqueous environment to stabilise or destabilise the protein, without 
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true binding. It is therefore important when conducting thermal shift assays to be 
mindful of the limitations of the method, and to utilise orthogonal biophysical methods 
to confirm ‘hits’. 
 
5.2 Expression of EthR for Biophysical Assays 
The thermal shift assays were conducted over multiple batches of protein and in 
triplicate. Initially, EthR used was obtained from the Baulard group (Institut Pasteur de 
Lille), however later batches were expressed in-house using the pET-15b-ethR plasmid 
provided by the Baulard group and prepared as previously described.121 The plasmid 
encodes EthR with an N-terminal histidine tag with the sequence 
MGSSHHHHHHSSGLVPRGSHM.  
Protein was expressed using Escherichia coli BL21(DE3) cells, to which pET-15b-
ethR was transformed. E. coli was grown in LB broth inoculated with ampicillin to an 
OD600nm of 0.6-0.7, at which point isopropylthiogalactosidase (IPTG) was added to a 
final concentration of 1_mM, and grown for an additional three hours. Cells were 
harvested by centrifugation at 12000 g at 4°C and subsequently re-suspended in lysis 
buffer (50 mM NaH2PO4, 300_mM NaCl, pH 7.5, 10 mM imidazole) and lysed by two 
passages through a French Pressure cell at 6.2 x 106 Pa, followed by centrifugation at 
20000 g for 25 min at 4°C. The supernatant was recovered and histidine-tagged EthR 
was separated from the whole-cell lysate using Ni-NTA agarose chromatography 
(Qiagen). His6-EthR was eluted from the column with 100 mM imidazole in lysis buffer 
and dialysed overnight against 50 mM NaH2PO4, 300 mM NaCl at 4°C for subsequent 
separation on a Superdex 200 gel filtration column (GE Healthcare) to ensure maximum 
purity. SDS-PAGE gels were used to confirm good purity and confirm protein presence at 
around 24 kDa. Identity of the protein was confirmed by in-gel trypsin digest and 
subsequent MALDI-TOF mass spectrometry. 
Approximately 1 mg ml-1 of purified protein in a total volume of approximately 
50_mL was obtained for four litres of initial growth, as determined by Nanodrop 
(ThermoScientific). Protein was dialysed against 10 mM TRIS HCl pH 7.5, 200 mM NaCl 
and stored at 4°C until use, concentrated as needed by spin concentration, operated 
according to the manufacturer’s recommended parameters (Vivaspin, Generon). 
 
5.3 Protocol Implementation: SYPRO Orange Excited at 505-535 nm 
Using a protocol for thermal shift assays developed in-house on both lysozyme and 
glucose isomerase,155 initial tests with DMSO-only and positive controls were conducted 
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to determine if previous experiments by Flipo et al.129 could be replicated in Durham, and 
that melting curves for EthR could be obtained. 
 Initially, this combined the protein concentrations and preparations from Flipo 
et al.129 with the operational protocol of the Applied Biosystems Fast 7500 qPCR for 
differential scanning fluorimetry.155 Experiments were conducted in 96-well PCR plates 
(ThermoScientific) and sealed with polyolefin film (ThermoScientific). Protein and 
SYPRO Orange were mixed to an initial concentration of 20 µM and 5X respectively, with 
this solution and the 40 µM compound solution being added to the well in a 1:1 ratio. 
Final sample concentrations for negative controls were 10 µM (0.24 mg ml-1) EthR, 2.5X 
SYPRO Orange, 1% DMSO, and for positive controls included 20 µM ligand. Samples were 
then heated from 24 to 95°C with a heating rate of 1°C/min. The fluorescence was 
measured at Ex/Em = 510/510 nm, and data interpreted by NAMI155 to give the melting 
temperature, Tm. 
This protocol adapted from Flipo et al.129 resulted in high background 
fluorescence, and poor melting curves for unbound EthR (figure 5.3).  
 
Figure 5.3: Melting curves (green) for unbound EthR as provided by NAMI.155 High background 
fluorescence obscures any signal. The green points show the raw fluorescence at each degree, the pale pink 
line is the result of interpolation to calculate the rate of change between points, and the solid red line 
indicates suggested melting temperature. 
 
Additionally, very weak transitions were observed for known low-affinity binders (such 
as BDM31343) although strong transitions were identified for known high-affinity 
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binders to EthR (such as BDM41906). Examples of these curves as analysed by NAMI can 
be seen in figure 5.4. However without a protein-only control, no shift could be 
determined from these curves. 
 
 
Figure 5.4: Melting curves (green) for EthR with BDM31343, left, and BDM41906, right. Despite weak 
transition for BDM3143, NAMI155 was able to interpolate a melting temperature (red line). 
 
Initially it was supposed that EthR, possessing a hydrophobic binding site, could be 
sequestering the SYPRO Orange such that weaker-binding compounds were unable to 
displace it; the high background fluorescence observed could therefore be a result of 
unquenched SYPRO Orange in the EthR binding site. However, adaptation of the protocol 
to allow the protein and target compound to incubate for 30 minutes prior to addition of 
SYPRO Orange showed no improvement, and where the protein had been incubated 
without compound for the same amount of time, only a weak transition was identified 
around 59°C. This would not be sufficient to identify low affinity ligands, nor is it a 
reliable negative control. Therefore, alternative strategies were investigated. 
 
5.4 Protocol Optimisation: SYPRO Orange Excited at 455-485 nm 
At an excitation wavelength of 510 nm, it was not possible to derive a melting curve for 
EthR, either in the native state without a ligand or bound to weak ligands. However, this 
protocol had worked for other model proteins and so alternative dyes were considered. 
Firstly, SYPRO Red (Invitrogen) and later Bis-ANS (Sigma Aldrich). 
 SYPRO Red is a molecular probe typically used, like SYPRO Orange, for protein 
gel staining; they are highly similar, but SYPRO Red is reported to have lower background 
fluorescence which was deemed desirable for use with EthR. Another key difference 
between the two SYPRO dyes are their excitation and emission spectra – SYRPO Red 
excites at a higher wavelength (maxima ~ 550 nm compared to ~ 480 nm for SYPRO 
Orange) and therefore the protocol described above in section 5.3 would not have to be 
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adapted. However, this too proved unsuitable, as comparison with a lysozyme control 
demonstrated weak transitions and high instrinsic fluorescence for EthR similar to that 
observed with SYPRO Orange (data not shown).  
Therefore, the decision was taken to reduce the excitation wavelength to this 
range (Ex/Em: 485/510 nm) and test SYPRO Orange with 10 µM EthR under varying 
concentrations of dye. This experiment was only run from 51-95°C as the EthR melting 
temperature was known to be in the region of 56-59°C from previously published 
data.159 Cconcentrations of 20X SYPRO Orange down to 2.5X SYPRO Orange were able to 
give good melting curves for EthR with even a concentration of 1.25X sufficient for NAMI 
to derive a melting temperature for EthR (56.3 ± 0.2°C). 
 
Figure 5.5: 10 µM EthR with varying concentrations of SYPRO Orange dye at Ex/Em: 485/510 nm.  
 
To determine the optimum EthR and SYPRO Orange concentrations, a grid screen-style 
thermal shift was used. Concentrations of EthR from 1.8 to 0.056 mg ml-1 were tested 
with decreasing concentrations of SYPRO Orange from 20X to 0.625X. Figure 5.6 shows 
the results as the table output from NAMI,155 annotated from one experiment. 
From figure 5.6, it is clear to see that at low protein concentrations, high SYPRO 
Orange concentrations provide too high a background fluorescence to accurately 
differentiate the protein melting curve signal. Conversely, at low SYPRO Orange 
concentrations, the dye content is not sufficient to give enough signal upon protein 
unfolding. 
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Figure 5.6: Partial table output from NAMI for EthR (1.8 – 0.056 mg ml-1) vs. SYPRO Orange (20X – 0.625X) 
screen. “DEN” denotes denatured samples or those curves for which NAMI could not assign a Tm. An 
estimated reference temperature of 57.5°C and a range of 0.5° was defined to colour code stabilising (blue) 
and destabilising (red) conditions, and highlight the ideal region of protein:dye concentrations. 
 
The ideal range for SYPRO Orange concentration therefore falls between 10X and 2.5X. 
The data for 5X across all concentrations of EthR gave the most promising melting 
curves, shown as figure 5.7, below. 
 
Figure 5.7: Fluorescence melting curves for varying concentrations of EthR with 5X SYPRO Orange. 
 
The best compromise between SYPRO Orange concentration and EthR concentration, 
which gave a deep and clear transition under melting, was chosen as 0.9 mg ml-1 with 5X 
20 30 40 50 60 70 80 90 100
EthR + 5X SYPRO Orange
1.8 mg ml-1 0.9 mg ml-1 0.45 mg ml-1
0.225 mg ml-1 0.1125 mg ml-1 0.056 mg ml-1
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SYPRO Orange (orange curve in figure 5.7, second from the top). For future experiments, 
the concentration of EthR was rounded to 1 mg ml-1. 
For thermal shift assay, protein was concentrated to 2.5 mg ml-1 by spin 
concentration (Vivaspin, Generon). Each well contained 8 µL of the 2.5 mg ml-1 EthR 
stock, 2-µL SYPRO Orange (diluted to 50X from 5000X stock, Invitrogen) and 10 µL of 
ligand sample. This gave final concentrations of 1 mg ml-1 EthR, 5X SYPRO Orange and 
ligand concentrations at either 400 µM, 320 µM, 160 µM or 40 µM.  
Each 96-well plate was used to assay up to 23 compounds plus one negative 
control, arranged such that A1, B1, C1, and D1 for example all contained the same 
compound in decreasing concentrations. Samples were then heated from 24 to 95°C with 
a heating rate of 1°C/min. The fluorescence was measured at Ex/Em = 485/510 nm, and 
data interpreted by NAMI155 to give the melting temperature, Tm. 
 
5.5 Results: Biophysical Identification of Potential EthR Binders 
For each of the 85 compounds tested and at each concentration (400, 320, 160 and 
80_µM), thermal shift assays were conducted in triplicate. Full tabulated results for each 
compound in triplicate can be found in Appendix B. 
 By using multiple concentrations of compound it was possible to assess which 
shifted the melting temperature of EthR in a concentration-dependent manner; this 
would indicate compounds which were truly affecting the protein melting temperature. 
A total of 42 negative control melting temperatures were taken for an ‘average’ EthR 
melting temperature of 59.3 ± 1.2°C in the absence of compound. Similarly, triplicate 
melting temperatures for each compound at each concentration were averaged, and the 
melting temperature of EthR subtracted to give the shift (ie. ΔTm). A total of twenty 
compounds from the initial screening cohort of 85 were selected as demonstrating a 
concentration-dependent shift in the melting temperature of EthR (figure 5.8). 
 
81 
 
 
Figure 5.8: Cohort of ‘hits’ represented as a bar chart of compound concentration and ΔTm.  
 
Selection criteria was lenient with dependent-like shifts in order to include a range of 
promising hits and potential binding affinities. Compounds were screened using a 
‘working code’ in order to prevent confusion between long alpha-numerical ZINC codes. 
Table 5.1 correlates the working code used during experimentation (NJT#) with the ZINC 
code of the compound. 
 
Table 5.1: Working codes of thermal shift ‘hit’ compounds with the original ZINC code.  
Code ZINC Code ZINC 
NJT03 ZINC67692217 NJT56 ZINC08987568 
NJT04 ZINC65406277 NJT57 ZINC09689958 
NJT10 ZINC67974892 NJT58 ZINC71795591 
NJT15 ZINC00237604 NJT60 ZINC14848503 
NJT17 ZINC32576321 NJT64 ZINC69416783 
NJT25 ZINC06726755 NJT72 ZINC03420970 
NJT31 ZINC24615603 NJT74 ZINC08980600 
NJT42 ZINC53275627 NJT80 ZINC01502258 
NJT48 ZINC69489717 NJT84 ZINC09087663 
NJT50 ZINC12794882 NJT85 ZINC19234873 
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5.5.1 Temperature-Dependent Thermal Shifts 
The twenty selected ‘hits’ demonstrate the ability to shift the melting temperature of 
EthR in a concentration-dependent manner. Figure 5.9 shows the top five compounds 
which shift the melting temperature of EthR by greater than 3°C. 
 
 
Figure 5.9: Cohort of ‘hits’ which showed a ΔTm of greater than 3°C at 400 µM. 
 
Compound NJT80, though 400 µM does not follow the concentration-dependent pattern, 
is included in the top five compounds as the shift is still greater than 3°C. The second 
cohort of five compounds are able to shift the melting temperature of EthR by greater 
than 1°C (figure 5.10). Interestingly, compound NJT85 is the only compound which 
causes a concentration-dependent negative shift in the melting temperature of EthR, 
suggesting a destabilising rather than stabilising interaction effect on the protein. 
 A proportion of 50% of the chosen ‘hit’ compounds demonstrate an ability to 
shift the melting temperature of EthR, in a concentration-dependent manner, to a 
measure of 1°C or greater. 
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Figure 5.10: Cohort of ‘hits’ which showed a ΔTm of greater than 1°C at 400 µM. NJT85 is notable as the 
only compound which showed a concentration-dependent destabilisation (or negative-shift) in EthR Tm. 
 
5.5.2 Small-Shift Compounds 
A total of ten compounds produced shifts smaller than 1°C and so within the error of the 
EthR melting temperature (59.3 ± 1.2°C), but were included as thermal shift ‘hits’ due to 
a concentration-dependent pattern to the shift in melting temperature caused by the 
compound. In this preliminary stage of ‘hit identification’ the decision was taken to be as 
generous and inclusive as possible in order to maximise the chances of identifying a 
range of promising EthR-binding compounds.  
 
5.6 Summary 
Of the 85 compounds tested from the virtual screening results, a total of twenty are able 
to shift the EthR melting temperature (in a positive, stabilising direction with one 
exception) with a range of success. The structures of these compounds can be found in 
appendix B, with the associated binding data as determined by SPR (chapter seven). Five 
compounds in particular show great promise, shifting the EthR melting temperature by 
greater than 3°C: NJT15, NJT25, NJT57, NJT60 and NJT80. Additionally, compound NJT85 
demonstrated a negative shift in protein melting temperature, suggesting a destabilising 
effect upon binding. All twenty, with keen emphasis on these six most promising and 
interesting hits, were taken forward into co-crystallisation trails and for preliminary 
assay by additional biophysical methods; namely surface plasmon resonance (SPR).  
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CHAPTER VI: 
SURFACE PLASMON RESONANCE STUDIES 
Surface plasmon resonance (SPR) is a chip-based method of binding and kinetic assay 
for biophysical interactions, adaptable for a variety of interactions.   
SPR measures biomolecular interactions in real-time, and technically label-
free.160 SPR can be used to determine interaction affinities, association and dissociation 
rates, and determine stoichiometry. This is achieved in practice due to the reflection of 
incident light from a coated metal-filmed chip. Chips for SPR have a variety of 
functionalised surfaces on which a binding partner can be immobilised, and subsequent 
binding of an analyte introduced at a constant flow rate over the chip surface causes 
changes in the refractive index of the incident light; the sensorgram of this interaction is 
provided in real-time.  
 
Figure 6.1: Surface plasmon resonance utilises functionalised chip surfaces to which ligands are 
immobilised. Analytes can then be injected over the flow cell, and the change in SPR angle of the reflected 
light is directly proportional to molecular mass change.161 
 
The change in magnitude of the signal is directly proportional to the mass of the molecule 
binding, and the rate of change in the sensorgram can be interpreted for association, 
dissociation and equilibrium rate constants. 
 The BIACore 3000 system (www.biacore.com, GE Healthcare) uses chips 
consisting of a glass slide with a thin gold film, with four channels known as “flow cells”. 
The chips are functionalised for immobilisation, for example the CM5 chip for covalent 
amine coupling; the Ni-NTA chip for polyhistidine-capture; and the SA chip 
functionalised with streptavidin, for biotin-tag capture. 
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 This chapter details the use of SPR to perform preliminary assessment of the 
ability of potential EthR inhibitors (identified via virtual screening and subsequent 
thermal shift assays) to bind EthR. 
 
6.1 Confirmation and Quantification of EthR-Binding by SPR 
SPR has been used as a functional assay to determine IC50 values for EthR inhibitors,119 
as well as to kinetically characterise their binding to EthR.159 Notably, Crauste et al. 
demonstrated the conformational change EthR undergoes upon binding to inhibitors is 
such that changes in the response unit were dose-dependent, and therefore EthR can be 
immobilised on a CM5 chip and binding can be determined by direct capture.159 
Additionally, they observed unexpected negative signals with the characteristic shape 
which they analysed successfully. Here, the method developed by Crauste et al. was 
implemented to test the novel binding compounds identified by virtual screening. 
However, without the EthR mutant G106W to use as a negative control, the reference cell 
used is simply unmodified surface lacking immobilised EthR.  
 
6.2 Method: Immobilisation of EthR 
EthR (20 µg/ml in 10 mM sodium acetate, pH 4.5) was immobilised on a CM5 chip in 
HBS-EP buffer supplemented with 1% DMSO by amine coupling according to 
recommended protocols to a target of 2000 RU. It is recommended kinetic experiments 
are performed at the lowest manageable immobilisation level, and an immobilisation 
level of 2000 RU would give a theoretical response of 28 RU for a 350 Da analyte. This 
corresponds to approximately 2 ng/mm2 of EthR on the chip surface. 
The Biacore surface preparation wizard was utilised for amine coupling 
immobilisation on flow cell 4, utilising flow cell 3 as a control. Briefly, 70 µL of 0.2M EDC 
and 0.05 M NHS was injected at a flow rate of 10 µL/min to activate the surface, followed 
by several short injections of EthR to achieve the desired immobilisation level (figure 
6.2). Once reached, the surface was deactivated with a 70 µL injection of 1 M 
ethanolamine pH 8.5. EthR was immobilised to a final level of 2245 RU. 
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Figure 6.2: SPR Sensorgram of EthR immobilisation on CM5 chip by amine coupling utilising EDC/NHS for 
activation, and ethanolamine for deactivation (labelled). 
 
6.2.2 Method: Determination and Quantification of Compound Binding 
Per the method described by Crauste et al.,159 ligands were injected for five minutes at a 
flow rate of 20 µL/min, a sufficient time to observed equilibrium for at least two 
concentrations. Figure 6.3 shows the type of sensorgram observed by Crauste et al.162 
 
 
Figure 6.3: Example sensorgram from Crauste et al.162 and a corresponding dose response curve (values 
multiplied by -1, as treated by authors in data processing). 
 
Due to limited compound stock, it was not possible to assay a wide range of 
concentrations, nor was it possible to always perform experiments more than twice. 
Concentrations used therefore vary between 250 and 5 µM, and experiments were 
performed at least in duplicate, and in triplicate where possible. 
  Compounds were injected over the chip surface at a flow rate of 20 µL/min. 
Ligands were prepared in HBS-EP buffer with a final DMSO concentration of 1% to match 
running buffer. Regeneration of the surface was observed during the course of the 
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running buffer, therefore a period of 20 minutes (15 minutes dissociation, 5 minutes 
regeneration time) was used to recover initial baseline. Figure 6.4 shows an example 
sensorgram, from injection start to the end of the dissociation phase. 
 
Figure 6.4: SPR sensorgram of compound 10 binding to EthR. Large difference injection start/stop peaks, 
arising from the small time delay between the two channels, are omitted for clarity. Programmed 
dissociation phase ends at 1400 s, 15 mins from injection end. 
 
6.3 Results 
Full raw spectra for each compound can be seen in Appendix C. Initially, separate fitting 
of ka and kd was performed in order to obtain estimates of these values for global fitting; 
subsequently global fitting was performed to the 1:1 Langmuir binding model with 
baseline drift. In this manner, estimations of the binding constants could be made, and 
are given in table 6.1.  
 However it can be observed from figure 6.4, exemplary of many sensorgrams 
obtained, that the magnitude of binding does not correlate with concentration as would 
have been expected. Maximum response unit values were extracted for each curve at the 
end of injection and were plotted against ligand concentration (figure 6.5).  
 
 
Figure 6.5: Dose-response curve for compound 10, corresponding to figure 6.4. 
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The corresponding dose-response curve for compound 10, used for figure 6.4, can be 
seen as figure 6.5. Dose-response curves were created in this manner for all SPR 
experiments with all compounds, and can also be found in appendix C. As can be clearly 
observed in figure 6.5, there is some considerable variation between maximal RU values 
for the same concentration (ie. 200 µM), and overall there is no observable 
concentration-dependent relationship.  
 Though not conclusive, some dose-response curves show promising trends. For 
compound 85 there is a notable upward trend, and for compound 25 a notable negative 
trend (figure 6.6). 
 
 
Figure 6.6: Dose-response curves for compounds 85 and 25. 
 
The slight increase in the dose-reponse relationship for compound 85 indicates binding, 
and potentially covers the beginnings of saturation where the curve-fit approaches a 
horizontal; a fuller concentration range will determine if this is the case. Compound 25 
shows a very different dose-response relationship, as the response units – directly 
correlated to mass on the surface of the chip – decreases with increasing concentration. 
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This profile of curve indicates compound 25 binds at low concentrations, but at 
concentrations exceeding 50 µM, this compound begins to dissociate from the protein, 
or causes some other loss of mass from the chip surface. Again, a fuller dose-response 
relationship will be elucidated from a further screen of wider concentrations. 
 
 
Figure 6.7: Dose-response curves for compounds 3, 4 17, 31, 42 and 48. 
 
Of the dose-response curves shown above in figure 6.7, several compounds show little 
variation (ie. compound 48, figure 6.7, bottom right). At a maximal response of 30-35 RU, 
this indicates complete binding but is insufficient to derive a binding affinity. 
Contrastingly, compound 31 shows an upward trend in dose-response.  
The dose-response curve for compound 50 (figure 6.8, top left) shows no binding 
whatsoever under the experimental conditions. This implies either an inability to bind 
EthR or a very weak affinity in excess of 250 µM. The dose-response curve for compound 
57 (figure 6.8, top right) shows little variation in binding at the concentrations used, 
which could indicate saturation has been reached. Data for compound 80 (figure 6.8, 
bottom right) is especially noisy, with a wide range within each concentration. 
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Ultimately, the curves obtained from these preliminary studies can only be used for 
tentative conclusions about binding capability, and not for binding affinity. 
 
Figure 6.8: Dose-response curves for compounds 50, 57, 58, 60, 64, and 80. 
 
In order to determine if these curves, particularly those which are more linear, show pre-
binding or saturation of the protein, these experiments will have to be repeated with a 
wider range of concentrations. This range must include sub-micromolar concentrations 
as well as those in excess of 250 µM in order to accurately determine binding affinity and 
acquire publication quality data. 
The BIAEvaluation software (v.3.1) was able to fit a 1:1 Languir binding model 
with baseline drift to all SPR binding data obtained. Despite presenting low Chi-squared 
values and a generally good appearance of fit, it is clear from the dose-response curves 
that the calculated binding affinities are estimates at best. They are presented here in 
table 6.1 as binding affinity estimates, but should be treated with due caution. Separate 
fitting of ka and kd was performed in order to obtain estimates of these values for global 
fitting; subsequently global fitting was performed to the 1:1 Langmuir binding model 
with baseline drift. 
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Table 6.1: Summarised binding affinity data for each compound. Chi-squared values are all within ideal 
values – 5% of a 25 Rmax corresponds to a χ2 of 1.25. Compounds 15, 60, 72, 74 and 84 were untested due 
to low compound stock. Compound 50 showed no binding and so did not undergo fitting. 
Compound KD / µM χ2 
03 106.0 0.725 
04 465.0 0.270 
10 71.7 0.708 
17 34.0 0.962 
25 14.4 0.303 
31 430.0 0.374 
42 284.0 0.099 
48 73.8 0.858 
56 12.9 0.588 
57 5.0 0.412 
58 465.0 0.270 
64 3.8 0.356 
80 178.0 1.14 
85 20.9 0.475 
 
6.4 Summary 
Pilot experiments undertaken with the remainder of each compound stock after 
crystallisation trials indicate many compounds capable of binding EthR, some with 
potentially low-micromolar affinity. For full binding affinity characterisation to occur, a 
wider range of concentrations will be required. 
 Only one compound from this cohort has been observed not to bind EthR at all, 
namely compound 50. Of the 14 compounds tested by SPR, this gives a hit rate of 93%. 
Once binding affinities have been accurately determined, the kinetic data can be used in 
conjunction with structural data (presented in chapter seven) to identify good hits to use 
as optimisation starting points. 
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CHAPTER VII: 
CO-CRYSTAL STRUCTURES OF EthR  
AND POTENTIAL INHIBITORS 
In conjunction with biophysical studies previously described, co-crystallisation 
experiments were undertaken to determine crystal structures of EthR bound to 
identified potential hit compounds. This chapter details the methods and results of 
crystallisation and co-crystallisation endeavours; as well as analysis of the resulting 
crystal structures with notable comparisons to the in silico predicted binding modes. 
 
7.1 Introduction 
Well-established, known conditions (referenced below for table 7.1) were used to first 
crystallise EthR in the absence of added compound. Once this could be achieved, co-
crystallisation would be undertaken under the same conditions using published co-
crystallisation methods for EthR to acquire liganded structures.1  
 
7.2 Native EthR Crystallisation Methods 
EthR, freshly purified and dialysed into a buffer containing 10 mM TRIS HCl pH 7.5 and 
200 mM NaCl, was concentrated to 9 mg ml-1. A 24-condition crystallisation screen was 
prepared covering previously published crystallisation conditions,111,119,124,127–129 
detailed in table 7.1. All solutions were prepared and sterile filtered in 10 mL stocks with 
ammonium sulphate (VWR), MES (2-(N-morpholino)ethanesulfonic acid, Melford 
Laboratories Ltd.) and glycerol (Melford Laboratories Ltd).  
 
7.3 Native EthR 
Six hanging-drop crystallisation trays of EthR at 9 mg ml-1 (drops consisting of 1 µL 
protein solution : 1 µL reservoir solution) were set up according to the conditions in table 
7.1. Protein crystals grew at 20°C within two days, in 41-85% of conditions; 
crystallisation was least successful at the highest ammonium sulphate concentration, 
and at the highest concentration and pH of MES (ie. row D, 0.15M MES pH 6.5).  
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Table 7.1: Crystallisation screen for EthR, utilised for native and ligand co-crystallisation. 
 1 2 3 4 5 6 
A 1.40 M 
(NH4)2SO4; 
0.1M MES  
pH 6.0; 
10% glycerol 
1.45 M 
(NH4)2SO4; 
0.1M MES  
pH 6.0; 
10% glycerol 
1.50 M 
(NH4)2SO4; 
0.1M MES 
pH 6.0; 
10% glycerol 
1.55 M 
(NH4)2SO4; 
0.1M MES  
pH 6.0; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.1M MES  
pH 6.0; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.1M MES  
pH 6.0; 
10% glycerol 
B 1.40 M 
(NH4)2SO4; 
0.1M MES  
pH 6.5; 
10% glycerol 
1.45 M 
(NH4)2SO4; 
0.1M MES  
pH 6.5; 
10% glycerol 
1.50 M 
(NH4)2SO4; 
0.1M MES 
pH 6.5; 
10% glycerol 
1.55 M 
(NH4)2SO4; 
0.1M MES  
pH 6.5; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.1M MES  
pH 6.5; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.1M MES  
pH 6.5; 
10% glycerol 
C 1.40 M 
(NH4)2SO4; 
0.15M MES  
pH 6.0; 
10% glycerol 
1.45 M 
(NH4)2SO4; 
0.15M MES  
pH 6.0; 
10% glycerol 
1.50 M 
(NH4)2SO4; 
0.15M MES 
pH 6.0; 
10% glycerol 
1.55 M 
(NH4)2SO4; 
0.15M MES  
pH 6.0; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.15M MES  
pH 6.0; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.15M MES  
pH 6.0; 
10% glycerol 
D 1.40 M 
(NH4)2SO4; 
0.15M MES  
pH 6.5; 
10% glycerol 
1.45 M 
(NH4)2SO4; 
0.15M MES  
pH 6.5; 
10% glycerol 
1.50 M 
(NH4)2SO4; 
0.15M MES 
pH 6.5; 
10% glycerol 
1.55 M 
(NH4)2SO4; 
0.15M MES  
pH 6.5; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.15M MES  
pH 6.5; 
10% glycerol 
1.60 M 
(NH4)2SO4; 
0.15M MES  
pH 6.5; 
10% glycerol 
 
Notably, crystallisation was most successful with freshly purified protein (ie. ≤ 2 days 
since size exclusion chromatography). Figure 8.1 features examples of the crystals 
obtained, all either needle or column-shaped in morphology. 
 
Figure 7.1: Crystal growth from conditions in row A, B, C and D. Scale bars A, B, D at 500 µM; C at 600 µM. 
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Crystals were mounted on an in-house diffractometer (Bruker Microstar with Cu-Kα 
rotating anode) to ascertain their identity as the desired protein. No ice rings or ice 
formation was observed, and the crystals were well frozen, indicating 10% glycerol 
sufficient as cryo-protectant as part of the crystallisation cocktail. Diffraction was 
observed to approximately 3.5 Å and was sufficient to determine the unit cell as being 
tetragonal P, with a = b = 122 Å, and a c length of 33 Å. These matched unit cells of 
published EthR crystal structures.  
 
7.4 Co-Crystallisation Methods 
Using the crystallisation screen detailed in table 8.1, crystal trays of EthR with all twenty 
hit compounds were established. A solution of 9 mg ml-1 EthR was allowed to equilibrate 
with a compound at room temperature for approximately 24 hours prior to setting up 
crystallisation experiments, by mixing 9 µL protein with 1 µL of compound (at a 
concentration of 33 mM in 100% DMSO); this gave a final compound concentration of 
3.3 mM, and a final DMSO content of 10%. Initially, a half-hour incubation period was 
used for protein-ligand equilibration, however trays established with the remaining 
protein-ligand cocktail, which had been left at room temperature overnight, proved far 
more successful.  
Of the successful trays, crystals were most abundant in trays of compound 85 - 
somewhat unexpected given the thermal shift assay had demonstrated this compound 
caused a negative effect on the melting temperature of the protein, indicative of a 
interaction which destabilised protein. A crystal from a tray of EthR co-crystallised with 
compound 85 was mounted in-house to ensure the unit cell resembled that of EthR. 
Diffraction was observed to around 3.5 Å, as with the native EthR crystals. The unit cell 
obtained was slightly different from those published, in that the crystal system best fitted 
by the matrix was found to be Orthogonal P, with cell lengths of 33 Å, 118 Å and 120 Å 
for a, b and c respectively. However, these match closely enough to previously obtained 
unit cells for EthR that there was cause for reasonable confidence these crystals were at 
least of the protein. For high-resolution data, crystals of EthR (native and co-crystallised 
with compounds) were flash-cooled162 in liquid nitrogen and transported to Diamond 
Light Source for data collection. 
 
7.5 Synchrotron Data Collection and Assessment of Ligand Density 
Crystals obtained from co-crystal trays for compounds 25, 57, 60, 80, and 85, and a 
further set of crystals representing compounds 3, 10, 15, 42, 50, and 74 were tested on 
beamlines I04-1 and I03 respectively at Diamond Light Source by remote access. For 
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each of the crystals, four images were taken (Δ = 45°) at 20% transmission of beam at 
wavelength (λ) 0.91741 Å, with 0.2s exposure time, and a resolution limit of 2.3_Å 
(detector distance = 310 mm). The aperture of the beam used was 70 µm by default, or 
reduced to 30 µm if deemed necessary for smaller crystal sizes. Strategy calculations are 
carried out automatically by EDNA Mxv1163 and Mosflm.164 Typically, the starting 
position suggested by Mosflm was utilised. The xia2 pipeline was used to initially 
determine data quality and (by rigid body refinement) the presence of ligand prior to 
manual processing. 
 Of the first cohort of potential co-crystals, ligand density was observed for data 
corresponding to experiments with 25, 57, 60, 80 and 85; for cohort two, ligand density 
was observed for data corresponding to experiments with 3, 10, 15, 42 and 74. 
Therefore, of the crystals tested, only crystals from conditions including compound 50 
failed to yield data with ligand density present; compound 50 was previously shown not 
to bind EthR in pilot SPR experiments (chapter six). 
 Upon confirmation of the presence of ligand density, the data were carefully 
reprocessed in XDS.165 Initially, all collected data were indexed and scaled, and the output 
examined to determine an appropriate place to cut low-quality, highest resolution data 
from the data set. This resolution limit was then used to re-index and re-scale the data. 
To convert the output of HKL co-ordinates and intensities from XDS into structure factors 
in the MTZ format for electron density refinement, Aimless166 was used as part of the 
CCP4i (v6.5) package.167 FreeR flags were generated for 5% of the data. 
 Each set of data per successful co-crystallisation experiment will now be 
discussed in further detail. In all but two cases, rigid body refinement in Refmac5168 was 
used to place the monomeric protein model with water and ligands removed. In the cases 
of EthR with compounds 3 and 10, this procedure failed and was followed by molecular 
replacement in Phaser.169,170 Refinement was carried by Refmac5 with additional 
modelling of side-chains, waters and ligands in Coot171. Ligand dictionaries were 
generated using PRODRG172 based on co-ordinates from virtual screening poses.  
 
7.5.1 Compound 3 
Data for a crystal of EthR co-crystallised with compound 3 were obtained to a resolution 
of 1.8 Å. Full scaling/integration statistics are given for each structure in Appendix D. 
Attempts to solve the structure of EthR with compound 3 via simple rigid body 
refinement were unsuccessful, resulting in a poor model fit and Rwork/Rfree factors of 45% 
and 48%, respectively. Molecular replacement in Phaser was employed to produce a 
better initial solution and starting protein model for subsequent refinement. As for the 
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rigid body refinement, the 3TP0 structure of EthR was utilised. Unit cell contents analysis 
by Phaser determined 52.6% solvent content based on a protein molecular weight of 24 
kDa and 1 molecule in the asymmetric unit. The output solution was given in space group 
P41212 (identical to the published space group), with an RFZ of 4.0, a TFX of 8.7 and an 
LLG of 106. Rigid body refinement was then repeated with the resulting model with 
initial Rwork/Rfree factors of 31.2/30.9%. Subsequent restrained refinements were 
performed with water molecules and side-chain rotamers fitted, at which point 
(Rwork/Rfree: 18.4%/22.7%) the ligand was fitted to the unbiased density (figure 7.2). 
 
Figure 7.2: (a) Unbiased Fo-Fc difference density in ligand binding region to which compound 3 was fitted, 
contoured at 3 σ. Image made in CCP4MG.173 (b) Space fill (molecular surface) model of EthR (grey), 
compound 3 in yellow. Image made in Chimera.174 
 
Unlike previously observed ligands, compound 3 occupies a position much lower in the 
binding pocket and is, ultimately, solvent exposed at the methyl-pyrimidinone group. 
Consequently, many commonly observed interactions between EthR and ligand binding 
partners are not observed here (ie. asparagine hydrogen bonds, phenylalanine stacking).  
Final R factors for restrained refinement are 18.3/22.6% respectively for Rwork 
and Rfree, with an RMS values for bond length and angle of 0.02 Å and 1.81° respectively.  
Figure 7.3 shows compound 3 with surrounding residues. Two hydrogen bonds are 
made, though that formed between tyrosine residue 148 and the pyrimidinone nitrogen 
is of better distance and geometry than that formed between Thr149 and the dioxane 
oxygen.  No stacking interactions between the various ring systems of the ligand and the 
protein can be observed, with the ligand out of range of Phe110, Trp207 and Trp103. 
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Figure 7.3: Compound 3 bound to EthR. Hydrogen bonds labelled with key residues shown.  
 
Virtual screening had suggested two potential binding modes for compound 3. Figure 7.4 
shows the five poses generated. The actual positions differ greatly, thus emphasising the 
necessity of experimental data over only modelled ligand poses. 
 
 
 
Figure 7.4: The experimentally derived ligand conformation (yellow) compared to the ranked poses from 
virtual screening. Four out of the five poses are oriented with the phenyldioxane group at the ‘top’; pose 
two exemplifies the ‘alternate’ conformation caused by a 180° flip in orientation. 
 
Despite the unconventional binding mode, the ligand is successfully modelled at full 
occupancy, and makes observable hydrogen bonds. However, estimated binding 
affinities from SPR suggest this compound binds weakly, which could be attributed to 
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this unexpected, highly solvent exposed binding mode. Overall, the co-crystal structure 
of compound 3 with EthR shows that the binding ability was predicted whereas the 
binding mode itself was not. This demonstrates the vitality for experimental validation 
of virtually modelled ligand poses. 
 
7.5.2 Compound 10 
Diffraction data for co-crystallisation of EthR and compound 10 were obtained and after 
ascertaining ligand presence, the data were re-integrated and re-scaled to a resolution 
of 1.5 Å. As with compound 3, initial attempts to provide a protein model for phasing via 
rigid body refinement failed, with initial R-factors exceeding 50% and poor model-
density fit. Molecular replacement was used instead, and Phaser169,170 produced a model 
in the expected space group of P41212, with one molecule in the asymmetric unit and a 
predicted solvent content of 53.5%. After rigid body refinement and restrained 
refinements, ligand density in the binding site was sufficient to begin modelling.  
 
Figure 7.5: Fo-Fc density map shown at 3 σ around the binding site.  
 
The ligand was placed but unsatisfied Fo-Fc difference density in and around occupied 
positions suggested insufficient occupancy even at 100% for this ligand orientation 
(figure 7.6).  
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Figure 7.6: Positive difference density (Fo-Fc) observed at 3 σ, with 2Fo-Fc (blue) contoured at 1 σ. Top, 
with ligand occupancy at 100%, this suggested the presence of a second molecule, each at 50% occupancy. 
Bottom, both ligands modelled with same density parameters. 
 
The only satisfactory modelling, therefore, was with both potential ligand orientations, 
A and B, each with 50% occupancy. This resolved the difference density observed and 
gave improved refinement statistics (table 7.2). 
 
Table 7.2: Refinement statistics for EthR with compound 10, before ligand placement, after single molecule 
placement, and the final refinement statistics with both orientations modelled.  
 Prior to 
placement 
Single 
conformation 
Final Structure 
Rwork/Rfree (%) 22.8 / 24.8 19.2 / 22.3 19.1 / 22.0 
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Only one of the predicted poses from GOLD is in a similar conformation as A (figure 7.7, 
yellow), with the alcohol tail toward the aperture of the channel (figure 8.7, blue). This 
pose was ranked second; all other poses share the same conformation as B.  
 
Figure 7.7: Labelled image of compound 10 bound to EthR in two orientations. Top panel shows both 
orientations, bottom left shows orientation A, bottom right shows orientation B. 
 
Conformation A, shown in figure 7.7 in the bottom left panel, forms the frequently-
observed hydrogen bound with Asn179 via the carbonyl at a short distance of 2.3 Å. 
Conformation B, shown in figure 7.7 in the bottom right panel, forms a hydrogen bond 
through the same carbonyl with Thr149, at a distance of 3.1 Å. No other atom in the 
ligand, in either conformation, appears to be involved in hydrogen bonding despite the 
presence of donors and acceptors.   
Ultimately, this is the first crystallographic evidence for EthR supporting 
multiple binding conformations of the same ligand, though previous docking studies122 
and the virtual screening results had suggested it to be possible. Such modelling was 
made possible by very high resolution data. Further computational exploration, beyond 
the scope of this thesis, is currently underway to probe this interesting feature of the 
EthR binding site and determine if multiple binding modes can be predicted through 
linear interaction energy calculations.175,176 
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7.5.3 Compound 15 
Initial experiments to crystallise EthR with compound 15 were unsuccessful due to the 
formation of a coloured film over the drops, presumably a result of precipitation of the 
hydrophobic ligand. To migate this effect, the concentration of compound was reduced 
from a 10:1 molar ratio to a 4:1 molar ratio of compound to protein, which yielded 
crystals of the same morphology as other crystallisation experiments with EthR.  
Upon initial rigid body refinement prior to manual data processing, difference 
density was observed indicating a ligand presence. However, after manual data 
processing (to 1.9 Å), rigid body refinement and subsequent restrained refinement, it 
became clear the density did not appear to match the expected ligand and was 
insufficient to confidently model a bound molecule (figure 7.8). 
 
Figure 7.8: Compound 15, inset, did not appear to match the ligand density (Fo-Fc) and could not be 
modelled in good confidence. Difference density is shown at 3 σ. 
 
The structure was refined to final Rwork/Rfree values of 19.3/21.3%, but the unbiased 
ligand density did not improve enough to allow sufficiently confident modelling.  
 Compound 15 had showed a moderate (3°C @ 400 µM) positive shift in thermal 
stability in the thermal shift assays (chapter five), and crystal structures have been 
obtained with ligands which caused a weaker stabilising shift (ie. compound 85, 
compound 42). Therefore we can speculate that the hydrophobicity of this ligand 
(highlighted by the poor solubility in the first co-crystallisation trial) is a barrier to good 
occupancy despite the lipophilicity of the EthR binding site. Alternatively, compound 15 
possesses a furan ring, a moiety which has been shown to be prone to degradation in 
DMSO stocks.177 It could be that such an effect has occurred here, with multiple divergent 
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species formed; averaging in the crystal structure then causes a loss of definition 
between these molecules.  
 Ultimately, with other structures to focus efforts on and no confident way 
forward for ligand modelling, the crystal structure for EthR with this ligand was not 
pursued any further. 
 
7.5.4 Compound 25 
Upon crystallisation of compound 25 it was revealed this compound did not match the 
compound expected; upon investigation of compound stocks this was discovered to be 
because the compound delivered was not, in fact, the one ordered. Compound 25 was 
therefore fortuitously crystallised with EthR, but cannot be compared to a docked ligand 
from the virtual screening campaign.  
To obtain the ligand structure for modelling, it was possible to trace the 
compound code back to a ZINC record. This compound would have been present in the 
original 6.1 million compound cohort obtained from ZINC but the pre-screen filtering 
would have excluded it from the screening set based on size alone (193 g mol-1).  
The crystal structure has the distinction of being the most high resolution 
structure of EthR to date, at 1.4 Å (Rwork/Rfree of 19.9/22.1%; full crystallographic 
refinement statistics given in appendix D). Figure 7.9 shows compound 25 and its 
position in the EthR binding site. Similar to published ligands crystallised with EthR, 
compound 25 consists of a piperidine ring with an amide group. 
 
Figure 7.9: Compound 25 crystallised bound to EthR, with ligand density (2Fo-Fc) shown at 2 σ. Inset, 
surface model of EthR and compound 25 with ligand in green to highlight position.   
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Despite being the smallest of the small molecules crystallised with EthR, only one 
molecule binds in the long, EthR binding channel. The ligand itself forms two hydrogen 
bonds: one to Asn179 at a distance of 2.8 Å via the carbonyl moiety, and a second to 
Asn176 via the nitrogen of the amide function at a distance of 2.9 Å.  
This ligand would make an excellent starting point for a fragment-based 
approach to develop new scaffolds, as an alternative to the small-molecule methods of 
discovery described in this thesis. This ligand beautifully exemplifies the common 
binding mode of many EthR ligands, those previously published and those presented 
here: binding is anchored by hydrogen bonds to the key asparagine residues in the 
central region, and supported by non-polar interactions along the rest of the interface.  
  
7.5.5 Compound 42 
Diffraction data for compound 42 were obtained to 1.95 Å and the structure was refined 
with one molecule bound to the protein. It was not immediately clear which ligand 
orientation best fit the experimental observations. As such both were initially modelled. 
However, the orientation shown in figure 7.10 was the best interpretation of the 
observable density. 
 The structure shows compound 42 binds with the propyl ring toward the deepest 
part of the pocket and the amide function toward the aperture. This is contrary to what 
would have been expected, which is that the carbonyl ring would form a hydrogen bond 
to the key asparagine residue 179; all attempts to model such an interaction resulted in 
poor density fit and unsatisfactory convergence. This compound makes no observable 
hydrogen bonds with the protein, which would begin to explain the poor estimated 
binding affinity observed by SPR (284 μM). 
 The ligand position results in phenylalanine F184 adopting two conformations, 
likely to prevent unfavourable clashes in solution. Of the ligands presented here, only 
compound 85 is capable of occupying the site such that the phenylalanine adopts the 
open conformation; all other ligands are shorter or adopt lower positions and the 
phenylalanine remains in its ‘closed’ orientation. 
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Figure 7.10: Top, compound 42 in the EthR binding site. This ligand makes no observable hydrogen bonds 
with the protein. Bottom, 2Fo-Fc density contour of compound 42 at 1 σ, with Fo-Fc difference density 
contoured at 3 σ.  
 
To ensure correct ligand modelling, the refined ligand was assessed by Mogul for 
torsional strain – particularly around the piperidine which seemed, visually, to adopt an 
unusual conformation. However, the only torsions which Mogul considered to be 
unusual were those associated with the propyl ring (table 7.3). 
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Table 7.3: Mogul torsion check results for compound 42 (labelled by atom designation). Number reflects 
the number of records found in the database; all other torsions were excluded for poor representation. 
Minimum and maximum torsion values in the database distribution, the distance to the nearest neighbour 
(in degrees) and the original query value of the search torsion. 
 
FRAGMENT Number Min. / ° Max. / ° | d(min) | / °  Query value / ° 
CAB CAD CAE CAF  6 6.918 37.046 48.103 -85.149 
OAI CAE CAD CAC  5 18.849 132.454 34.141 166.595 
OAI CAE CAD CAB  12 9.817 164.882 20.135 94.144 
CAC CAD CAE CAF  12 7.071 145.412 1.793 -12.698 
OAU CAT CAQ CAP  92 6.098 142.382 0.749 -64.914 
CAK CAL NAN CAO  130 0.432 179.913 0.683 -20.1 
OAI CAH CAJ CAK  41 21.727 179.74 0.671 164.309 
CAK CAL NAN CAS  130 0.432 179.913 0.655 167.107 
CAR CAQ CAT NAV  92 40.084 175.405 0.641 -124.873 
CAG CAH CAJ CAK  61 0.457 158.203 0.626 -13.383 
CAJ CAK CAL NAN  204 52.484 179.845 0.47 128.586 
OAM CAL CAK CAJ  251 0.036 127.702 0.197 -70.306 
CAH CAJ CAK CAL  53 29.44 179.779 0.109 73.881 
OAM CAL NAN CAS  348 0.084 179.698 0.052 6.295 
OAU CAT CAQ CAR  92 6.098 142.382 0.024 59.436 
CAP CAQ CAT NAV  92 40.084 175.405 0.02 110.777 
OAM CAL NAN CAO  348 0.084 179.698 0.009 179.087 
 
Given the CAD-CAE bond is rotatable, it is likely the prolyl ring is fairly flexible in solution, 
reflected by a diffuse but clear, average density.  
Comparison of the experimentally derived ligand conformation was made to the 
poses derived from virtual screening (figure 7.11). These demonstrate overall very good 
prediction and agreement. Unusually, no alternate conformation was predicted within 
the five poses for compound 42. One potential explanation for this is that the very polar 
carbonyl-amide tail would not be well suited to the more hydrophobic top of the channel, 
whereas at the aperture position is has more chance of being solvent exposed. 
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Figure 7.11: Comparison of the ranked ligand binding poses (grey) to the experimentally derived 
crystallographic ligand position (pink). Overall, this binding position was very well predicted. 
 
Ultimately, the crystal structure of compound 42 shows ligands which do not form 
hydrogen bonds to EthR are still capable of binding with full occupancy, and that in some 
cases, EthR clearly supports only one ligand-binding orientation.  
 
7.5.6 Compound 57 
Compound 57 was one which showed a strong concentration-dependent shift 
relationship in the initial thermal shift assays performed with EthR. Diffraction data were 
refined to a resolution of 2.1 Å by methods previously detailed. The crystal structure of 
this compound with EthR shows one conformation of the ligand bound, with clearly 
defined, unambiguous ligand density. 
 Compound 57 (figure 7.12) forms a hydrogen bond with Thr149 through O22, 
the alcohol oxygen in the linker region of the ligand, donating a hydrogen to the lone pair 
of the threonine side chain oxygen at a distance of 2.8 Å. This ligand alcohol oxygen is 
also able to donate to the carbonyl of the Asn176 side chain at 2.8 Å distance. Finally, as 
anticipated from ligands bearing an amide carbonyl, the ligand carbonyl acts as a 
hydrogen bond acceptor to Asn179 at a distance of 2.9 Å. 
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Figure 7.12:  Close up image of ligand, compound 57, and the putative weak hydrogen bond formed with 
methionine via a CH···S interaction. 
 
Additionally, the sulphur atom of Met142 is oriented such that it is in a position to form 
a C-H···S interaction with the benzyldioxole group at a distance of 3.4 Å (figure 7.13). 
Although weak interactions, intermolecular C-H···S hydrogen bonds have been observed. 
They are not well studied due to their infrequency in chemical crystal structures178 but 
one notable study utilised experimental and theoretical methods to conclude sulphur is 
capable of weak interactions with aliphatic groups,179 and another study utilising ab 
initio and DFT calculations determined such CH···S interactions follow findings on CH···O 
hydrogen bonds, where interaction strength is greatest for sp3 carbon donors, weaker 
for sp2 and weakest for sp donors.180 
 
 
Figure 7.13:  Close up image of ligand, compound 57, and the putative weak hydrogen bond formed with 
methionine residue 142 via a CH···S interaction. 
 
108 
 
If indeed this ligand is forming a weak hydrogen bond via Met142, it is not likely to 
greatly affect binding affinity; the energy predicted for CH···S interactions is around     
0.25 kcal mol-1 (1.04 kJ mol-1) and therefore a mere fraction of the energy gained by a 
typical NH···O hydrogen bond. However, such interactions are likely to contribute overall 
to stabilising and supporting the ligand within the binding site, much like 
hydrophobic/Van der Waals interactions, which are on a similar energetic scale. 
 Comparisons between the crystallographic ligand and the poses suggested by 
virtual screening (figure 7.14) show the third-ranked pose is a far better, almost 
identical, prediction than the top ranked pose, though this too is also very similar. 
Notably, the second-ranked pose positions the dioxolane oxygens where in the 
experimental structure these positions are occupied by the nitrile oxygens. 
 
Figure 7.14: Comparison of the experimental ligand position (grey) with the virtual screening poses 
(green). Poses ranked 1 and 3 are very similar, whereas the lowest ranked poses are vastly different.  
 
Again, two alternate binding modes are suggested, but here only one is confirmed 
experimentally. As before, this demonstrates excellent binding prediction but also the 
need for experimental validation. 
 
7.5.7 Compound 60 
Diffraction data for compound 60 were obtained to 1.6 Å and processed as previously 
described. Figure 7.15 shows the unbiased Fo-Fc map after rigid body refinement, water 
molecule placement and several rounds of restrained refinement with isotropic B-
factors. 
 It was immediately apparent that the compound would not satisfy the density as 
one singular conformation as the density indicated a molecule longer than compound 60. 
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(NMR analysis on a sample of compound from stocks confirmed the ligand character, 
data not shown). 
 
Figure 7.15: Unbiased Fo-Fc map (3σ) of the ligand binding site. 
The virtual screening poses, shown in figure 7.16, demonstrate that one pose, with the 
benzodioxane at the bottom of the channel exposed to solvent is preferred over the 
alternate conformation. 
 
Figure 7.16: Ranked virtual screening poses of compound 60. 
Figure 7.17 shows attempts to model both potential orientations of compound 60 in this 
quite symmetrical ligand density, with some success. However, as with compound 10, 
positive difference density (unbiased) remained for both models which indicated that 
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perhaps in this case, as with compound 10, multiple binding modes are present in one 
structure. 
 
Figure 7.17: Each potential ligand orientation of compound 60 modelled in the density (2Fo-Fc, 1.5σ). The 
Fo-Fc map is also shown (green/red), contoured at 3 σ. Neither case thoroughly satisfies the density, and 
unbiased positive density remains. 
 
In one orientation, the nitrogen of the conjugated pyrimidine is within a contact distance 
of 3.0 Å, and the peptide carbonyl forms the often-observed hydrogen bond to Asn179 at 
a distance of 2.8 Å. Alternatively, the carbonyls interact with Thr149 (2.7 Å, forming a 
hydrogen bond) and Asn176 (2.0 Å, a clash with a the carbonyl) in the opposite 
conformation.  
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Subsequently, both ligands were modelled simultaneously at 50% occupancy to give a 
final model which is the best interpretation of the ligand density available, with an 
Rwork/Rfree of 18.3%/22.1%. This model, however, continues to indicate significant 
positive difference density which is not covered by the ligands, as well as significant 
negative density over parts of the modellied ligand, indicating an insufficient fit (figure 
7.18). 
 
Figure 7.18: Top, ligand 2Fo-Fc map in blue, with unbiased Fo-Fc map in green (positive) and red 
(negative). The middle and bottom panels show each of the two orientations, with hydrogen bonds in black 
dashed lines and clashesin magenta dashed lines. 
 
Figure 7.18 also shows this modelling, while also resulting in novel hydrogen bonds, 
results in close contacts or clashes with the protein. For example, the dioxane oxygens 
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are capable of hydrogen bonding to Glu125, previously unseen in any crystal structure. 
The middle panel of figure 7.18 shows this, and a hydrogen bond formed to Thr149. 
However, this causes a clash with Asn176 by the peptide carbonyl. The bottom panel of 
figure 7.18 shows the peptide nitrogen in one orientation forms a hydrogen bond to 
Asn176, and the carbonyl to Asn179. This results in the carbonyl on the conjugated 
pyrimidine to clash with Leu183. 
In conclusion, this model is the best interpretation of the density, however 
further study (more crystal structures, derived from both co-crystallisation and ligand 
soaking) would be necessary to give more confidence to the modelling performed here.  
 
7.5.8 Compound 74 
For a crystal obtained from co-crystallisation experiments of EthR with compound 74, 
data were obtained to a resolution of 1.5 Å and refined without ligand as previously 
described. Difference density was immediately apparent, indicating a bound compound 
(figure 7.19). 
 
 
Figure 7.19: Though the difference density (3 σ) appeared to match superficially to compound 74, bottom 
left, all attempts to model the ligand proved fruitless. 
 
However, it was not possible to fit compound 74 to this density, despite initial optimism. 
All exploratory attempts to model and refine compound 74 (figure 7.19) did not yield 
reasonable results in both model fit and chemical sensibility. The two potential 
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orientations suggested from virtual screening were modelled as proposed orientations 
(figure 7.20) but were unsuccessful.  
 
 
Figure 7.20: Ligand 2Fo-Fc density contoured at 1 σ, with Fo-Fc difference density at 3 σ. Neither ligand 
orientation (nor attempts to alter position laterally in binding site) were able to satisfy experimental data. 
Proposed orientation B shows hydrogen atoms to demonstrate ligand chemistry. 
 
The inability to model either orientation satisfactorily suggests there may by multiple 
binding poses, which results in static disorder over the averaging of the unit cell 
contents. However, this cannot be demonstrated with the data at hand, and as the data 
were obtained to 1.5 Å it is unlikely higher resolution data will be sufficient to inform 
this structure further. Alternatively, it could be the result of compound degradation, 
either in DMSO solution or by radiation damage. Negative difference density can be 
observed on the sulphur atom of M142, which could be an indicator of the latter. 
 The results of co-crystallisation experiments with compound 74 are therefore 
inconclusive.  
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7.5.9 Compound 80 
As with several other ligands, though difference density suggested presence of a ligand, 
it was not possible to confidently place nor model compound 80 in the structure obtained 
(resolution 1.7 Å). Figure 7.21 shows the difference density at 3 σ, however with the 
sigma level reduced as far as 1 σ, it was not possible to identify an orientation or 
confident position of the ligand for modelling.  
 
 
Figure 7.21:  Difference density (3 σ) indicates the presence of a ligand in the binding site, but insufficient 
information can be derived from it to confidently model compound 80 (inset). 
 
7.5.10  Compound 85 
Compound 85 was of particular interest throughout the experimental phase of this 
research due to it being the highest scoring compound of the cohort for testing. This was 
further exacerbated by compound 85 being the only compound to show a negative, 
concentration-dependent shift in EthR melting temperature, not just in his cohort but 
also in screens by our collaborators (private communication). Finally, the SPR pilot 
experiments showed a positive trend in the dose-response curve, and crystals of EthR in 
co-crystallisation conditions were smaller and more abundant than observed with other 
compounds. It was hoped a crystal structure of EthR bound to compound 85 would be 
achieved which could be compared to the virtual screening results. 
 The crystal structure of EthR bound to compound 85 was refined to a resolution 
of 1.8 Å. Initial unbiased difference density was observed for the ligand at 3 σ (figure 
7.22, inset) and was sufficient to model the ligand (figure 7.22). 
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Compound 85 is a long, lipophilic ligand which binds such that the F184 side-chain is 
forced up into its ‘open’ conformation to permit the oxane ring. A hydrogen bond is made 
between the carbonyl of the pyrimidinone to Asn179 at a distance of 2.6 Å. Additionally, 
a CH∙∙∙O interaction is formed between the ligand and protein, between CAH and Thr148 
(3.2 Å), further implying these weak hydrogen bonds play a role in ligand-binding 
stabilisation. Finally, the lack of density around the terminal methyl-substituted phenyl 
ring implies a high degree of rotation which is permissible in this more open region near 
the channel aperture.  
 
Figure 7.22: Compound 85 modelled with 2Fo-Fc density at 1 σ. Inset, unbiased Fo-Fc map at 3 σ. 
 
Comparison of the crystal structure ligand with the virtual screening poses (figure 7.23) 
shows poor prediction of the binding mode. Only one ligand orientation is observed in 
the crystal structure, and only one ligand orientation was predicted in the virtual 
screening; these are not matched, and as such there is poor agreement between the 
crystal structure ligand and the predicted poses.  
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Figure 7.23: Comparison of the experimentally derived position of compound 85 (grey) to the ranked 
virtual screening poses (purple). 
The crystal structure of compound 85 with EthR demonstrates supposedly 
“destabilising” compounds which cause mildly negative thermal denaturation shifts 
(chapter five) are no barrier to successful co-crystallisation, despite this seeming 
somewhat counterintuitive. 
 Finally, the poor agreement between prediction and experimental observation 
once again reinforces the need for experimental data over computational modelling 
when it comes to docking for drug discovery. And yet in this case, in silico screening 
predicted compound 85 to be a binder of EthR; though the screening was incorrect in 
predicting the mode and pose, the compound indeed binds EthR. This represents a mixed 
success for the computational modelling, but a great success for co-crystallisation of 
novel binding compounds with EthR. 
 
7.6 Summary 
Compounds with the potential to bind EthR were first identified by virtual screening, and 
tested by thermal shift assay to determine the likelihood of binding. This yielded 20 
potential ligands which were used for co-crystallisation experiments.  
 Crystallisation of EthR alone was attempted first using known, published 
conditions. These were very successful and yielded crystals with the correct morphology, 
the correct unit cells, and which diffracted in-house to 3.5 Å. Co-crystallisation was then 
attempted with all 20 compounds. Crystals were obtained for many co-crystallisation 
experiments and were subsequently tested at Diamond Light Source on MX beamlines 
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I03 and I04-1. Data were obtained in the range of 2.1 – 1.4 Å for the EthR-compound 
complexes, and of the ten data-sets which initially showed ligand density, all but three 
were sufficient enough to model with good confidence.  
 For crystals obtained co-crystallised with compounds 15, 74 and 80, the density 
is not of sufficient quality to determine the ligand composition, identity, nor orientation 
with any confidence; as such no ligand can be modelled.  
 Crystal structures of EthR bound with compounds 3, 10, 25, 42, 57, 60 and 85 
have been obtained, and give rise to interesting observations and conclusions. Firstly, 
compound 3 occupies a very different position to that predicted by virtual screening. 
This compound sits far lower in the binding channel than all other ligands co-crystallised 
with EthR, either presented here or published previously. 
 Most compounds bind EthR in only one orientation, with the absolute pose 
predicted by virtual screening to some success. Alternatively, compound 10 binds with 
two observable orientations, which has been suggested in the virtual screening results 
and docking work with EthR previously. 
 The crystal structure of compound 25 bound to EthR is the lowest resolution 
structure of EthR known to date at 1.4 Å. Compound 25 is also the smallest of the ligands 
presented here and demonstrates the key carbonyl-piperidine motif common to the 
published series of EthR inhibitors. This compound will therefore be helpful to SAR 
(structure-activity relationship) studies in altering that key chemistry in the search for a 
novel, potent series of compounds. 
 Compound 42 bound to EthR demonstrates hydrogen bonding between the 
ligand and protein is not necessary in this case to drive binding, due to the highly 
lipophilic nature of the EthR binding site. However, if this scaffold were to be adapted, it 
will be necessary to introduce hydrogen bonding between the ligand and protein in order 
to yield a potent binder. 
 The crystal structure of compound 57 showed one binding orientation, with 
hydrogen bonds made to both key asparagine residues. Moreover, there is some 
evidence for weak C-H···S hydrogen bonds which may contribute to overall binding 
stability. 
 Compound 60 was, similar to compound 10, modelled with two ligand 
conformations, however the hydrogen bonds formed are at the expense of clashes 
between the ligand and protein. In this case, further studies to repeatedly observe similar 
binding modes would give more confidence to the modelling performed. 
 Finally, compound 85, the highest scoring ligand from the virtual screening, was 
co-crystallised successfully with EthR, despite the thermal shift assay indicating a weak, 
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destabilising effect on the protein environment. The implied free rotation of the terminal 
methyl-substituted phenyl shows the area around the channel aperture allows a higher 
degree of flexibility in some cases, though was successfully occupied by a ligand in the 
case of compound 3.  Compound 85 makes the key hydrogen bond to Asn179, but also is 
supported by a weak C-H···O interaction, stronger than the C-H···S interaction observed 
in compound 85 but unlikely to have a strong influence on binding. This further implies 
a pattern of weak hydrogen bonds between unlikely donors and classical acceptors 
which have the potential to stabilise ligand binding.  
Further work is currently underway with several of these examples to model 
both ligand orientations by molecular dynamics methods and quantify the binding 
energy by the linear interaction method. Additionally, the calculation of per-residue 
interaction energies will allow the pinpointing of those amino acids which contribute to 
the protein-ligand binding event, and additionally quantify their role. Of particular 
interest are interactions such as C-H···S and C-H···O weak hydrogen bonds. For EthR, 
which has few classical hydrogen bonding opportunities in the binding site for targeting 
in hit-to-lead optimisation, the potential to exploit such interactions, albeit for small 
benefit, is promising. 
In conclusion, the successful co-crystallisation of predicted EthR-binders has not 
only demonstrated the success of the virtual screening campaign and subsequent hit 
selection by thermal shift, but has also given rise to new observations (multiple binding 
modes, alternate binding positions, weak hydrogen bond interactions) which will prove 
useful and potentially vital to further anti-EthR drug development. 
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CONCLUSION 
The overriding aim of the work presented here was to use computational methods to 
identify small molecules with unique scaffolds capable of binding EthR, with a view to 
developing those hits into new inhibitor series distinct from the current clinical lead 
candidate, BDM41906.1 
 
 
Figure 8.1: Chemical structure of current clinical lead candidate targeting EthR, BDM41906.1 
 
To achieve this the ZINC database2 was utilised as a source of small molecule compounds 
structures and the docking software GOLD3–5 was used for virtual screening with those 
compounds. A protocol was derived through the use of improvised decoy sets (lacking 
negative data, a similarity set was created to test docking protocols) and knowledge of 
the protein structure.  
 Through physical and physiochemical filters implemented in KNIME6 the initial 
compound database from ZINC was whittled down to 1.3 million compounds capable of 
fitting the binding site (ie. a volume < 700 Å3) and with at least one ring structure, among 
other attributes. This smaller database of compounds was then clustered by ring 
chemistry as a method of sampling chemical space within a large set of ‘drug like’ 
molecules.7–9 Roughly equal numbers of compounds were taken from each of the 25 
clusters to produce a final screening set of 409,200 compounds.  
 Virtual screening was implemented in GOLD against EthR, with five poses 
generated per ligand. The decision was made to implement no additional constraints, for 
example on hydrogen bond formation, to open up such interactions as filters after 
docking. Ultimately, a total of over two million poses were generated for 409,195 
compounds. The best pose of each ligand was extracted, and the top ten percent of those 
were imported into GoldMine, which was used in the post-screening phase to filter 
outliers and unfavourably interacting ligands, pruning the initial set of 40,919 
compounds exponentially. A potential biophysical screening set of 284 compounds was 
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scrutinised manually and with the aid of Mogul to eliminate further those ligands which 
were, in a variety of ways, unsuitable; this included unusual torsion angles, poorly 
interacting groups or geometries, and finally duplicate scaffolds. Once those compounds 
which were no longer commercially available were removed, a cohort of 85 compounds 
remained for biophysical testing against EthR. 
 The first method of testing was by thermal shift assay10 to identify those 
compounds capable of changing the melting temperature of EthR. This would indicate 
some interaction with the protein or environment. Of the 85 compounds purchased, only 
83 could be tested – one failed quality control at the source and could not be acquired 
elsewhere (NJT07) and one was totally insoluble in both DMSO and buffer (NJT36). The 
thermal shift assay utilised four different concentrations of compound representing 
molar ratios of 2:1, 4:1, 8:1 and 10:1, and compounds which caused concentration-
dependent changes in the EthR melting temperature were selected for further analysis. 
Of the 83 compounds, 20 showed this effect and were taken forward. 
 Pilot experiments for SPR binding analysis was conducted parallel to co-
crystallisation experiments. For the SPR (surface plasmon resonance), previous 
experiments by a collaborating group11 were used as a template. Up to six concentrations 
of each compound were injected over a CM5 surface modified with immobilised EthR, 
with an unmodified surface used as a control. Several compounds of the cohort of 20 
could not be tested by SPR as the last of the compound stock had been used for co-
crystallisation experiments. SPR indicated thirteen of the fourteen tested compounds 
identified by thermal shift assay bind EthR, corresponding to a confirmed hit rate of 16% 
for the tested biophysical set of 83 compounds.  
 To co-crystallise EthR with the twenty thermal shift assay hits, 9 mg ml-1 EthR 
was incubated overnight at room temperature with a final concentration of 3.3 mM 
compound (previously dissolved in 100% DMSO to 33 mM). Crystal structures were 
obtained for seven complexes with EthR, presented in chapter seven. 
 Ultimately, the approach utilised in the course of this work has yielded multiple 
hit compounds which bind EthR. The computational methods provided a cohort rich with 
true binding compounds, with a confirmed hit rate in the 83 chosen for analysis of 15.6%. 
This is highly respectable, but may only be the tip of the iceberg, as there are several hits 
from the thermal shift assay which remain untested, and the preliminary SPR 
experiments will need to be expanded to truly quantify EthR-ligand binding. 
 EthR is a target for cocktail therapies against Mycobacterium tuberculosis as it is 
part of the ethionamide bioactivation pathway. For the compounds presented here, two 
major questions remain: (1) though they bind EthR, do the compounds truly inhibit the 
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protein; and (2) do they act to reduce the necessary dose of ethionamide required to kill 
the bacteria. 
 To address the first question, we can certainly infer this to be the case; the crystal 
structures obtained so far show EthR bound and adopting the familiar inactive 
conformation. However to be certain, a further SPR assay with the target sequence of 
EthR will be necessary. The second question is the true test of the novel scaffolds, and is 
underway; several compounds from this cohort have been re-purchased and sent to our 
collaborators at the Institut Pasteur de Lille for testing against Mycobacterium 
tuberculosis. If successful, the compounds will then move forward into structure-activity 
relationship studies and the resulting optimisation will give rise to new potential clinical 
candidates for tackling tuberculosis. 
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APPENDIX A 
A1 Annotated SDF (Structure Data File), Example: Testosterone 
 
 
  Testosterone 
 
  
46 49  0  0  0  0  0  0  0  0999 V2000 
    
32.7221  -48.2471   -0.4674 C   0  0  0  0  0  0  0  0  0  0  0  0 
    
31.8304  -48.9551   -0.8864 O   0  0  0  0  0  0  0  0  0  0  0  0 
 
[…]    
    
36.3538  -45.8781   -0.0541 C   0  0  2  0  0  0  0  0  0  0  0  0 
    
34.9920  -46.5074    0.3418 C   0  0  1  0  0  0  0  0  0  0  0  0 
    
34.0245  -49.8763    0.0985 H   0  0  0  0  0  0  0  0  0  0  0  0 
    
36.1685  -48.5912    2.1283 H   0  0  0  0  0  0  0  0  0  0  0  0 
    
[…] 
 
33.7636  -44.9408   -0.5628 H   0  0  0  0  0  0  0  0  0  0  0  0 
    
34.7216  -46.1534    1.3716 H   0  0  0  0  0  0  0  0  0  0  0  0 
  
44  4  1  0  0  0  0  
  
38 17  1  0  0  0  0  
  
[…] 
 
16 34  1  0  0  0  0  
  
16 35  1  0  0  0  0  
 
M  END 
 
> <Lipinski's Rule of Five> 
 
0 
 
> <XLogP> 
 
3.2229999999999994 
 
> <VABC Volume Descriptor> 
 
282.7658831627233 
 
> <Rotatable Bonds Count> 
 
2 
 
> <Topological Polar Surface Area> 
 
37.3 
$$$$ 
Header inc. molecule name, plus user/date info, additional comments. 
Total # atoms, total # bonds, 
atom lists, chiral flag setting 
and file type version 
ATOM BLOCK 
X, y, z co-ordinates 
Element 
Table referring to properties such as 
valence, # of hydrogens, charge etc. 
BOND BLOCK 
Atom #, Atom #, followed by properties such as 
bond type, stereo and topology. 
PROPERTIES BLOCK 
With ><name> and value 
End file 
End structure block 
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A2 KNIME Clustering Pipeline 
Figure A1: The clustering pipeline created in KNIME for the 1.3 million compounds derived from initial 
pre-filtering. Orange nodes are SDF Reader input, red nodes are SDF Write output, and yellow nodes are 
filters or concatenating nodes.  
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A3 Virtual Screening CONF File 
  GOLD CONFIGURATION FILE 
 
  AUTOMATIC SETTINGS 
autoscale = 0.2 
 
  POPULATION 
popsiz = auto 
select_pressure = auto 
n_islands = auto 
maxops = auto 
niche_siz = auto 
 
  GENETIC OPERATORS 
pt_crosswt = auto 
allele_mutatewt = auto 
migratewt = auto 
 
  FLOOD FILL 
radius = 10 
origin = 32.5127 73.6746 11.1142 
do_cavity = 1 
floodfill_atom_no = 0 
cavity_file =  
floodfill_center = point 
 
  DATA FILES 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5imidaz.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5oxadiaz.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5oxaz.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5oxodiox.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5pyraz.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5pyrrol.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5tetraz.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5thiadiaz.sd
f 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5thiaz.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5thio.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/5triaz.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6diox.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6morph.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6oxane.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6pip.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6pyraz.sdf 5 
Genetic algorithm settings 
Search efficiency: 20% 
Centre point with x, y, z, radius and the 
option to produce a cavity structure 
file 
Source of input ligand structures, utilising 
complete file destination including all 
directories. 
umber denotes how many GA runs to 
perform, and therefore how many poses to 
generate per ligand. 
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ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6pyrida.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6pyrim.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/6tria.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/7cycle.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/other.sdf 5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/otherhet.sdf 
5 
ligand_data_file 
/home/nataliet/Documents/ZINC_180912_DrugsNow/CLUSTERED/miniset/sulphonyls.s
df 5 
param_file = DEFAULT 
set_ligand_atom_types = 1 
set_protein_atom_types = 0 
directory = minidock 
tordist_file = DEFAULT 
make_subdirs = 1 
save_lone_pairs = 1 
fit_points_file = fit_pts.mol2 
read_fitpts = 0 
 
  FLAGS 
internal_ligand_h_bonds = 1 
flip_free_corners = 1 
match_ring_templates = 1 
flip_amide_bonds = 1 
flip_planar_n = 1 flip_ring_NRR flip_ring_NHR 
flip_pyramidal_n = 1 
rotate_carboxylic_oh = flip 
use_tordist = 1 
postprocess_bonds = 1 
rotatable_bond_override_file = DEFAULT 
diverse_solutions = 1 
divsol_rmsd = 1 
divsol_cluster_size = 1 
solvate_all = 1 
 
  TERMINATION 
early_termination = 0 
n_top_solutions = 3 
rms_tolerance = 1.5 
 
  CONSTRAINTS 
force_constraints = 0 
 
  COVALENT BONDING 
covalent = 0 
 
  SAVE OPTIONS 
save_score_in_file = 1 
save_protein_torsions = 1 
output_file_format = MACCS 
 
  FITNESS FUNCTION SETTINGS 
initial_virtual_pt_match_max = 3 
relative_ligand_energy = 1 
gold_fitfunc_path = plp 
score_param_file = DEFAULT 
 
  PROTEIN DATA 
protein_datafile = NJTflipped_1U9N.mol2 
 
1 = yes ; 0 = no 
 
Ligand flexibility flags 
 
Early termination 
turned off 
 
Diverse solutions turned on: 
RMSD 1 Å between clusters of size 1. 
 
CHEMPLP 
scoring function 
 
Source protein structure 
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A4 Script for Removal of Problematic Punctuation in SDF Property Headers 
In attempting to open a GoldMine of a test set, it was determined with the help of Dr. Richard Sykes (CCDC) 
that hyphens and parentheses were preventing conversion of SDF headers into the SQLite database fields. 
Dr. Sykes wrote the following python script to remove the offending characters. It additionally removed 
any corrupted files. 
 
import sys 
import os 
import string 
import shutil 
 
d = 'minidock' 
sp = set(string.printable) 
for path, dirs, files in os.walk(d): 
    for f in files: 
        if f.endswith('.sdf'): 
            fname = os.path.join(path, f) 
            txt = open(fname).read() 
            txt = txt.replace('H-bond', 'H_bond') 
            txt = txt.replace('(mercaptyl)', 'mercaptyl') 
            f = open(fname, 'w') 
            f.write(txt) 
            f.close() 
            sf = set(txt) 
            if sf - sp: 
                print 'BAD FILE', fname 
                shutil.move(fname, fname + '.BAD') 
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A5 Python Script for Filtering top 10% Screening Output by Score 
Over 2 million poses had been generated by the virtual screening protocol. With the help of Dr. Tjelvar 
Olsson, we crafted a script which would access the file which denotes all poses for each ligand, pull out the 
name of the highest scoring ligand, and if that score placed the ligand in the highest 10% of ligands (ie. 
NUM_TO_KEEP), it would be written to a file for output. 
 
import sys 
import os 
import os.path 
 
DIR_NAME = "/home/guest2/not-backed-up/screen-1U9N.mol2-1U9N" 
NUM_COMPOUNDS = 409195 
NUM_TO_KEEP = NUM_COMPOUNDS / 10 
best_poses = [] 
 
for i in range(NUM_COMPOUNDS): 
    db_num = i + 1 
    sub_dir = "database_m%i" % db_num 
    tot_dir = os.path.join(DIR_NAME, sub_dir)  
    try: 
        for file_name in os.listdir(tot_dir): 
            if file_name.startswith('database'): 
               file_path = os.path.join(tot_dir, file_name) 
               for i, line in enumerate(open(file_path, 'r')): 
                   if i == 4: 
                       words = line.split() 
                       identifer = int(words[0].strip()) 
                       score = float(words[1].strip()) 
                       best_sol_name = 'gold_soln_database_m%i_%i.sdf' % 
(db_num, identifer) 
                       best_sol_path = os.path.join(tot_dir, best_sol_name) 
                       best_poses.append( (score, best_sol_path) ) 
    except: 
        pass 
 
best_poses.sort() 
best_poses.reverse() 
for i, (score, file_path) in enumerate(best_poses): 
    if i < NUM_TO_KEEP: 
        file_handle = open(file_path, 'r') 
        text = file_handle.read() 
        print text, 
  
409,195 ligands, each with 5 poses; 
keep the highest scoring 40,919 
This section enters the 
ranking file to identify the 
pose number with the 
highest score 
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APPENDIX B 
B1 Compound Nomenclature and Virtual Screening Score 
Table B1: A working code beginning “NJT” was used when handling compounds to avoid long alphanumeric 
codes which could lead to confusion/mislabelling. This table denotes all compounds used for analysis. Note: 
NJT07 is not listed as it failed quality control at the supplier and could not be sourced elsewhere. 
Additionally, NJT25 arose from an ordering error and as such is not listed with other virtual screening 
results. Finally, NJT37 was completely insoluble, and so no assays were performed with it. 
ZINC 
REFERENCE 
NJT 
REFERENCE 
SCORE 
RANK 
COMPANY COMPANY 
REFERENCE 
RAW 
SCORE 
ZINC12201617 NJT01 22 ChemBridge 86370596 89.1069 
ZINC00616109 NJT02 19 ChemBridge 7778963 89.2407 
ZINC67692217 NJT03 29 ChemBridge 58238331 87.9500 
ZINC65406277 NJT04 33 ChemBridge 50509137 87.2316 
ZINC72158865 NJT05 38 ChemBridge 75389916 86.8409 
ZINC65507786 NJT06 11 ChemBridge 89710978 91.3825 
ZINC67973854 NJT08 18 ChemBridge 94793758 89.3759 
ZINC67654656 NJT09 23 ChemBridge 26569393 88.5067 
ZINC67974892 NJT10 45 ChemBridge 95652737 85.5077 
ZINC71775561 NJT11 46 ChemBridge 96176937 85.4536 
ZINC19952823 NJT12 47 ChemBridge 68375090 85.4176 
ZINC72172695 NJT13 49 ChemBridge 97057671 85.2338 
ZINC65526448 NJT14 55 ChemBridge 92870208 84.5794 
ZINC00237604 NJT15 59 ChemBridge 5304371 84.1084 
ZINC67955631 NJT16 72 ChemBridge 91757787 83.4029 
ZINC32576321 NJT17 73 ChemBridge 64993287 83.3492 
ZINC11817892 NJT18 76 ChemBridge 73552030 83.2528 
ZINC67673539 NJT19 94 ChemBridge 27987503 81.5626 
ZINC20109834 NJT20 95 ChemBridge 69520354 81.5585 
ZINC67975203 NJT21 24 ChemBridge 95916741 88.4118 
ZINC00132569 NJT22 9 ChemBridge 7618548 92.8909 
ZINC67820979 NJT23 12 ChemBridge 72213543 91.2764 
ZINC00714237 NJT24 56 ChemBridge 5652915 84.4833 
ZINC01216083 NJT26 80 ChemBridge 6088631 82.9549 
ZINC02438552 NJT27 6 ChemBridge 9116022 95.2030 
ZINC01226689 NJT28 7 ChemBridge 5249858 93.3650 
ZINC04828017 NJT29 10 ChemBridge 7962144 92.2616 
ZINC20137454 NJT30 43 ChemBridge 9228506 85.8673 
ZINC24615603 NJT31 44 ChemBridge 9283033 85.6908 
ZINC00425482 NJT32 67 ChemBridge 9331185 83.7565 
ZINC09236877 NJT33 91 ChemBridge 6985499 81.7739 
ZINC17076365 NJT34 25 Vitas M STK470583 88.3717 
ZINC13758755 NJT35 52 Vitas M STL050026 84.9144 
ZINC71775333 NJT36 58 Vitas M STL167978 84.1745 
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ZINC00924619 NJT37 60 Vitas M STK011909 84.1005 
ZINC69462812 NJT38 3 Enamine Z1025693264 96.1781 
ZINC40151811 NJT39 20 Enamine Z596096640 89.2407 
ZINC58327836 NJT40 21 Enamine Z1101450797 89.2192 
ZINC52487551 NJT41 54 Enamine Z646440516 84.7711 
ZINC53275627 NJT42 62 Enamine Z167023036 83.9472 
ZINC46957685 NJT43 51 Enamine Z422902610 85.0971 
ZINC44936750 NJT44 34 Enamine Z415248090 87.0520 
ZINC71839930 NJT45 27 Enamine Z908777508 88.3083 
ZINC69461964 NJT46 42 Enamine Z1085724378 85.9954 
ZINC05187134 NJT47 28 Enamine Z54071047 88.0150 
ZINC69489717 NJT48 85 Enamine Z1139229987 82.3846 
ZINC12876413 NJT49 90 Enamine Z102922270 81.8401 
ZINC12794882 NJT50 71 Enamine Z119631558 83.5383 
ZINC22831673 NJT51 31 Enamine Z90609697 87.4262 
ZINC65575010 NJT52 70 Enamine Z558478778 83.5945 
ZINC12609641 NJT53 57 Enamine Z279903378 84.4802 
ZINC14168858 NJT54 26 Enamine Z24677903 88.3478 
ZINC10777920 NJT55 2 Enamine Z226510926 97.5458 
ZINC08987568 NJT56 68 Enamine Z224851022 83.6657 
ZINC09689958 NJT57 86 Enamine Z30508852 82.2755 
ZINC71795591 NJT58 30 Enamine Z281523990 87.9420 
ZINC71794585 NJT59 16 Enamine Z257202932 90.7126 
ZINC14848503 NJT60 35 Enamine Z237505970 86.9967 
ZINC22281715 NJT61 89 Enamine Z225731946 81.8996 
ZINC45517734 NJT62 36 Enamine Z351674606 86.9565 
ZINC09725714 NJT63 37 Enamine Z197481400 86.8884 
ZINC69416783 NJT64 74 Enamine Z1001812522 83.3350 
ZINC24418394 NJT65 32 Enamine Z153679482 87.2489 
ZINC25187332 NJT66 93 Enamine Z25094450 81.5864 
ZINC23053302 NJT67 81 Enamine Z281178970 82.8968 
ZINC65490004 NJT68 69 Enamine Z225720568 83.6479 
ZINC69669548 NJT69 87 Enamine Z1139749166 82.0951 
ZINC69381663 NJT70 78 Enamine Z324839670 82.9982 
ZINC08706459 NJT71 5 Enamine Z226452786 95.2065 
ZINC03420970 NJT72 8 Enamine Z24107796 93.0210 
ZINC58441335 NJT73 82 Enamine Z649796534 82.5989 
ZINC08980600 NJT74 39 Enamine Z226124130 86.5464 
ZINC58145475 NJT75 63 Enamine Z846030592 83.9063 
ZINC18962750 NJT76 61 Enamine Z98973900 84.0079 
ZINC03905710 NJT77 13 Ambinter Amb16755507 91.1945 
ZINC04370962 NJT78 92 Ambinter Amb20448045 81.7662 
ZINC33004106 NJT79 84 Ambinter Amb16657739 82.4998 
ZINC01502258 NJT80 40 Ambinter Amb16766591 86.3118 
ZINC00499610 NJT81 77 Ambinter Amb19773311 83.1186 
ZINC03903089 NJT82 50 Ambinter Amb6875571 85.1973 
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ZINC04870694 NJT83 66 Ambinter Amb5371151 83.8413 
ZINC09087663 NJT84 79 Ambinter Amb5367264 82.9583 
ZINC19234873 NJT85 1 Ambinter Amb13914491 99.5423 
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B2 Thermal Shift Raw Data 
Table B2: The raw melting temperature data for all tested compounds. 
COMPOUND CONCENTRATION / µM 1 2 3 AVERAGE SHIFT / °C 
NJT01 400 59.4 59.2 59.5 59.37 0.119 
NJT01 320 59.2 59.3 59.7 59.40 0.152 
NJT01 160 59.5 59.7 59.7 59.63 0.386 
NJT01 80 59.6 58.8 59.5 59.30 0.052 
NJT02 400 59.4 59.3 59.5 59.40 0.152 
NJT02 320 59.3 59.3 59.6 59.40 0.152 
NJT02 160 59.5 60.0 59.5 59.67 0.419 
NJT02 80 59.6 59.8 59.6 59.67 0.419 
NJT03 400 60.5 60.6 60.8 60.63 1.386 
NJT03 320 60.6 60.3 60.8 60.57 1.319 
NJT03 160 60.1 61.3 60.2 60.53 1.286 
NJT03 80 60.2 60.4 59.4 60.00 0.752 
NJT04 400 59.8 60.1 60.3 60.07 0.819 
NJT04 320 60.0 60.1 60.0 60.03 0.786 
NJT04 160 59.9 61.9 60.0 59.95 0.702 
NJT04 80 59.6 60.0 59.3 59.63 0.386 
NJT05 400 59.2 59.5 59.5 59.40 0.152 
NJT05 320 59.4 59.3 59.5 59.40 0.152 
NJT05 160 59.4 59.1 59.6 59.37 0.119 
NJT05 80 59.5 59.9 58.9 59.43 0.186 
NJT06 400 59.0 59.8 59.7 59.50 0.252 
NJT06 320 42.1 60.6 59.8 60.20 0.952 
NJT06 160 59.6 59.9 59.5 59.67 0.419 
NJT06 80 59.5 59.8 59.3 59.53 0.286 
NJT07 400 59.3 59.7 59.6 59.53 0.286 
NJT07 320 59.2 59.8 59.6 59.53 0.286 
NJT07 160 59.3 60.1 59.4 59.60 0.352 
NJT07 80 59.5 59.8 59.4 59.57 0.319 
NJT08 400 59.3 59.5 59.1 59.30 0.052 
NJT08 320 59.3 59.5 59.7 59.50 0.252 
NJT08 160 59.3 59.8 59.5 59.53 0.286 
NJT08 80 59.6 59.5 59.5 59.53 0.286 
NJT09 400 59.2 59.2 59.3 59.23 -0.014 
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NJT09 320 59.2 59.1 59.3 59.20 -0.048 
NJT09 160 31.0 59.7 59.4 59.55 0.302 
NJT09 80 59.6 59.7 59.2 59.50 0.252 
NJT10 400 61.1 61.1 61.5 61.23 1.986 
NJT10 320 60.8 61.0 60.9 60.90 1.652 
NJT10 160 60.4 60.3 60.5 60.40 1.152 
NJT10 80 60.3 60.1 59.9 60.10 0.852 
NJT11 400 59.2 59.2 59.3 59.23 -0.014 
NJT11 320 59.2 59.3 59.3 59.27 0.019 
NJT11 160 59.5 58.4 59.3 59.07 -0.181 
NJT11 80 59.7 59.2 59.2 59.37 0.119 
NJT12 400 59.1 59.1 59.2 59.13 -0.114 
NJT12 320 59.3 59.3 59.5 59.37 0.119 
NJT12 160 59.3 59.4 59.2 59.30 0.052 
NJT12 80 59.5 59.4 59.3 59.40 0.152 
NJT13 400 82.4 59.3 59.6 59.45 0.202 
NJT13 320 59.4 59.3 59.8 59.50 0.252 
NJT13 160 59.6 59.4 59.7 59.57 0.319 
NJT13 80 58.8 58.4 59.4 58.87 -0.381 
NJT14 400 59.6 59.2 59.4 59.40 0.152 
NJT14 320 59.3 59.2 59.4 59.30 0.052 
NJT14 160 59.0 59.3 59.7 59.33 0.086 
NJT14 80 59.5 59.3 60.7 59.83 0.586 
NJT15 400 62.9 63.4 61.9 62.73 3.486 
NJT15 320 62.3 62.6 62.1 62.33 3.086 
NJT15 160 61.3 62.3 61.7 61.77 2.519 
NJT15 80 61.6 61.0 61.3 61.30 2.052 
NJT16 400 59.3 59.2 59.2 59.23 -0.014 
NJT16 320 59.2 59.3 59.7 59.40 0.152 
NJT16 160 59.2 59.3 59.1 59.20 -0.048 
NJT16 80 58.7 58.8 59.4 58.97 -0.281 
NJT17 400 60.0 59.7 59.9 59.87 0.619 
NJT17 320 59.5 59.7 59.9 59.70 0.452 
NJT17 160 59.2 59.5 59.7 59.47 0.219 
NJT17 80 59.6 59.2 59.5 59.43 0.186 
NJT18 400 59.5 59.3 59.5 59.43 0.186 
143 
 
NJT18 320 59.2 59.2 59.0 59.13 -0.114 
NJT18 160 59.5 59.4 59.4 59.43 0.186 
NJT18 80 59.3 59.4 59.5 59.40 0.152 
NJT19 400 59.0 59.1 59.0 59.03 -0.214 
NJT19 320 59.2 59.2 59.0 59.13 -0.114 
NJT19 160 59.3 59.2 59.3 59.27 0.019 
NJT19 80 59.5 59.5 59.4 59.47 0.219 
NJT20 400 59.8 59.6 59.5 59.63 0.386 
NJT20 320 59.7 59.3 59.5 59.50 0.252 
NJT20 160 59.2 59.5 59.6 59.43 0.186 
NJT20 80 59.6 59.3 59.7 59.53 0.286 
NJT21 400 59.5 59.2 59.2 59.30 0.052 
NJT21 320 59.5 59.3 59.2 59.33 0.086 
NJT21 160 59.2 59.4 59.4 59.33 0.086 
NJT21 80 59.4 59.0 59.4 59.27 0.019 
NJT22 400 59.6 59.3 59.2 59.37 0.119 
NJT22 320 59.2 59.2 59.3 59.23 -0.014 
NJT22 160 59.5 59.3 59.4 59.40 0.152 
NJT22 80 59.6 59.2 59.5 59.43 0.186 
NJT23 400 59.8 59.2 59.1 59.37 0.119 
NJT23 320 59.6 59.2 59.2 59.33 0.086 
NJT23 160 59.5 59.3 59.3 59.37 0.119 
NJT23 80 59.7 59.5 59.4 59.53 0.286 
NJT24 400 59.3 58.9 59.4 59.20 -0.048 
NJT24 320 59.5 59.5 59.4 59.47 0.219 
NJT24 160 59.5 59.2 59.4 59.37 0.119 
NJT24 80 59.5 59.2 59.4 59.37 0.119 
NJT25 400 68.7 68.0 68.6 68.43 9.186 
NJT25 320 68.6 68.3 67.9 68.27 9.019 
NJT25 160 67.0 67.4 67.2 67.20 7.952 
NJT25 80 66.0 66.3 66.3 66.20 6.952 
NJT26 400 59.5 60.0 59.7 59.73 0.486 
NJT26 320 59.5 60.0 59.8 59.77 0.519 
NJT26 160 60.8 60.2 59.9 60.30 1.052 
NJT26 80 59.5 59.3 59.2 59.33 0.086 
NJT27 400 89.7 59.3 60.0 59.65 0.402 
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NJT27 320 59.7 59.5 59.9 59.70 0.452 
NJT27 160 60.0 59.7 59.6 59.77 0.519 
NJT27 80 59.7 59.5 59.4 59.53 0.286 
NJT28 400 59.5 58.8 35.1 59.15 -0.098 
NJT28 320 59.3 34.7 27.0 59.30 0.052 
NJT28 160 44.6 59.5 60.1 59.80 0.552 
NJT28 80 59.7 59.7 59.3 59.57 0.319 
NJT29 400 59.6 59.2 59.9 59.57 0.319 
NJT29 320 59.6 59.9 59.5 59.67 0.419 
NJT29 160 59.7 59.5 59.8 59.67 0.419 
NJT29 80 59.8 59.3 59.3 59.47 0.219 
NJT30 400 60.0 59.5 60.3 59.93 0.686 
NJT30 320 59.9 59.7 60.2 59.93 0.686 
NJT30 160 59.3 59.5 59.9 59.57 0.319 
NJT30 80 59.9 59.7 59.5 59.70 0.452 
NJT31 400 59.9 59.6 60.4 59.97 0.719 
NJT31 320 89.1 59.5 60.0 59.75 0.502 
NJT31 160 59.7 59.5 59.7 59.63 0.386 
NJT31 80 59.8 59.7 59.5 59.67 0.419 
NJT32 400 59.3 59.3 59.4 59.33 0.086 
NJT32 320 59.4 59.0 59.5 59.30 0.052 
NJT32 160 59.5 59.2 59.5 59.40 0.152 
NJT32 80 59.8 59.4 59.4 59.53 0.286 
NJT33 400 59.1 59.0 59.8 59.30 0.052 
NJT33 320 59.4 58.9 59.7 59.33 0.086 
NJT33 160 59.4 59.3 59.4 59.37 0.119 
NJT33 80 59.6 59.4 59.6 59.53 0.286 
NJT34 400 59.4 58.6 59.5 59.17 -0.081 
NJT34 320 59.4 57.2 59.5 59.45 0.202 
NJT34 160 59.4 59.2 59.5 59.37 0.119 
NJT34 80 59.7 59.5 59.2 59.47 0.219 
NJT35 400 59.4 59.0 59.5 59.30 0.052 
NJT35 320 59.4 59.1 59.7 59.40 0.152 
NJT35 160 89.4 59.3 59.5 59.40 0.152 
NJT35 80 59.6 59.4 59.1 59.37 0.119 
NJT36 400 89.4 59.1 59.5 59.30 0.052 
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NJT36 320 59.3 59.2 59.5 59.33 0.086 
NJT36 160 59.5 59.4 59.7 59.53 0.286 
NJT36 80 59.6 59.4 59.4 59.47 0.219 
NJT38 400 77.8 59.0 58.8 58.90 -0.348 
NJT38 320 60.0 59.2 59.2 59.47 0.219 
NJT38 160 60.5 59.3 59.3 59.70 0.452 
NJT38 80 60.3 59.5 59.8 59.87 0.619 
NJT39 400 59.3 59.0 58.7 59.00 -0.248 
NJT39 320 59.7 59.2 59.0 59.30 0.052 
NJT39 160 60.0 59.3 59.1 59.47 0.219 
NJT39 80 60.1 59.5 59.3 59.63 0.386 
NJT40 400 59.9 59.5 58.8 59.40 0.152 
NJT40 320 74.2 59.4 59.0 59.20 -0.048 
NJT40 160 60.0 59.6 59.3 59.63 0.386 
NJT40 80 60.1 59.6 59.3 59.67 0.419 
NJT41 400 59.1 59.1 58.7 58.97 -0.281 
NJT41 320 59.5 59.1 59.0 59.20 -0.048 
NJT41 160 59.8 59.3 59.0 59.37 0.119 
NJT41 80 59.8 59.2 59.3 59.43 0.186 
NJT42 400 60.7 59.7 59.8 60.07 0.819 
NJT42 320 60.6 59.8 59.7 60.03 0.786 
NJT42 160 60.2 59.7 59.5 59.80 0.552 
NJT42 80 60.1 59.6 59.5 59.73 0.486 
NJT43 400 59.5 59.2 58.8 59.17 -0.081 
NJT43 320 59.7 59.3 59.0 59.33 0.086 
NJT43 160 60.0 59.4 59.4 59.60 0.352 
NJT43 80 60.0 59.4 58.5 59.30 0.052 
NJT44 400 59.5 59.3 58.9 59.23 -0.014 
NJT44 320 59.5 59.4 58.9 59.27 0.019 
NJT44 160 59.8 59.5 59.2 59.50 0.252 
NJT44 80 59.8 59.6 59.2 59.53 0.286 
NJT45 400 74.3 59.3 59.1 59.20 -0.048 
NJT45 320 60.1 59.4 59.2 59.57 0.319 
NJT45 160 59.7 59.5 59.2 59.47 0.219 
NJT45 80 60.0 59.5 59.3 59.60 0.352 
NJT46 400 59.6 59.0 58.8 59.13 -0.114 
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NJT46 320 59.7 59.2 58.9 59.27 0.019 
NJT46 160 59.7 59.5 59.2 59.47 0.219 
NJT46 80 59.8 59.5 59.2 59.50 0.252 
NJT47 400 58.8 59.2 58.7 58.90 -0.348 
NJT47 320 59.8 59.4 58.9 59.37 0.119 
NJT47 160 60.0 59.4 59.2 59.53 0.286 
NJT47 80 60.0 59.6 59.2 59.60 0.352 
NJT48 400 60.6 59.4 59.6 59.87 0.619 
NJT48 320 60.5 59.5 59.3 59.77 0.519 
NJT48 160 60.3 59.5 59.3 59.70 0.452 
NJT48 80 60.1 59.4 59.1 59.53 0.286 
NJT49 400 73.4 59.6 59.6 59.60 0.352 
NJT49 320 60.4 59.4 59.2 59.67 0.419 
NJT49 160 60.3 59.3 59.2 59.60 0.352 
NJT49 80 59.8 59.3 59.3 59.47 0.219 
NJT50 400 59.8 60.1 59.6 59.83 0.586 
NJT50 320 60.6 59.9 59.6 60.03 0.786 
NJT50 160 60.4 59.9 59.5 59.93 0.686 
NJT50 80 60.1 59.6 59.3 59.67 0.419 
NJT51 400 59.8 59.7 59.3 59.60 0.352 
NJT51 320 59.8 59.9 59.0 59.57 0.319 
NJT51 160 59.9 59.8 59.4 59.70 0.452 
NJT51 80 59.8 59.6 59.2 59.53 0.286 
NJT52 400 59.8 59.0 59.0 59.27 0.019 
NJT52 320 60.1 59.2 59.1 59.47 0.219 
NJT52 160 59.8 59.3 59.2 59.43 0.186 
NJT52 80 59.8 59.3 59.0 59.37 0.119 
NJT53 400 59.5 59.2 58.9 59.20 -0.048 
NJT53 320 59.8 59.3 58.9 59.33 0.086 
NJT53 160 59.7 59.3 59.1 59.37 0.119 
NJT53 80 59.8 59.4 59.2 59.47 0.219 
NJT54 400 60.0 59.1 59.5 59.53 0.286 
NJT54 320 60.3 59.2 59.2 59.57 0.319 
NJT54 160 60.1 59.5 59.2 59.60 0.352 
NJT54 80 60.3 59.3 59.2 59.60 0.352 
NJT55 400 59.9 59.4 59.3 59.53 0.286 
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NJT55 320 60.2 59.3 59.3 59.60 0.352 
NJT55 160 59.9 59.3 59.1 59.43 0.186 
NJT55 80 60.2 59.4 59.1 59.57 0.319 
NJT56 400 60.3 60.1 59.8 60.07 0.819 
NJT56 320 60.2 59.7 59.6 59.83 0.586 
NJT56 160 60.3 59.7 59.4 59.80 0.552 
NJT56 80 60.0 59.6 59.0 59.53 0.286 
NJT57 400 65.8 65.4 65.6 65.60 6.352 
NJT57 320 64.4 64.5 65.0 64.63 5.386 
NJT57 160 63.7 63.6 63.1 63.47 4.219 
NJT57 80 61.5 61.6 61.0 61.37 2.119 
NJT58 400 61.4 59.1 59.5 60.00 0.752 
NJT58 320 61.0 59.0 59.5 59.83 0.586 
NJT58 160 77.8 59.1 59.6 59.35 0.102 
NJT58 80 75.4 58.9 58.7 58.80 -0.448 
NJT59 400 59.1 58.4 59.0 58.83 -0.414 
NJT59 320 59.2 58.4 59.4 59.00 -0.248 
NJT59 160 59.0 58.9 59.4 59.10 -0.148 
NJT59 80 59.2 60.2 58.9 59.43 0.186 
NJT60 400 64.8 66.1 65.6 65.50 6.252 
NJT60 320 63.9 65.2 60.4 63.17 3.919 
NJT60 160 62.6 63.6 62.3 62.83 3.586 
NJT60 80 61.9 61.1 60.9 61.30 2.052 
NJT61 400 58.8 58.5 58.9 58.73 -0.514 
NJT61 320 58.3 58.7 59.1 58.70 -0.548 
NJT61 160 59.0 58.5 58.5 58.67 -0.581 
NJT61 80 59.0 58.5 58.6 58.70 -0.548 
NJT62 400 58.7 58.3 58.9 58.63 -0.614 
NJT62 320 58.7 58.3 59.0 58.67 -0.581 
NJT62 160 59.0 58.4 58.5 58.63 -0.614 
NJT62 80 59.1 58.5 58.4 58.67 -0.581 
NJT63 400 60.0 59.4 59.8 59.73 0.486 
NJT63 320 59.9 59.0 59.9 59.60 0.352 
NJT63 160 59.4 58.7 58.5 58.87 -0.381 
NJT63 80 59.3 58.7 58.2 58.73 -0.514 
NJT64 400 61.1 59.9 60.5 60.50 1.252 
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NJT64 320 61.0 59.2 60.3 60.17 0.919 
NJT64 160 60.3 59.4 59.5 59.73 0.486 
NJT64 80 59.8 59.6 58.9 59.43 0.186 
NJT65 400 58.6 58.0 58.8 58.47 -0.781 
NJT65 320 59.3 58.3 59.2 58.93 -0.314 
NJT65 160 59.0 58.6 58.2 58.60 -0.648 
NJT65 80 59.0 58.7 58.3 58.67 -0.581 
NJT66 400 58.7 58.3 59.1 58.70 -0.548 
NJT66 320 58.7 58.5 59.2 58.80 -0.448 
NJT66 160 59.0 58.5 58.0 58.50 -0.748 
NJT66 80 59.1 58.7 58.3 58.70 -0.548 
NJT67 400 59.0 58.7 58.7 58.80 -0.448 
NJT67 320 58.7 59.0 58.6 58.77 -0.481 
NJT67 160 59.1 58.7 58.5 58.77 -0.481 
NJT67 80 59.0 58.7 58.6 58.77 -0.481 
NJT68 400 59.2 58.7 58.9 58.93 -0.314 
NJT68 320 59.1 58.7 58.8 58.87 -0.381 
NJT68 160 59.0 58.6 58.7 58.77 -0.481 
NJT68 80 59.0 58.7 58.7 58.80 -0.448 
NJT69 400 59.2 58.7 58.7 58.87 -0.381 
NJT69 320 59.0 58.5 58.4 58.63 -0.614 
NJT69 160 59.1 58.7 58.3 58.70 -0.548 
NJT69 80 59.1 58.8 58.7 58.87 -0.381 
NJT70 400 59.2 58.7 59.0 58.97 -0.281 
NJT70 320 59.1 58.5 58.7 58.77 -0.481 
NJT70 160 59.0 58.5 58.5 58.67 -0.581 
NJT70 80 59.0 59.0 58.7 58.90 -0.348 
NJT71 400 59.1 58.5 58.6 58.73 -0.514 
NJT71 320 59.0 59.0 58.7 58.90 -0.348 
NJT71 160 59.0 58.5 58.6 58.70 -0.548 
NJT71 80 59.0 58.5 59.0 58.83 -0.414 
NJT72 400 60.0 59.2 60.1 59.77 0.519 
NJT72 320 59.8 59.1 59.9 59.60 0.352 
NJT72 160 59.6 59.3 59.7 59.53 0.286 
NJT72 80 59.3 58.8 59.3 59.13 -0.114 
NJT73 400 59.2 59.0 58.7 58.97 -0.281 
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NJT73 320 59.2 58.8 58.5 58.83 -0.414 
NJT73 160 59.3 58.8 58.6 58.90 -0.348 
NJT73 80 59.0 58.7 58.6 58.77 -0.481 
NJT74 400 60.8 59.5 58.5 59.60 0.352 
NJT74 320 60.6 60.1 58.6 59.77 0.519 
NJT74 160 60.3 60.3 58.4 59.67 0.419 
NJT74 80 60.1 59.3 58.8 59.40 0.152 
NJT75 400 59.2 59.3 58.1 58.87 -0.381 
NJT75 320 59.2 59.2 58.0 58.80 -0.448 
NJT75 160 59.2 60.0 58.3 59.17 -0.081 
NJT75 80 59.1 59.1 58.3 58.83 -0.414 
NJT76 400 59.2 59.5 58.1 58.93 -0.314 
NJT76 320 59.0 58.8 58.1 58.63 -0.614 
NJT76 160 59.0 58.6 58.3 58.63 -0.614 
NJT76 80 59.0 58.6 58.2 58.60 -0.648 
NJT77 400 57.9 57.8 58.7 58.13 -1.114 
NJT77 320 57.9 59.2 59.2 58.77 -0.481 
NJT77 160 58.3 59.5 58.1 58.63 -0.614 
NJT77 80 58.5 59.6 58.6 58.90 -0.348 
NJT78 400 57.4 57.8 59.0 58.07 -1.181 
NJT78 320 57.9 59.5 59.0 58.80 -0.448 
NJT78 160 58.2 59.3 58.1 58.53 -0.714 
NJT78 80 58.1 59.4 58.2 58.57 -0.681 
NJT79 400 58.4 58.3 58.7 58.47 -0.781 
NJT79 320 58.4 60.1 58.7 59.07 -0.181 
NJT79 160 58.3 59.4 58.5 58.73 -0.514 
NJT79 80 57.9 58.8 58.3 58.33 -0.914 
NJT80 400 62.5 62.6 63.0 62.70 3.452 
NJT80 320 61.7 64.0 63.8 63.17 3.919 
NJT80 160 60.5 63.4 62.0 61.97 2.719 
NJT80 80 59.9 62.2 60.1 60.73 1.486 
NJT81 400 58.0 58.5 57.7 58.07 -1.181 
NJT81 320 57.9 58.3 59.2 58.47 -0.781 
NJT81 160 58.2 58.3 59.4 58.63 -0.614 
NJT81 80 57.9 58.1 59.6 58.53 -0.714 
NJT82 400 57.8 58.2 57.4 57.80 -1.448 
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NJT82 320 58.0 58.1 59.6 58.57 -0.681 
NJT82 160 57.4 58.3 58.6 58.10 -1.148 
NJT82 80 58.1 58.5 59.5 58.70 -0.548 
NJT83 400 59.9 58.2 59.2 59.10 -0.148 
NJT83 320 59.6 61.7 59.3 60.20 0.952 
NJT83 160 59.3 60.9 59.3 59.83 0.586 
NJT83 80 58.8 60.1 59.5 59.47 0.219 
NJT83 400 71.5 71.6 70.8 71.30 12.052 
NJT83 320 71.3 72.2 71.2 71.57 12.319 
NJT83 160 59.3 72.1 59.3 63.57 4.319 
NJT83 80 58.8 60.1 59.5 59.47 0.219 
NJT84 400 60.5 60.7 61.0 60.73 1.486 
NJT84 320 60.2 60.2 60.4 60.27 1.019 
NJT84 160 60.1 62.0 60.9 61.00 1.752 
NJT84 80 58.9 61.9 61.0 60.60 1.352 
NJT85 400 57.6 57.6 57.9 57.70 -1.548 
NJT85 320 57.4 57.9 58.8 58.03 -1.214 
NJT85 160 57.5 58.8 59.2 58.50 -0.748 
NJT85 80 58.2 59.0 59.2 58.80 -0.448 
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B3 Tabulated Thermal Shift Data 
Table B3: Temperature shift data is derived from the average readings calculated for each compound at 
each concentration, as displayed in table B2, as well as the average EthR melting temperature of 59.25°C 
derived from 42 negative control readings. 
COMPOUND 400 µM 320 µM 160 µM 80 µM 
NJT01 0.119 0.152 0.386 0.052 
NJT02 0.152 0.152 0.419 0.419 
NJT03 1.386 1.319 1.286 0.752 
NJT04 0.819 0.786 0.702 0.386 
NJT05 0.152 0.152 0.119 0.186 
NJT06 0.252 0.952 0.419 0.286 
NJT08 0.052 0.252 0.286 0.286 
NJT09 -0.014 -0.048 0.302 0.252 
NJT10 1.986 1.652 1.152 0.852 
NJT11 -0.014 0.019 -0.181 0.119 
NJT12 -0.114 0.119 0.052 0.152 
NJT13 0.202 0.252 0.319 -0.381 
NJT14 0.152 0.052 0.086 0.586 
NJT15 3.486 3.086 2.519 2.052 
NJT16 -0.014 0.152 -0.048 -0.281 
NJT17 0.619 0.452 0.219 0.186 
NJT18 0.186 -0.114 0.186 0.152 
NJT19 -0.214 -0.114 0.019 0.219 
NJT20 0.386 0.252 0.186 0.286 
NJT21 0.052 0.086 0.086 0.019 
NJT22 0.119 -0.014 0.152 0.186 
NJT23 0.119 0.086 0.119 0.286 
NJT24 -0.048 0.219 0.119 0.119 
NJT25 9.186 9.019 7.952 6.952 
NJT26 0.486 0.519 1.052 0.086 
NJT27 0.402 0.452 0.519 0.286 
NJT28 -0.098 0.052 0.552 0.319 
NJT29 0.319 0.419 0.419 0.219 
NJT30 0.686 0.686 0.319 0.452 
NJT31 0.719 0.502 0.386 0.419 
NJT32 0.086 0.052 0.152 0.286 
NJT33 0.052 0.086 0.119 0.286 
NJT34 -0.081 0.202 0.119 0.219 
NJT35 0.052 0.152 0.152 0.119 
NJT36 0.052 0.086 0.286 0.219 
NJT38 -0.347 0.220 0.453 0.620 
NJT39 -0.247 0.053 0.220 0.386 
NJT40 0.153 -0.047 0.386 0.420 
NJT41 -0.280 -0.047 0.120 0.186 
NJT42 0.820 0.786 0.553 0.486 
152 
 
NJT43 -0.080 0.086 0.353 0.053 
NJT44 -0.014 0.020 0.253 0.286 
NJT45 -0.047 0.320 0.220 0.353 
NJT46 -0.114 0.020 0.220 0.253 
NJT47 -0.347 0.120 0.286 0.353 
NJT48 0.620 0.520 0.453 0.286 
NJT49 0.353 0.420 0.353 0.220 
NJT50 0.586 0.786 0.686 0.420 
NJT51 0.353 0.320 0.453 0.053 
NJT52 0.020 0.220 0.186 0.120 
NJT53 -0.047 0.086 0.120 0.220 
NJT54 0.286 0.320 0.353 0.353 
NJT55 0.286 0.353 0.186 0.320 
NJT56 0.820 0.586 0.553 0.286 
NJT57 6.353 5.386 4.220 2.120 
NJT58 0.753 0.586 0.103 -0.447 
NJT59 -0.414 -0.247 -0.147 0.186 
NJT60 6.253 3.920 3.586 2.053 
NJT61 -0.514 -0.547 -0.580 -0.547 
NJT62 -0.614 -0.580 -0.614 -0.580 
NJT63 0.486 0.353 -0.380 -0.514 
NJT64 1.253 0.920 0.486 0.186 
NJT65 -0.780 -0.314 -0.647 -0.580 
NJT66 -0.547 -0.447 -0.747 -0.547 
NJT67 -0.447 -0.480 -0.480 -0.480 
NJT68 -0.314 -0.380 -0.480 -0.447 
NJT69 -0.380 -0.614 -0.547 -0.380 
NJT70 -0.280 -0.480 -0.580 -0.347 
NJT71 -0.514 -0.347 -0.547 -0.414 
NJT72 0.520 0.353 0.286 -0.114 
NJT73 -0.280 -0.414 -0.347 -0.480 
NJT74 0.353 0.520 0.420 0.153 
NJT75 -0.380 -0.447 -0.080 -0.414 
NJT76 -0.314 -0.614 -0.614 -0.647 
NJT77 -1.114 -0.481 -0.614 -0.348 
NJT78 -1.181 -0.448 -0.714 -0.681 
NJT79 -0.781 -0.181 -0.514 -0.914 
NJT80 3.452 3.919 2.719 1.486 
NJT81 -1.181 -0.781 -0.614 -0.714 
NJT82 -1.448 -0.681 -1.148 -0.548 
NJT83 (1) -0.148 0.952 0.586 0.219 
NJT83 (2) 12.052 12.319 4.319 0.219 
NJT84 1.486 1.019 1.752 1.352 
NJT85 -1.548 -1.214 -0.748 -0.448 
 
 
153 
 
APPENDIX C 
 
This appendix presents the raw SPR data from pilot experiments, with fitting data and 
residual plots for each. All sensorgrams show injection phases and dissociation phases 
(in buffer). 
 
C1 Raw SPR Data: Compound 3 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
40.8 4.31E-03     9.47E+03 1.06E-04   0.725 
  12.2 3.59E+00 2.40E-04 2.50E-04   8.59 0.0145  
  0.0498 -1.68 -0.0122 2.00E-04   0.0326 1.25E-02  
  15.5 -1.23 4.75E-03 1.50E-04   9.07 0.0104  
  2.73 -2.14 -8.36E-04 1.00E-04   1.33 8.39E-03  
  12.6 -3.08 4.19E-04 5.00E-05   4.05 6.35E-03  
  158 -3.86 5.81E-03 5.00E-06   7.13 4.51E-03  
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C2 Raw SPR Data: Compound 4 
 
ka 
(1/Ms) 
kd 
(1/s) 
Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
187 0.0132 6.91    1.41E+04 7.09E-05   0.69 
   1.22 -8.35E-03 2.50E-04   5.38 0.0599  
   -0.444 -3.06E-04 2.50E-04   5.38 0.0599  
   0.768 4.57E-04 2.00E-04   5.1 0.0506  
   1.13 1.28E-03 2.00E-04   5.1 0.0506  
   2.3 1.92E-03 1.50E-04   4.69 0.0412  
   1.99 1.09E-03 1.50E-04   4.69 0.0412  
   2.27 -1.22E-03 1.00E-04   4.04 0.0319  
   1.77 1.40E-03 1.00E-04   4.04 0.0319  
   2.82 1.71E-03 5.00E-05   2.86 0.0226  
   5.18 4.74E-03 5.00E-05   2.86 0.0226  
   3.11 1.42E-03 2.50E-05   1.8 0.0179  
   3.57 1.81E-03 2.50E-05   1.8 0.0179  
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C3 Raw SPR Data: Compound 10 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
33.1 2.37E-03     1.39E+04 7.17E-05   0.708 
  23.8 -0.539 6.30E-03 2.50E-04   18.5 0.0106  
  12.5 -1.88 -3.79E-03 2.00E-04   9.19 8.99E-03  
  27.3 -3.58 1.37E-03 1.50E-04   18.4 7.33E-03  
  49.8 -0.145 7.54E-03 1.00E-04   29 5.68E-03  
  70.7 -1.23 6.82E-03 5.00E-05   29 4.03E-03  
  619 2.23 6.79E-03 5.00E-06   40.3 2.54E-03  
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C4 Raw SPR Data: Compound 17 
 
 
ka 
(1/Ms) 
kd 
(1/s) 
Rmax 
(RU) 
RI 
(RU) 
Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
187 0.0132 6.91    1.41E+04 7.09E-05   0.69 
   1.22 -8.35E-03 2.50E-04   5.38 0.0599  
   -
0.444 
-3.06E-04 2.50E-04   5.38 0.0599  
   0.768 4.57E-04 2.00E-04   5.1 0.0506  
   1.13 1.28E-03 2.00E-04   5.1 0.0506  
   2.3 1.92E-03 1.50E-04   4.69 0.0412  
   1.99 1.09E-03 1.50E-04   4.69 0.0412  
   2.27 -1.22E-03 1.00E-04   4.04 0.0319  
   1.77 1.40E-03 1.00E-04   4.04 0.0319  
   2.82 1.71E-03 5.00E-05   2.86 0.0226  
   5.18 4.74E-03 5.00E-05   2.86 0.0226  
   3.11 1.42E-03 2.50E-05   1.8 0.0179  
   3.57 1.81E-03 2.50E-05   1.8 0.0179  
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C5 Raw SPR Data: Compound 25 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req (RU) kobs 
(1/s) 
Chi2 
0.732 1.10E-05     6.67E+04 1.50E-05   0.303 
  118 -0.472 1.80E-03 2.50E-04   112 1.94E-04  
  96.3 -2.24 -3.50E-04 2.50E-04   90.8 1.94E-04  
  129 -2.33 2.23E-04 2.00E-04   120 1.57E-04  
  102 -3.53 -5.10E-04 2.00E-04   94.4 1.57E-04  
  180 -1.75 5.42E-04 2.00E-04   167 1.57E-04  
  2.20E-03 -6.18 -3.52E-03 1.50E-04   2.00E-03 1.21E-04  
  138 -3.36 -9.61E-04 1.50E-04   125 1.21E-04  
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C6 Raw SPR Data: Compound 31 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI 
(RU) 
Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
9.01 3.88E-03 24.2    2.32E+03 4.30E-04   0.374 
   2.1 3.32E-03 2.50E-04   8.88 6.13E-03  
   1.3 -3.33E-04 2.50E-04   8.88 6.13E-03  
   3.13 3.01E-03 2.00E-04   7.67 5.68E-03  
   5.98 5.41E-03 2.00E-04   7.67 5.68E-03  
   3.43 1.93E-03 1.50E-04   6.25 5.23E-03  
   1.03 2.04E-03 1.50E-04   6.25 5.23E-03  
   0.43 3.74E-03 1.00E-04   4.56 4.78E-03  
   -
0.0612 
6.73E-05 1.00E-04   4.56 4.78E-03  
   -3.45 2.70E-03 5.00E-05   2.52 4.33E-03  
   -3.02 2.69E-03 5.00E-05   2.52 4.33E-03  
   -4.9 -3.02E-04 2.50E-05   1.33 4.10E-03  
   -4.9 -3.78E-04 2.50E-05   1.33 4.10E-03  
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C7 Raw SPR Data: Compound 42 
 
ka 
(1/Ms) 
kd 
(1/s) 
Rmax 
(RU) 
RI 
(RU) 
Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
71.4 0.0203 14    3.53E+03 2.84E-04   0.0986 
   3.12 7.13E-04 2.50E-04   6.55 0.0381  
   2.71 3.40E-04 2.50E-04   6.55 0.0381  
   2.91 1.39E-03 2.00E-04   5.78 0.0345  
   2.98 3.81E-04 2.00E-04   5.78 0.0345  
   4.22 6.83E-04 1.50E-04   4.84 0.031  
   4.23 9.58E-04 1.50E-04   4.84 0.031  
   5.8 1.34E-04 1.00E-04   3.65 0.0274  
   6.53 1.47E-03 1.00E-04   3.65 0.0274  
   7.61 1.04E-03 5.00E-05   2.1 0.0238  
   7.55 1.53E-03 5.00E-05   2.1 0.0238  
   10.3 2.17E-03 2.50E-05   1.13 0.022  
   10.2 1.76E-03 2.50E-05   1.13 0.022  
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C8 Raw SPR Data: Compound 48 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI 
(RU) 
Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
116 8.54E-03 23.2    1.35E+04 7.38E-05   0.858 
   7.14 -2.75E-03 2.50E-04   17.9 0.0375  
   12 -5.09E-04 2.50E-04   17.9 0.0375  
   13.3 -4.63E-05 2.50E-04   17.9 0.0375  
   14.2 9.16E-04 2.00E-04   16.9 0.0317  
   15.2 1.61E-03 2.00E-04   16.9 0.0317  
   16 7.72E-04 2.00E-04   16.9 0.0317  
   16.3 1.23E-03 1.50E-04   15.5 0.0259  
   16.5 1.67E-03 1.50E-04   15.5 0.0259  
   17.6 2.76E-03 1.50E-04   15.5 0.0259  
   17.6 4.11E-03 1.00E-04   13.3 0.0201  
   16.4 2.63E-03 1.00E-04   13.3 0.0201  
   16.6 1.12E-03 1.00E-04   13.3 0.0201  
   17.8 3.02E-03 5.00E-05   9.35 0.0143  
-20
-10
0
10
20
30
40
50
-50 150 350 550 750 950 1150 1350 1550
R
es
p
o
n
se
 U
n
it
s 
/ 
R
U
Time / s
250 uM 200 uM 150 uM 100 uM 50 uM
161 
 
 
C9 Raw SPR Data: Compound 50 
 
 
Compound 50 showed no evidence of binding, once uninterpretable sensorgrams were 
removed (below) therefore no further analysis was carried out. 
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C10 Raw SPR Data: Compound 56 
 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI 
(RU) 
Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
399 5.14E-03 25.9    7.77E+04 1.29E-05   0.588 
   3.05 3.61E-03 5.00E-05   20.6 0.0251  
   4.86 2.41E-03 5.00E-05   20.6 0.0251  
   7.52 5.85E-03 2.50E-05   17.1 0.0151  
   6.06 3.55E-03 2.50E-05   17.1 0.0151  
   5.19 3.25E-03 2.50E-05   17.1 0.0151  
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C11 Raw SPR Data: Compound 57 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) [Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
58.8 2.94E-04    2.00E+05 4.99E-06   0.412 
  20.9 -1.91 1.60E-04   20.2 9.71E-03  
  18.4 0.586 1.20E-04   17.7 7.35E-03  
  18.1 0.0806 1.20E-04   17.4 7.35E-03  
  20.8 1.35 8.00E-05   1.96E+01 5.00E-03  
  31.2 -0.0607 6.00E-05   28.8 3.82E-03  
  28.1 0.0648 6.00E-05   25.9 3.82E-03  
  44.5 0.976 4.00E-05   39.6 2.65E-03  
  89 2.12 2.00E-05   71.2 1.47E-03  
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C12 Raw SPR Data: Compound 58 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
10.7 4.98E-03 36.5    2.15E+03 4.65E-04   0.27 
   -2.87 3.33E-03 2.50E-04   12.7 7.66E-03  
   -4.37 5.26E-03 2.00E-04   11 7.12E-03  
   -5.65 3.99E-03 2.00E-04   11 7.12E-03  
   -4.38 5.58E-03 1.50E-04   8.89 6.59E-03  
   -5.9 4.99E-03 1.50E-04   8.89 6.59E-03  
   -3.96 -7.95E-04 1.00E-04   6.45 6.05E-03  
   -3.94 2.22E-03 1.00E-04   6.45 6.05E-03  
   -1.18 7.09E-04 5.00E-05   3.54 5.52E-03  
   -0.988 6.58E-05 5.00E-05   3.54 5.52E-03  
   2.34 1.18E-03 2.50E-05   1.86 5.25E-03  
   2.16 2.51E-03 2.50E-05   1.86 5.25E-03  
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C13 Raw SPR Data: Compound 64 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
69.9 2.64E-04     2.65E+05 3.78E-06   0.356 
  2.56 -0.271 -2.43E-03 2.50E-04   2.52 0.0177  
  0.0216 -0.973 -1.39E-03 2.00E-04   0.0212 0.0142  
  0.824 -1.25 -1.95E-03 1.50E-04   0.804 0.0107  
  1.15 -0.283 -4.76E-04 1.00E-04   1.11 7.25E-03  
  1.93 -0.542 -1.86E-05 5.00E-05   1.79 3.76E-03  
  12.3 4.3 5.47E-05 5.00E-06   7.02 6.13E-04  
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C14 Raw SPR Data: Compound 80 
 
 
ka 
(1/Ms) 
kd (1/s) Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA 
(1/M) 
KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
1.05 1.86E-04     5.63E+03 1.78E-04   1.14 
  242 2.31 8.39E-03 2.50E-04   141 4.48E-04  
  301 -3.43 -1.14E-03 2.00E-04   160 3.96E-04  
  0.388 -0.816 -3.68E-03 2.00E-04   0.206 3.96E-04  
  0.245 -1.8 -6.46E-04 1.50E-04   0.112 3.44E-04  
  7.88 -2.85 -3.20E-03 1.50E-04   3.61 3.44E-04  
  1.68 -3.4 -6.88E-04 1.00E-04   0.607 2.91E-04  
  44.1 -3.87 -2.94E-03 5.00E-05   9.69 2.39E-04  
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C15 Raw SPR Data: Compound 85 
 
ka 
(1/Ms) 
kd 
(1/s) 
Rmax 
(RU) 
RI (RU) Drift 
(RU/s) 
[Analyte] 
(M) 
KA (1/M) KD (M) Req 
(RU) 
kobs 
(1/s) 
Chi2 
54.1 1.13E-
03 
11.2    4.80E+04 2.09E-05   0.475 
   -0.167 7.15E-03 2.50E-04   10.3 0.0147  
   1.87 9.57E-03 2.00E-04   10.1 1.19E-02  
   0.185 4.68E-03 1.50E-04   9.81 9.24E-03  
   0.189 4.18E-03 1.00E-04   9.25 6.54E-03  
   1.97 6.54E-03 5.00E-05   7.89 3.83E-03  
   1.1 3.73E-03 5.00E-06   2.16 1.40E-03  
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APPENDIX D 
 
D1 Preliminary Data Collection and Refinement Statistics 
Table D1: Preliminary data collection and refinement statistics for co-crystal data presented in chapter eight. Note: * number in brackets represents last resolution shell. 
 
Compound 3 10 15 (-ligand) 25 42 57 60 74 (-ligand) 80 (-ligand)  85 
Beamline DLS-I03 DLS-I03 DLS-I03 DLS-I04-1 DLS-I03 DLS-I04-1 DLS-I04-1 DLS-I03 DLS-I04-1 DLS-I04-1 
Wavelength [Å] 0.96000 0.96000 0.96000 0.91741 0.96000 0.91741 0.91741 0.96000 0.91741 0.91741 
Space Group P41212 P41212 P41212 P41212 P41212 P41212 P41212 P41212 P41212 P41212 
a, b[Å] 121.76 122.54 118.76 120.08 120.48 121.41 121.39 121.54 121.54 120.89 
c [Å] 33.63 33.82 33.49 33.66 33.65 33.69 33.76 33.78 33.60 33.68 
α,β,γ [°] 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution range [Å] 86.10-1.80 86.65-1.50 83.98 84.91-1.40 85.19-1.95 85.85-2.10 85.84-1.60 85.94-1.50 85.94-1.70 85.48-1.80 
Wilson B factor [Å] 32.1 24.7 37.8 24.3 34.2 31.7 31.5 26.3 35.3 36.0 
I/sigma* 21.3 (4.2) 12.5 (3.2) 21.0 (3.7) 22.6 (3.2) 13.6 (4.0) 14.3 (2.9) 17.5 (3.2) 18.7 (4.6) 20.5 (1.9) 14.9 (3.1) 
Rmerge [%]* 6.0 (52.8) 8.7 (62.2) 5.9 (60.4) 3.8 (45.5) 8.4 (54.6) 11.5 (65.8) 5.3 (52.0) 5.4 (44.8) 4.6 (67.0) 7.2 (61.3) 
Completeness [%]* 99.6 (98.1) 99.7 (100) 995. (97.5) 99.2 (96.3) 99.7 (99.5) 99.4 (96.9) 99.9 (100.0) 99.9 (100.0) 98.7 (92.7) 98.4 (95.8) 
CC1/2 99.9 (93.5) 99.8 (90.9) 99.9 (92.0) 100 (90.1) 99.7 (88.6) 99.8 (86.7) 99.9 (90.0) 99.9 (95.9) 100.0 (78.1) 99.9 (85.9) 
R [%] 18.3 19.0 19.3 19.9 18.5 19.3 18.3 20.1 19.1 21.6 
Rfree [%] 22.6 22.0 21.3 22.1 23.8 23.5 22.1 22.0 22.6 25.9 
# Residues 188 188 188 188 188 188 188 188 188 188 
# waters 122 93 63 62 86 63 85 93 84 14 
RMSD bond length [Å] 0.02 0.02 0.02 0.02 0.02 0.019 0.03 0.03 0.02 0.02 
RMSD bond angles [°] 1.81 1.91 1.78 1.84 1.89 1.86 2.54 2.26 1.77 1.89 
